Clinical trial NCT05052983
Conditions: Prurigo Nodularis
Keywords: Prurigo Nodularis Nemolizumab CD14152
Sponsor: Galderma R&D
Start date: 2022-01-24; Completion date: 2023-09-11
Enrollment: 34 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The main objective of this study is to assess the long-term durability of response over a 24-week period following withdrawal of nemolizumab in participants with prurigo nodularis (PN) who previously responded to treatment in the Long-term-Extension (LTE) study RD.06.SPR.202699 (NCT05052983). The secondary objective of this study is to assess the safety of nemolizumab compared to placebo over a 24-week period in participants with PN who previously responded to treatment in the LTE study.

Detailed description:

Arms: arm 1: None arm 2: None
Interventions: intervention 1: Nemolizumab intervention 2: Placebo
Intervention descriptions: intervention 1: Participants received either 1 \[30 milligram (mg)\] or 2 (2\*30 mg) subcutaneous (SC) injection(s) of nemolizumab every 4 weeks (Q4W) for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by interactive response technology (IRT). intervention 2: Participants received either 1 (30 mg) or 2 (2\*30 mg) SC injection(s) of placebo every 4 weeks for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by IRT.

Protocol documents:
Prot_000.pdf: 
Document electronically signed in eDMS Regulatory Global
Signature page 1 of 1
Name
Reason for Signature
Date
31-Jan-2023 00:07:43 UTC
31-Jan-2023 00:10:42 UTC
31-Jan-2023 09:26:30 UTC
Version: 
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 -
12Dec2022
3.0
PPD
PPD
PPD
PPD
PPD
PPD


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 1 of 100
1
CLINICAL STUDY PROTOCOL
Galderma S.A.
Galderma Research & Development, LLC
Protocol Title: A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of 
Effect and Safety of Nemolizumab for 24 Weeks in Subjects with Prurigo Nodularis
Protocol Number: RD.06.SPR.203890
IND Number:
EudraCT Number:
2021-003928-32
Name of Investigational Product:
Nemolizumab (CD14152)
Phase of Development:
3b
Indication:
Prurigo nodularis
Sponsor:
Galderma S.A.
Zählerweg 10
6300 Zug
Switzerland 
Galderma Research & Development, LLC
2001 Ross Avenue, Suite 1600
Dallas, TX 75201
United States
Protocol Version: 
2.0
Protocol Date:
12 December 2022
-CONFIDENTIAL-
This document and its contents are the property of and confidential to Galderma S.A./Galderma R&D, LLC. Any 
unauthorized copying or use of this document is prohibited.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0
CCI




Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 3 of 100
INVESTIGATOR SIGNATURE PAGE
Protocol Title:
A Double-Blind, Placebo-Controlled, Randomized Study to Assess the 
Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects 
with Prurigo Nodularis
Protocol Number:
RD.06.SPR.203890
Confidentiality and Current Good Clinical Practice (GCP)/E6(R2) Compliance Statement 
I, the undersigned, have reviewed this protocol, including appendices, and I will conduct the study 
as described in compliance with this protocol (and amendments), GCP, and relevant International 
Council for Harmonisation (ICH) guidelines.
I am thoroughly familiar with the appropriate use of the study drug, as described in this protocol 
and any other information provided by Galderma S.A./Galderma R&D, LLC. including, but not 
limited to, the current Investigator’s Brochure.
Once the protocol has been approved by the independent ethics committee (IEC)/institutional 
review board (IRB), I will not modify this protocol without obtaining prior approval of Galderma 
S.A./Galderma R&D, LLC. and of the IEC/IRB. I will submit the protocol amendments and/or any 
informed consent form modifications to Galderma S.A./Galderma R&D, LLC. and the IEC/IRB, 
and approval will be obtained before any amendments are implemented.
I ensure that all persons or party assisting me with the study are adequately qualified and informed 
about the Galderma S.A./Galderma R&D, LLC. study drug and of their delegated study-related 
duties and functions as described in the protocol.
I ensure that source documents and trial records that include all pertinent observations on each of 
the study center’s trial subjects will be attributable, legible, contemporaneous, original, accurate, 
and complete. 
I understand that all information obtained during the conduct of the study with regard to the 
subjects’ state of health will be regarded as confidential. No subjects’ names will be disclosed. All 
subjects will be identified by assigned numbers on all case report forms, laboratory samples, or 
source documents forwarded to the Sponsor. Clinical information may be reviewed by the Sponsor 
or its agents or regulatory agencies. Agreement must be obtained from the subject before disclosure 
of subject information to a third party.
Information developed in this clinical study may be disclosed by Galderma S.A./Galderma R&D, 
LLC. to other clinical Investigators, regulatory agencies, or other health authority or government 
agencies as required.
Name, Title
Investigator Signature
Institution
Date (DD-Mmm-YYYY)
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 4 of 100
2
SYNOPSIS
Title of Study:
A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and 
Safety of Nemolizumab for 24 Weeks in Subjects with Prurigo Nodularis
Protocol 
Number:
RD.06.SPR.203890
Investigators/ 
Study Centers:
Centers enrolling subjects from the long-term extension (LTE) study (RD.06.SPR.202699) will 
be eligible to participate in this study 
Phase of 
Development:
Phase 3b
Objectives:
Primary objective: To assess the long-term durability of response over a 24-week period following 
withdrawal of nemolizumab in subjects with prurigo nodularis (PN) who previously responded to 
treatment in the LTE study RD.06.SPR.202699
Secondary objective: To assess the safety of nemolizumab compared to placebo over a 24-week 
period in subjects with PN who previously responded to treatment in the LTE study
Study 
Endpoints:
PRIMARY
Time from baseline to relapse, defined as meeting at least 1 of the following criteria:

Increase in (weekly average of the) Peak Pruritus Numeric Rating Scale (PP NRS) score 
≥4 points from baseline

Increase in Investigator Global Assessment (IGA) score ≥2 points from baseline
The estimand of primary endpoint is defined as the following:
Estimands
Treatment: randomized treatment with subcutaneous (SC) injections of nemolizumab or 
placebo at Week 0, 4, 8, 12, 16, and 20
Population: all randomized subjects (intent-to-treat [ITT] population)
Endpoint: time to relapse meeting at least 1 of the defined criteria
Intercurrent events: time to relapse will be censored at the last IGA or PP NRS assessment 
prior to treatment discontinuation or use of prohibited medication
Summary measure: hazard ratio of nemolizumab and placebo
SECONDARY
The secondary efficacy endpoints include: 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 5 of 100
•
Proportion of subjects with increase in PP NRS score ≥4 points from baseline at each 
scheduled visit 

Proportion of subjects maintaining IGA success, defined as IGA score of 0 (clear) or 1
(almost clear) at each scheduled visit

Proportion of subjects with increase in IGA ≥2 points from baseline at each scheduled 
visit

Absolute and percent change from baseline in PP NRS at each scheduled visit

Absolute and percent change from baseline in Sleep Disturbance (SD) NRS at each 
scheduled visit

Change from baseline in Dermatology Life Quality Index (DLQI) at Week 16 and Week 
24
Safety endpoints:

Incidence and severity of adverse events (AEs), including treatment-emergent AEs 
(TEAEs), AEs of special interest (AESIs), serious AEs (SAEs), treatment-related AEs, 
and AEs that lead to discontinuation
Study Design:
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to 
evaluate the durability of response and safety of nemolizumab in adult subjects who participated 
in the nemolizumab PN LTE study (RD.06.SPR.202699) and achieved a clinical response (i.e., 
IGA score of 0 or 1 and ≥4-point improvement in weekly average of PP NRS score from baseline 
of the lead-in study) at Week 52 of the LTE study. 
Subjects must enroll in this study at the time of completion of the Week 52 visit in the LTE study 
(RD.06.SPR.202699) to prevent any lapse in study treatment. After the Week 52 visit of the LTE 
study is complete, approximately 40 subjects will be randomized 1:1 to receive either 1 or 2 
injections of nemolizumab or placebo, stratified by dosing regimen. Subjects will continue to 
receive the same dosing regimen received in the LTE study (i.e., 1 or 2 SC injections of study 
drug administered every 4 weeks [Q4W]). Subjects with a body weight <90 kg in the LTE study 
will receive a 30-mg dose. Subjects weighing ≥90 kg in the LTE study will receive a 60-mg dose.
Subjects’ participation in the study will be up to approximately 32 weeks. The study consists of a 
24-week treatment period and an 8-week follow-up period (12 weeks after their last study drug 
injection at Week 20). Refer to Figure 1 for an overview of the study design.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 6 of 100
Figure 1.
Study Design (Synopsis)
* Clinical responder is defined as a subject with an Investigator Global Assessment (IGA) score= 
0 or 1 and improvement in Peak Pruritus Numeric Rating Scale (PP NRS) score of ≥4 points from 
baseline of the lead-in study at Week 52 visit of the LTE study. Note: Lead-in study baseline is 
defined as baseline PP NRS score in the Phase 3 studies RD.06.SPR.202685 or 
RD.06.SPR.203065 for subjects who rolled over into the LTE from these studies. For subjects 
who entered the LTE from the Phase 2 study RD.03.SPR.115828, the baseline PP NRS score at 
entry into the LTE study RD.06.SPR.202699 will be used.
** Relapse is defined as an increase in weekly average of PP NRS score ≥4 points from baseline 
or an increase in IGA score ≥2 from baseline at any point during the study. Subjects who relapse 
at any point during the treatment period or who complete through Week 24 are eligible for LTE 
re-entry.
Abbreviations: BL = baseline; LTE = long-term extension; R = randomization; W = week.
Baseline Assessment
After signing the informed consent form (ICF), all subjects will be evaluated for study 
participation, based on eligibility criteria. The study assessments at the time of completion of the 
Week 52 visit from the PN LTE lead-in study RD.06.SPR.202699 will be used as baseline 
assessments for the current study.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 7 of 100
Treatment Period
Eligible subjects will be randomized to receive 1 or 2 injections of nemolizumab or placebo 
according to their dosage group in the LTE study, as assigned by interactive response technology 
(IRT). Study drug will then be administered Q4W for 24 weeks with final dose administered at 
Week 20 (see Table 1). 
Table 1.
Treatment Summary (Synopsis)
LTE Lead-in Study
Lead-in Study Assigned 
Treatment
Dose Q4W for 24 weeks a
RD.06.SPR.202699
Nemolizumab 
30 mg  
(1 injection)
Blinded
Nemolizumab 30 mg 
(1 injection)
Blinded Placebo 
(1 injection)
Nemolizumab 
2 × 30 mg
(2 injections)
Blinded
Nemolizumab 2 × 30 mg 
(2 injections)
Blinded 2 × Placebo 
(2 injections)
Abbreviations: LTE = long-term extension; Q4W = every 4 weeks. 
a Dose will be assigned based on dose received in LTE lead-in study. 
Clinical assessments will occur according to the Schedule of Assessments in the protocol through 
the Week 24 visit. 
If a subject meets the criteria for relapse at any point during the treatment period, the subject will 
exit the study and re-enter the LTE study (see Figure 2). Subjects who exit the study before 
Week 24 should complete an early termination visit. Subjects who complete the study through 
Week 24 are eligible to re-enroll in the LTE study. 
Subjects who prematurely discontinue study drug for reasons other than relapse will be 
encouraged to complete the scheduled study visits. These subjects will only be eligible for re-
enrollment in the LTE study if they continue with study visits through Week 24.
Subjects who discontinue the study for reasons other than relapse before Week 24 or who will not 
continue nemolizumab treatment in the LTE study should complete a follow-up visit, 12 weeks 
(±7 days) after the last study drug injection.
Follow-Up Period
A follow-up visit will be conducted 8 weeks after completing the treatment period and/or 
12 weeks after the last study drug injection for all subjects who will not continue nemolizumab 
treatment in the LTE study.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 8 of 100
An independent data monitoring committee (IDMC) will review and monitor subject safety 
throughout the study, and an independent adjudication committee (IAC) will review all asthma-
related events throughout the study.
Selection of 
Subjects:
Inclusion Criteria 
Individuals must meet all the following criteria to be included in the study:
1.
Subjects who achieved a clinical response at Week 52 of the LTE study RD.06.SPR.202699, 
defined as:

IGA score of 0 (clear) or 1 (almost clear) 
AND

≥4 point improvement in weekly average of PP NRS score from baseline of the lead-in 
study 
Note: Lead-in study baseline is defined as baseline PP NRS score in Phase 3 studies 
RD.06.SPR.202685 or RD.06.SPR.203065 for subjects who rolled over into the LTE 
from these studies. For subjects who entered the LTE study from the Phase 2 study 
RD.03.SPR.115828, the baseline PP NRS score at entry into the LTE study 
RD.06.SPR.202699 will be used.
2.
Subjects with uninterrupted dosing of nemolizumab in the LTE study RD.06.SPR.202699 for 
3 months before the Week 52 visit
3.
Subjects willing and able to transfer into the study at the time of completion of the Week 52 
visit in the LTE study RD.06.SPR.202699
4.
Female subjects of childbearing potential (i.e., fertile, following menarche and until 
becoming postmenopausal unless permanently sterile) must agree to use an adequate and 
approved method of contraception throughout the study and for 12 weeks after the last study 
drug injection.
Adequate and approved methods of contraception applicable for the subject and/or her partner 
are defined below:

True abstinence, when in line with the preferred and usual lifestyle of the subject. 
Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) 
and withdrawal are not acceptable methods of contraception (see Appendix 2)

Progestogen-only oral hormonal contraception

Combination of male condom with cap, diaphragm, or sponge with spermicide (double 
barrier methods).
Note: “Double barrier methods” refers to simultaneous use of a physical barrier by 
each partner. Use of a single barrier method (e.g., condom) with a spermicide is not 
acceptable.

Combined (estrogen- and progestogen-containing) oral, intravaginal, or transdermal 
hormonal contraception

Injectable or implanted hormonal contraception
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 9 of 100

Intrauterine devices or intrauterine hormone-releasing system

Bilateral tubal ligation or tube insert (such as the Essure system) at least 3 months before 
the study

Bilateral vasectomy of partner at least 3 months before the study
5.
Female subjects of non-childbearing potential must meet one of the following criteria:

Absence of menstrual bleeding for 1 year prior to baseline without any other medical 
reason, confirmed with follicle-stimulating hormone (FSH) level in the postmenopausal 
range

Documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least 3 
months before the study
Note: Bilateral tubal ligation is not accepted as reason for non-childbearing potential
6.
Subject willing and able to comply with all of the time commitments and procedural 
requirements of the clinical study protocol, including periodic weekly recordings by the 
subject using an electronic handheld device provided for this study
7.
Understand and sign an ICF before any investigational procedure(s) are performed
Exclusion Criteria 
Individuals meeting any of the following criteria are ineligible to participate in this study:
1.
Subjects who, during their participation in a prior nemolizumab study, experienced an AE 
which in the opinion of the Investigator could indicate that continued treatment with 
nemolizumab may present an unreasonable risk for the subject
2.
Body weight <30 kg
3.
Receipt of prohibited medications, including rescue therapy, in the LTE study 
RD.06.SPR.202699 within 6 months of the Week 52 visit (Section 9.6.3). 
4.
Pregnant women (positive pregnancy test result at baseline visit), breastfeeding women, or 
women planning a pregnancy during the clinical study
5.
Any medical or psychological condition that may put the subject at significant risk according 
to the Investigator’s judgment, if he/she participates in the clinical study, or may interfere 
with study assessments (e.g., poor venous access or needle-phobia)
6.
Planning or expected to have a major surgical procedure during the clinical study 
7.
Subjects unwilling to refrain from using prohibited medications during the clinical study
8.
History of alcohol or substance abuse within 6 months of baseline
9.
Subjects with confirmed or suspected coronavirus disease 2019 (COVID-19) infection within 
2 weeks before baseline
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 10 of 100
10. Any condition the Investigator deems incompatible with subject participation in the study
Planned Sample 
Size:
Approximately 40 subjects are planned to be enrolled in this study.
Investigational 
Therapy:
Nemolizumab (CD14152) or placebo will be provided as lyophilized powder for solution for 
injection for SC use only after reconstitution in a pre-filled, single-use, dual-chamber syringe 
(DCS).
During the treatment period, eligible subjects will be randomized to receive either 1 or 2 injections 
of nemolizumab or placebo, administered Q4W for 24 weeks (last injection at Week 20). Subjects 
will receive the same dosage (1 or 2 SC injections) as received in the lead-in LTE study 
RD.06.SPR.202699, as assigned by IRT.
Subjects will have the option to self-inject study drug while at the study center under staff 
supervision. Subjects will be trained on injecting the study drug and will be allowed to inject study 
drug following appropriate training. If the subject does not wish to perform the injections, study 
staff can administer study drug at each visit. Table 2 presents details on the investigational therapy.
Table 2.
Investigational Therapy
Investigational product
Comparator/Placebo
Name
Nemolizumab
CD14152 placebo
Internal code
CD14152
NA
Pharmaceutical 
form
Lyophilized powder for solution 
for injection supplied in a DCS 
Lyophilized powder for solution 
for injection supplied in a DCS 
Packaging
DCS packaged with a plunger 
rod (not assembled) and a 27G 
½’’ safety needle
DCS packaged with a plunger rod 
(not assembled) and a 27G ½’’ 
safety needle
Storage conditions
Stored between 2°C to 8°C (36°F 
to 46°F); protected from freezing; 
protected from light
Stored between 2°C to 8°C (36°F 
to 46°F); protected from freezing; 
protected from light 
Dosage a
30 mg (1 injection) or 60 mg (2 
injections); see Table 1
1 injection or 2 injections; see 
Table 1
Route
SC use by subjects or clinic staff 
after reconstitution
SC use by subjects or clinic staff 
after reconstitution
Dose regimen
Q4W
Q4W
Treatment 
duration
24 weeks with last injection at 
Week 20
24 weeks with last injection at 
Week 20
Abbreviations: DCS = dual-chamber syringe (single use); NA = not applicable; Q4W = every 4 weeks; SC = 
subcutaneous.
a Subjects will receive blinded study medication as assigned by IRT, based on the assigned dosage in the 
lead-in LTE study RD.06.SPR.202699. 
If a subject relapses (i.e., experiences an increase in PP NRS score of ≥4 points from baseline or 
an increase in IGA score ≥2 points from baseline), the subject will exit the study and will be 
eligible to re-enter the LTE study for active treatment (see Figure 2).
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 11 of 100
Treatment 
Duration:
The expected duration of each subject’s participation in the study is up to 32 weeks, including a 
24-week treatment period and an 8-week follow-up period (12-weeks after the last study drug 
injection).
Efficacy:
The following efficacy assessments are planned according to the Schedule of Assessments 
(Table 7):

IGA

PP NRS

SD NRS
The following quality of life assessment is planned according to the Schedule of Assessments 
(Table 7):

Dermatology Life Quality Index (DLQI)
Safety:
The following safety assessments are planned according to the Schedule of Assessments 
(Table 7):

AEs, including TEAEs, AESIs, SAEs, treatment-related AEs, and AEs leading to 
discontinuation

Physical examination and vital signs 

Clinical laboratory tests 

12-lead ECGs

Respiratory examination and assessments
Proof of 
Exposure/ 
Immunogenicity
:
Proof of exposure (POE) and immunogenicity assessments are planned according to the Schedule 
of Assessments (Table 7):

Serum nemolizumab concentrations for POE

Anti-drug antibody (ADA) assessments: screening, confirmatory, titer, and neutralizing 
antibody (Nab) assays
Statistical 
Methods and 
Planned 
Analyses:
The ITT population will consist of all randomized subjects. The safety population will include all 
randomized subjects who receive at least 1 dose of study drug. The POE analysis population will 
include all subjects in the safety population who provide at least 1 post-baseline evaluable drug 
concentration value. The per-protocol population will consist of all subjects in the ITT population 
who have no major protocol deviations that would have a significant effect on the efficacy of the 
study treatment. The ITT population will be the primary population for all efficacy analyses, and 
all safety data will be summarized based on the safety population. The per-protocol population 
will be used as the population for sensitivity analyses of the primary and key secondary efficacy 
endpoints. 
Primary Efficacy Endpoints:
Median time to relapse, 25th and 75th percentiles, and 95% confidence interval (CI) will be 
presented. Kaplan-Meier survival plots will be produced. Time to relapse from baseline will be 
analyzed using Cox proportional hazards model adjusted for dosing regimens, comparing the 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 12 of 100
nemolizumab group (30 mg or 60 mg Q4W) with placebo. Hazards ratio with 95% CI and survival 
curve will be presented. If the assumption of proportionality for Cox proportional hazards model 
is not met, then another appropriate method will be used.
If a subject withdraws from the study, takes prohibited medication, or completes the study without 
any relapse, time to relapse response will be censored respectively at the time of the last efficacy 
assessment (PP NRS and IGA) prior to study withdrawal, use of prohibited medication, or 
completion of the study. If a subject has no efficacy assessment after randomization, then time to 
relapse will be censored at Day 1.
Secondary Efficacy Endpoints:
Binary secondary endpoints will be analyzed using a Cochran-Mantel-Haenszel test adjusted for 
randomized stratification variable. The estimate of the treatment difference (nemolizumab minus 
placebo), p-value and 2-sided 95% CI will be presented. These analyses will be based on observed 
case (OC) or imputation with the missing response considered as a non-responder for efficacy 
endpoints (i.e., IGA success) or as a relapse for relapse endpoints (i.e., increase in IGA or PP NRS 
score). 
Continuous secondary endpoints will be analyzed using analysis of covariance (ANCOVA) based 
on OC with treatment group and dose regimen as factors, and baseline value as the covariate where 
applicable. They will also be analyzed using mixed effect model for repeated measure (MMRM) 
approach, including treatment group and dose regimen as factors, visit, interaction term between 
treatment and visit, and the corresponding baseline value as an independent covariate where 
applicable. The estimated treatment difference for each endpoint at each visit will be displayed in 
the summary of statistical analysis together with the 95% CI and associated p-value. As sensitivity 
analyses, multiple imputation methods may be used to handle the missing data for some selected 
secondary endpoints. All secondary endpoints will be presented descriptively using OC.
Further details will be provided in the Statistical Analysis Plan.
Safety Analyses:
The incidence of TEAEs, AESIs, SAEs, treatment-related AEs, and AEs leading to study drug 
discontinuation will be included in incidence tables, summarized by system organ class and 
preferred term. Additionally, the incidence of TEAEs by maximum severity will be presented by 
system organ class and preferred term. 
Clinical laboratory data and vital signs will be summarized, including observed values and change 
from baseline values, as well as numbers of subjects with values outside limits of the normal 
range, including shifts from baseline at each time point. Summary tables will be provided for 12-
Lead ECG, Physical Examination (Full and Symptom-oriented), Asthma Control Test (ACT), 
peak expiratory flow (PEF), and respiratory examination by treatment group and visit where 
appropriate. 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 13 of 100
Proof of Exposure and Immunogenicity Analyses:
Summary statistics will be used to describe the POE to nemolizumab. Descriptive statistics 
(arithmetic and geometric mean, standard deviation, coefficient of variation [CV%], minimum 
[min], maximum [max], and median) of the serum concentrations versus time will be presented.
Incidence of positive ADA results will be summarized (absolute occurrence, percent of subjects, 
and treatment-related ADA). 
Sample size:
No formal sample size calculations were performed for this study. The sample size will be based 
on the sample size and the actual clinical response rate of the LTE study. Based on the current 
assumption, it is expected that approximately 40 subjects will be randomized. 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 14 of 100
3
TABLE OF CONTENTS
1
CLINICAL STUDY PROTOCOL ..............................................................................................1
PROTOCOL APPROVAL SIGNATURE...........................................................................................2
INVESTIGATOR SIGNATURE PAGE .............................................................................................3
2
SYNOPSIS ..................................................................................................................................4
3
TABLE OF CONTENTS ..........................................................................................................14
3.1
List of In-text Tables.....................................................................................................19
3.2
List of In-text Figures....................................................................................................19
4
LIST OF ABBREVIATIONS....................................................................................................20
5
INTRODUCTION .....................................................................................................................22
5.1
Background on Prurigo Nodularis ................................................................................22
5.2
Background on Nemolizumab.......................................................................................23
Nonclinical Studies ......................................................................................................23
Pharmacokinetic Profile ...............................................................................................23
Clinical Studies ............................................................................................................23
5.3
Risk/Benefit Assessment...............................................................................................24
5.4
Dose Selection Rationale ..............................................................................................26
6
STUDY OBJECTIVES AND ENDPOINTS.............................................................................27
6.1
Study Objectives ...........................................................................................................27
Primary Objective ........................................................................................................27
Secondary Objective ....................................................................................................27
6.2
Study Endpoints ............................................................................................................27
Primary Endpoint .........................................................................................................27
Secondary Endpoints....................................................................................................27
6.2.2.1
Efficacy Endpoints .................................................................................................27
6.2.2.2
Safety Endpoints.....................................................................................................28
7
INVESTIGATIONAL PLAN....................................................................................................29
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 15 of 100
7.1
Description of Overall Study Design and Plan .............................................................29
Study Visit Schema ......................................................................................................32
7.2
Discussion of Study Design ..........................................................................................33
7.3
End of Study..................................................................................................................34
8
SELECTION OF STUDY POPULATION ...............................................................................35
8.1
Inclusion Criteria...........................................................................................................35
8.2
Exclusion Criteria..........................................................................................................36
8.3
Removal of Subjects from Therapy or Assessments ....................................................37
Pregnancy.....................................................................................................................38
Coronavirus Disease 2019 (COVID-19) Infection.......................................................39
9
TREATMENTS.........................................................................................................................41
9.1
Details of Study Drug ...................................................................................................41
Study Drug Administered.............................................................................................41
Identity of the Study Drugs ..........................................................................................41
Preparation ...................................................................................................................42
Injection........................................................................................................................43
Packaging and Labeling ...............................................................................................43
Storage..........................................................................................................................43
9.2
Dosage Schedule...........................................................................................................43
9.3
Measures to Minimize Bias: Study Treatment Assignment and Blinding....................44
Method of Study Treatment Assignment .....................................................................44
Blinding........................................................................................................................44
9.4
Dosage Modification.....................................................................................................46
9.5
Accountability and Compliance....................................................................................46
Dispensing and Return of Study Drug .........................................................................47
Treatment Compliance .................................................................................................47
9.6
Prior and Concomitant Therapies..................................................................................47
Permitted Concomitant Therapy ..................................................................................48
Rescue Therapy............................................................................................................49
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 16 of 100
Prohibited Therapy.......................................................................................................49
Product Technical Complaints .....................................................................................51
10
STUDY PROCEDURES...........................................................................................................52
10.1
Informed Consent..........................................................................................................52
10.2
Study Procedures...........................................................................................................52
Schedule of Assessments .............................................................................................53
10.3
Duration of Subject Participation..................................................................................58
Early Termination Visit................................................................................................58
Unscheduled Visit ........................................................................................................58
11
EFFICACY ASSESSMENTS ...................................................................................................59
11.1
Investigator Global Assessment....................................................................................59
11.2
Numeric Rating Scales..................................................................................................59
Peak Pruritus Numeric Rating Scales...........................................................................59
Sleep Disturbance Numeric Rating Scale ....................................................................59
11.3
Quality of Life Questionnaires......................................................................................59
Dermatology Life Quality Index ..................................................................................59
12
SAFETY ASSESSMENTS .......................................................................................................60
.....................................................................................................................60
........................................................................................................60
....................................................................................................60
............................................................................................60
.....................................................................................61
Hematology..................................................................................................................62
Clinical Chemistry........................................................................................................62
Urinalysis .....................................................................................................................62
Pregnancy Testing........................................................................................................62
Follicle-stimulating Hormone ......................................................................................62
Virology .......................................................................................................................63
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 17 of 100
Tuberculosis Testing ....................................................................................................63
...............................................................................................63
Asthma Control Test ....................................................................................................63
Respiratory Examination..............................................................................................63
Peak Expiratory Flow...................................................................................................64
Respiratory Referrals....................................................................................................64
..............................................................................................................65
Adverse Events.............................................................................................................65
Adverse Events of Special Interest...............................................................................68
Serious Adverse Events................................................................................................69
Procedure for Reporting Serious Adverse Events........................................................69
Procedure for Reporting Adverse Events of Special Interest.......................................70
Suspected Unexpected Serious Adverse Reactions .....................................................71
Procedures for Reporting Pregnancy............................................................................72
Overdose.......................................................................................................................73
....................................................................73
..........................................................................73
13
OTHER ASSESSMENTS .........................................................................................................74
13.1
Proof of Exposure .........................................................................................................74
Blood Samples..............................................................................................................74
CD14152 Quantification in Biological Sampling........................................................74
13.2
Immunogenicity Analysis .............................................................................................74
14
STATISTICAL ANALYSIS .....................................................................................................75
14.1
Determination of Sample Size ......................................................................................75
14.2
Analysis Populations.....................................................................................................75
14.3
Efficacy Analysis ..........................................................................................................76
Analysis of Primary Efficacy Endpoint .......................................................................76
Analysis of Secondary Efficacy Endpoints..................................................................77
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 18 of 100
14.4
Safety Analysis .............................................................................................................77
14.5
Proof of Exposure and Anti-Drug Antibody Analysis..................................................79
14.6
Interim Analysis............................................................................................................79
15
STUDY MANAGEMENT........................................................................................................80
15.1
Approval and Consent...................................................................................................80
Regulatory Guidelines..................................................................................................80
Institutional Review Board/Independent Ethics Committee........................................80
Informed Consent.........................................................................................................80
15.2
Data Management .........................................................................................................80
15.3
Source Documents ........................................................................................................81
15.4
Record Retention...........................................................................................................81
15.5
Monitoring ....................................................................................................................81
15.6
Quality Control and Quality Assurance ........................................................................82
15.7
Protocol Amendment and Protocol Deviation ..............................................................82
Protocol Amendment....................................................................................................82
Protocol Deviations......................................................................................................82
15.8
Ethical Considerations ..................................................................................................83
15.9
Financing and Insurance ...............................................................................................83
15.10
Publication Policy/Disclosure of Data ..........................................................................83
15.11
Subject Confidentiality..................................................................................................84
16
REFERENCES ..........................................................................................................................85
17
APPENDICES ...........................................................................................................................87
Appendix 1
Specific Guidance for Study Conduct and Subject Safety during the Coronavirus 
Disease 2019 (COVID 19) Pandemic....................................................................87
Appendix 2
Contraception Guidelines .......................................................................................92
Appendix 3
Investigator Global Assessment (IGA) ..................................................................94
Appendix 4
Pruritus (Peak) Numeric Rating Scale (PP NRS)...................................................95
Appendix 5
Sleep Disturbance Numeric Rating Scale (SD NRS).............................................96
Appendix 6
Dermatology Life Quality Index (DLQI) ...............................................................97
Appendix 7
Asthma Control Test (ACT)...................................................................................99
Appendix 8
Approximate Total Blood Volumes .....................................................................100
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 19 of 100
3.1
List of In-text Tables
Table 1.
Treatment Summary (Synopsis)..........................................................................................7
Table 2.
Investigational Therapy.....................................................................................................10
Table 3.
Treatment Summary..........................................................................................................31
Table 4.
Description and Usage of Study Drug...............................................................................42
Table 5.
Dosage Schedule by Treatment Group..............................................................................44
Table 6.
Prohibited Therapy............................................................................................................49
Table 7.
Schedule of Assessments ..................................................................................................54
Table 8.
Estimand of Primary Endpoint..........................................................................................76
3.2
List of In-text Figures
Figure 1. Study Design (Synopsis) .....................................................................................................6
Figure 2. Subject Transition between CD14152 Studies 202699 and 203890.................................30
Figure 3. Study Design .....................................................................................................................32
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 20 of 100
4
LIST OF ABBREVIATIONS
Abbreviation
Definition
ACT
Asthma Control Test
AD
atopic dermatitis
ADA
anti-drug antibody
AE
adverse event
AESI
adverse event of special interest
ALT
alanine aminotransferase
ANCOVA
analysis of covariance
AST
aspartate aminotransferase
CFR
Code of Federal Regulations
CI
confidence interval
CMH
Cochran-Mantel-Haenszel
COVID-19
coronavirus disease 2019
CPK
creatine phosphokinase
CRO
contract research organization
CV
coefficient of variation
CYP450
cytochrome P450
DCS
dual-chamber syringe
DLQI
Dermatology Life Quality Index
eCRF
electronic case report form
ECG
electrocardiogram
EDC
electronic data capture
ET
early termination
FSH
follicle-stimulating hormone
GCP
Good Clinical Practice
HBcAb
hepatitis B core antibody
HBsAg
hepatitis B surface antigen
HCV
hepatitis C virus
HIPAA
Health Insurance Portability and Accountability Act
HIV
human immunodeficiency virus
IAC
independent adjudication committee
IB
Investigator’s Brochure
ICF
informed consent form
ICH
International Council for Harmonisation 
IDMC
independent data monitoring committee
IEC
independent ethics committee
IFU
Instructions for Use
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 21 of 100
Abbreviation
Definition
IGA
Investigator’s Global Assessment
IL-31
interleukin-31
IRB
institutional review board
IRT
interactive response technology
ITT
intent-to-treat
LTE
long-term extension
MedDRA
Medical Dictionary for Regulatory Activities 
NK
neurokinin
NRS
numeric rating scale
OC
observed case
PD
pharmacodynamic
PEF
peak expiratory flow
PI
Principal Investigator
PK
pharmacokinetic
PN
prurigo nodularis
POE
proof of exposure
PP
peak pruritus
PTC
product technical complaint
QoL
quality of life
RTSM
Randomization and Trial Supply Management
SAE
serious adverse event
SAP
statistical analysis plan
SC
subcutaneous
SD
standard deviation
SD NRS
sleep disturbance numeric rating scale
SUSAR
suspected unexpected serious adverse reaction
TB
tuberculosis
TEAE
treatment-emergent adverse event
ULN
upper limit of normal
UPT
urine pregnancy test
US
United States
WHO
World Health Organization
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 22 of 100
5
INTRODUCTION
5.1
Background on Prurigo Nodularis
Prurigo nodularis (PN) is characterized by the presence of multiple (up to hundreds), symmetrically 
distributed, highly pruritic, hyperkeratotic, erosive or crusted nodules and papules.1 Chronic itching 
is believed to induce and maintain the characteristic PN skin lesions through an itch-scratch cycle.2
This leads to an impaired quality of life (QoL) and high burden, due not only to the severe itch, but 
also the chronic skin lesions and lack of treatment options.3
No reliable data exist for the incidence and prevalence of PN in the general population, but it seems 
to be more frequent and intense in females and the elderly.4,5
The physiopathology of PN is still not fully understood; however, the interactions between cutaneous 
nerve fibers, neuropeptides and immune cells seem to play an important role in the onset of PN.6
A large spectrum of underlying conditions that induce chronic pruritus can be associated with PN, 
including dermatological (e.g., atopic dermatitis [AD]), systemic (e.g., chronic kidney failure), 
neurological (e.g., brachioradial pruritus), psychiatric, or mixed origin disorders.7 An atopic 
predisposition seemed to be most common, occurring in nearly half of subjects with PN. 4
The goal of PN treatment is to break the itch-scratch cycle and allow the skin to heal. There is no 
standardized or approved therapy for PN to date and evidence from controlled studies is limited.8
The current treatment recommendations for PN include identification and treatment of any underlying 
disease, moisturizers and antipruritics, topical therapies (corticosteroids, calcineurin inhibitors), and 
oral antihistamines as first-line agents.9 Phototherapy, oral or intra-lesional steroids, topical vitamin 
D3 (calcipotriol), capsaicin, cryotherapy, and antidepressants (amitriptyline, selective serotonin 
reuptake inhibitors) are used as second-line therapies with variable efficacy. In the third-line setting, 
systemic treatments such as cyclosporine,10 antiepileptic drugs (gabapentin, pregabalin)11 and 
thalidomide12 showed moderate-to-good response in pruritus reduction after several months of 
administration, but their use is limited by their unfavorable safety profile. Other off-label therapeutic 
options proposed for pruritus based on limited evidence include opioid receptor agonists and 
antagonists (naltrexone),13
NKR1-antagonists (aprepitant),14
and antibiotics (roxithromycin, 
erythromycin).15
The T cell-derived cytokine interleukin-31 (IL-31) has been suggested to be a key player in the 
development of pruritus in PN. Skin biopsies from PN patients with an atopic background showed a 
50-fold upregulation of IL-31 mRNA compared to skin from healthy individuals and a 4.5-fold 
upregulation compared to skin from AD patients.16
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 23 of 100
IL-31 seems to be an important cytokine for the regulation of PN and a potential therapy target.
5.2
Background on Nemolizumab
Nemolizumab (CD14152) is a humanized anti-human IL-31 receptor A monoclonal modified 
immunoglobulin G 2 antibody comprising a structure of 2 H-chains (445 amino acid residues) and 2 
L-chains (214 amino acid residues) connected by 16 disulfide bonds. Nemolizumab inhibits the 
binding of IL-31 to IL-31 receptor A and subsequent transduction of the IL-31 signal into the cell.
Nonclinical Studies
The Investigator’s Brochure (IB) contains detailed information on nonclinical studies.17
Pharmacokinetic Profile
Nemolizumab PK profile was assessed in healthy volunteers and in subjects with AD after single and 
repeated doses with weight-based (0.1 mg/kg to 3 mg/kg) and flat (10 mg to 90 mg) doses. The PK 
profile of nemolizumab was also assessed in the Phase 2a study SPR.115828 with PN subjects, where 
a nemolizumab dose of 0.5 mg/kg was administered.
Overall PK assessments showed a dose proportional increase of nemolizumab serum concentrations 
after a single (mg/kg) injection and a less-than-proportional increase after repeated administrations 
of flat doses between 30 mg and 90 mg. Subcutaneous administration of nemolizumab results in slow 
absorption with peak serum concentrations achieved after 4 to 9 days. The terminal elimination half-
life of nemolizumab was approximately 2 weeks after single and repeated administrations. No 
significant systemic accumulation was observed, and steady state concentrations were achieved from 
16 weeks of treatment without a loading dose and from 4 weeks of treatment when a loading (flat 2×) 
dose was administered. The systemic exposure to nemolizumab appeared to be slightly lower in AD 
subjects compared to healthy volunteers. 
Similar nemolizumab PK profiles were observed in subjects with AD and in subjects with PN. The 
similarity in nemolizumab exposure between the 2 populations was also confirmed using population 
PK modeling. The IB contains additional detailed information on the nemolizumab PK profile.17
A low immunogenicity potential was observed in subjects with PN and in subjects with AD. No 
subjects had positive anti-drug antibodies (ADA) that included immunoglobulin E (IgE), and no 
subjects developed neutralizing antibodies. In both subject populations, concentration-time profiles 
and PK parameters of ADA-positive subjects were not different from the ADA-negative subjects.
Clinical Studies
The IB contains detailed information on clinical studies.17
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 24 of 100
Studies have been completed in healthy subjects and subjects with AD, uremic pruritus, and PN 
(including the Phase 2a study RD.03.SPR.115828 and the Phase 3 pivotal study RD.06.SPR.203065).
Three additional Phase 3 studies in PN subjects are ongoing: 1 pivotal study (RD.06.SPR.202685), 1 
long-term extension (LTE) study (RD.06.SPR.202699), and 1 dose optimization/long-term study 
(M525101-11) to assess the safety and efficacy of nemolizumab in subjects with a clinical diagnosis 
of PN. 
There are also Phase 2 and Phase 3 studies in AD subjects, a Phase 3 study in subjects with pruritus 
associated with Chronic Kidney Disease and a Pharmacokinetic study for an Auto-Injector device
ongoing. 
5.3
Risk/Benefit Assessment
Pruritus is the cardinal symptom in PN and is often difficult to treat with current therapies. Chronic 
itching is believed to induce and maintain the characteristic PN skin lesions through an itch-scratch 
cycle. Therefore, the goal of PN treatments target pruritus remission to allow skin healing and 
improvement in patients’ QoL.
Results of a previous clinical study with nemolizumab demonstrated a marked effect on both PN 
lesions and pruritus. The decrease in itching sensation was rapid, within the first week following the 
first injection and improved with subsequent administrations. This improvement in the signs and 
symptoms of PN was consistent with the observed improvement in QoL (evaluated using the 
Dermatology Life Quality Index [DLQI]). Continuous treatment with nemolizumab also led to an 
improvement in the overall severity of PN, which was evaluated with various scales (i.e., Investigator 
Global Assessment [IGA], Peak Pruritus [PP] Numeric Rating Scale [NRS], and Prurigo Activity 
Score). Based on the results of the Phase 2a study (RD.03.SPR.115828) nemolizumab was clinically 
and statistically significantly superior to placebo in reducing the weekly average of PP NRS scores at 
Week 4 (difference between treatment groups -38.0%; 95% confidence interval [CI] -51.0, -25.0; 
p<0.001). The statistically significant improvements in IGA success and Prurigo Activity Score 
observed in the nemolizumab group were greater than those observed in the placebo group.
Based on the currently available information on nemolizumab and the risks associated with biologic 
agents in general, the important potential risks of nemolizumab treatment include local and systemic 
injection-related reactions, newly-diagnosed asthma or worsening of asthma, exacerbation of AD, 
and skin and non-skin infections. 
The following specific risk-minimization and safety follow-up measures have been planned in this 
clinical study: 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 25 of 100
a.
The protocol will exclude subjects who experienced an adverse event (AE) in the prior lead-in 
study that, in the opinion of the Investigator, could indicate continued treatment with 
nemolizumab would present an unreasonable risk for the subject. 
b. In the Phase 2b dose-ranging study (RD.03.SPR.114322) in AD, a dose-dependent increase of 
asthma flares (1 [1.8%], 2 [3.6%], 7 [12.3%], and 10 [17.5%] in placebo, 10-mg, 30-mg, and 90-
mg treatment arms, respectively) in subjects with pre-existing asthma was observed. Events were 
mostly mild or moderate (1 severe event with highest dose), manageable, and reversible under 
treatment with study drug. At all visits, subjects with a history of asthma will complete a 
respiratory exam, the Asthma Control Test (ACT), and peak expiratory flow (PEF) testing. 
Subjects diagnosed with de novo asthma will complete respiratory assessments at all visits starting 
with the visit in which the diagnosis was confirmed. Subjects without a medical history of asthma 
will undergo periodic respiratory assessments. Subjects with a medical history of asthma will be 
referred to the physician managing their asthma if ACT ≤19, PEF <80% of the predicted value, 
and/or unexpected worsening of asthma is observed or reported. Subjects without a medical 
history of asthma will be referred to a respiratory specialist if respiratory changes suggestive of 
asthma are observed or reported and/or respiratory assessments suggest a decline in subject’s 
health. An independent adjudication committee (IAC) will review all asthma AEs reported during 
the course of the study. 
c.
As no data are available in pregnant or breastfeeding women, these patients are not eligible for 
this study. 
d. Patients who have recently received live or non-live vaccines may be considered for enrollment 
after an appropriate time has elapsed before baseline/Day 1 (Section 9.6.3). Administration of live 
vaccines is prohibited during the study. Administration of non-live vaccines is prohibited with the 
exception of seasonal, emergency, and coronavirus disease 2019 (COVID-19) vaccinations 
(Section 9.6.1). See Appendix 1 for additional guidance for management of subjects and study 
conduct during the COVID-19 pandemic.
e.
A slight trend of dose-dependent increase of peripheral edema was reported in the nemolizumab 
Phase 2a study (CIM003JG) for AD. Most events were mild (11 of 21), no case was serious, and 
none resulted in premature treatment discontinuation; no case was associated with renal or cardiac 
AEs. Peripheral edema will be followed as an AE of special interest (AESI) in this study.
f.
An independent data monitoring committee (IDMC) will monitor the safety data regularly 
throughout the study, including AESIs listed in Section 12.7.2, which were defined based on the 
currently available safety information on nemolizumab and the risks associated with biologic 
agents in general.
In conclusion, when taking into consideration the currently available data of nemolizumab and the 
risk-minimization approaches to be implemented, the benefit/risk ratio of nemolizumab is considered 
to be favorable in this study.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 26 of 100
5.4
Dose Selection Rationale
In the Phase 2 study (RD.03.SPR.115828), nemolizumab was tested as a 0.5 mg/kg subcutaneous 
(SC) injection administered Q4W in subjects with PN. The 0.5 mg/kg dose demonstrated efficacy in 
the treatment of PN with an acceptable safety profile and a very good immunogenicity profile.
The Phase 3 studies are conducted with a flat, fixed dose. The dose was selected with the aim of 
improving dosing convenience and avoiding potential errors that could be made while calculating, 
preparing, and/or administering a weight-based dose. The switch from weight-based dosing to a flat 
dose was based on an assessment of observed clinical data, and modeling & simulation tools. 
Overall, subjects will continue to receive the same dose received in the LTE study (i.e., 1 or 2 SC 
injections of study drug administered Q4W). The dose was determined at baseline of the relevant 
lead-in study. Subjects with a body weight <90 kg were administered a 30 mg dose Q4W with a 
loading dose of 60 mg at baseline. Subjects weighing ≥90 kg were administered a 60 mg dose of 
nemolizumab Q4W (without loading dose). This dose adjustment was proposed to account for the 
impact of body weight on nemolizumab systemic exposure and subsequently to provide consistent 
efficacy response to nemolizumab across the body weight spectrum. 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 27 of 100
6
STUDY OBJECTIVES AND ENDPOINTS
6.1
Study Objectives
Primary Objective
To assess the long-term durability of response over a 24-week period following withdrawal of 
nemolizumab in subjects with PN who previously responded to treatment in the LTE study 
RD.06.SPR.202699
Secondary Objective
To assess the safety of nemolizumab compared to placebo over a 24-week period in subjects with PN 
who previously responded to treatment in the LTE study
6.2
Study Endpoints
Primary Endpoint
Time from baseline to relapse, defined as meeting at least 1 of the following criteria: 

Increase in (weekly average of the) PP NRS score ≥4 points from baseline

Increase in IGA score ≥2 points from baseline
The estimand of primary endpoint is defined as the following: 
Estimand
Treatment: randomized treatment with subcutaneous injections of nemolizumab or placebo at Week 0, 4, 8, 12, 16, 
and 20
Population: all randomized subjects (intent-to-treat population)
Endpoint: time to relapse meeting at least 1 of the defined criteria
Intercurrent events: time to relapse will be censored at the last assessment of IGA and PP NRS prior to treatment 
discontinuation or use of prohibited medication
Summary measure: hazard ratio of nemolizumab and placebo
Secondary Endpoints
6.2.2.1
Efficacy Endpoints
The secondary efficacy endpoints include:

Proportion of subjects with increase in PP NRS score ≥4 points from baseline at each 
scheduled visit 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 28 of 100

Proportion of subjects maintaining IGA success, defined as IGA score of 0 (clear) or 1 (almost 
clear) at each scheduled visit

Proportion of subjects with increase in IGA ≥2 points from baseline at each scheduled visit

Absolute and percent change from baseline in PP NRS at each scheduled visit

Absolute and percent change from baseline in Sleep Disturbance Numeric Rating Scale (SD 
NRS) at each scheduled visit

Change from baseline in DLQI at Week 16 and Week 24
6.2.2.2
Safety Endpoints
The safety endpoints of this study are as follows:

Incidence and severity of AEs, including treatment-emergent AEs (TEAEs), AESIs, serious 
AEs (SAEs), treatment-related AEs, and AEs that lead to discontinuation
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 29 of 100
7
INVESTIGATIONAL PLAN
7.1
Description of Overall Study Design and Plan
This is a Phase 3b multicenter, randomized, double-blind, placebo-controlled, parallel-group 
withdrawal study to evaluate the durability of response and safety of nemolizumab in adult subjects 
with PN who participated in the nemolizumab PN LTE study (RD.06.SPR.202699) and achieved a 
clinical response (i.e., IGA score of 0 or 1 and ≥4-point improvement in weekly average of PP NRS 
score from baseline of the lead-in study) at Week 52 of the LTE study. 
Subjects who agree to enroll in this study must do so at the time of completion of the Week 52 visit 
in the LTE study (RD.06.SPR.202699) to prevent any lapse in study treatment. After the Week 52
visit of the LTE study is complete, approximately 40 subjects who choose to enter this study will be 
randomized 1:1 to either continue the same dosing regimen received in the LTE study (i.e., 1 or 2 SC 
injections of study drug administered Q4W), or to discontinue nemolizumab and receive placebo. 
Subjects’ participation in the study will be up to approximately 32 weeks. The study consists of a 24-
week treatment period and an 8-week follow-up period (12 weeks after their last study drug injection 
at Week 20). 
Relapse is defined as an increase in (weekly average of the) PP NRS score ≥4 points from baseline 
or an increase in IGA score ≥ 2 from baseline at any point during the study. If a subject meets the 
criteria for relapse, then the subject may be considered for re-entry into the LTE study 
(RD.06.SPR.202699) (see Figure 2).
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 30 of 100
Figure 2.
Subject Transition between CD14152 Studies 202699 and 203890
*Clinical responder (CR) is defined as a subject with an Investigator Global Assessment (IGA) score= 0 or 1 and improvement in Peak Pruritus Numeric 
Rating Scale (PP NRS) score of ≥4 from baseline of the lead-in study at Week 52 visit of the long-term extension (LTE) study. Note: Lead-in study 
baseline is defined as baseline PP NRS score in the Phase 3 studies RD.06.SPR.202685 or RD.06.SPR.203065 for subjects who rolled over into the 
LTE from these studies. For subjects who entered the LTE study from the Phase 2 study RD.03.SPR.115828, the baseline PP NRS score at entry into 
the LTE study RD.06.SPR.202699 will be used.
** Relapse is defined as an increase in weekly average of PP NRS score ≥4 points from baseline or an increase in IGA score ≥2 from baseline at any 
point during the study
See Appendix 1 for additional guidance for management of subjects and study conduct during the 
COVID-19 pandemic.
Baseline Assessment 
After signing the informed consent form (ICF), all subjects will be evaluated for study participation, 
based on eligibility criteria. The study assessments at the time of completion of the Week 52 visit 
from the PN LTE lead-in study RD.06.SPR.202699 will be used as baseline assessments for the 
current study. 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 31 of 100
Treatment Period
Eligible subjects will be randomized to receive either 1 or 2 injections of nemolizumab or placebo 
according to their dosage group in the LTE study, as assigned by interactive response technology 
(IRT). Study drug will then be administered Q4W for 24 weeks with final dose administered at Week 
20.
Refer to Table 3 for a summary of study treatment.
Table 3.
Treatment Summary
LTE Lead-in Study
Lead-in Study Assigned Treatment
Dose Q4W for 24 weeks a
RD.06.SPR.202699
Nemolizumab 
30 mg  
(1 injection)
Blinded
Nemolizumab 30 mg 
(1 injection)
Blinded Placebo 
(1 injection)
Nemolizumab 
2 × 30 mg
(2 injections)
Blinded
Nemolizumab 2 × 30 mg 
(2 injections)
Blinded 2 × Placebo 
(2 injections)
Abbreviation: LTE = long-term extension; Q4W = every 4 weeks. 
a Dose will be assigned based on dose received in LTE lead-in study. 
Clinical assessments will occur according to the Schedule of Assessments in the protocol through the 
Week 24 visit. 
If a subject meets the criteria for relapse at any point, the subject will exit the study and re-enter the 
LTE study (see Figure 2). Subjects who exit the study before Week 24 should complete an early 
termination (ET) visit. Subjects who complete the study through Week 24 are eligible to re-enroll in 
the LTE study. 
Subjects who prematurely discontinue study drug for reasons other than relapse will be encouraged 
to complete the scheduled study visits. These subjects will only be eligible for re-enrollment in the 
LTE study if they continue with study visits through Week 24.
Subjects who discontinue the study for reasons other than relapse before Week 24 or who will not 
continue nemolizumab treatment in the LTE study should complete a follow-up visit, 12 weeks (±7 
days) after the last study drug injection.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 32 of 100
Follow-up Period
A follow-up visit will be conducted 8 weeks (±7 days) after completing the treatment period and/or 
12 weeks (±7 days) after the last study drug injection for all subjects who will not continue 
nemolizumab treatment in the LTE study. Twelve weeks corresponds to approximately 5 half-lives 
of nemolizumab when administered subcutaneously Q4W at the doses used in this study.
Study Visit Schema
An overview of the study is presented in Figure 3.
Figure 3.
Study Design
*Clinical responder is defined as a subject with an Investigator Global Assessment (IGA) score= 0 or 1 and improvement 
in Peak Pruritus Numeric Rating Scale (PP NRS) score of ≥4 points from baseline of the lead-in study at Week 52 visit
of the LTE study. Note: Lead-in study baseline is defined as baseline PP NRS score in the Phase 3 studies 
RD.06.SPR.202685 or RD.06.SPR.203065 for subjects who rolled over into the LTE from these studies. For subjects who 
entered the LTE study from the Phase 2 study RD.03.SPR.115828, the baseline PP NRS score at entry into the LTE study 
RD.06.SPR.202699 will be used.
** Relapse is defined as an increase in weekly average of PP NRS score ≥4 points from baseline or an increase in IGA 
score ≥2 from baseline at any point during the study. Subjects who relapse at any point during the treatment period or 
who complete through Week 24 are eligible for LTE re-entry. 
Abbreviations: BL = baseline; LTE = long-term extension; R = randomization; W = week.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 33 of 100
7.2
Discussion of Study Design
This study will evaluate the durability of response and safety of nemolizumab in adult subjects with 
PN. The general study design is based upon the prior Phase 3 and LTE study (RD.06.SPR.202699) 
designs conducted in adult subjects with PN. The rationale for the nemolizumab dose and dose 
regimen is provided in Section 5.4.
Eligible subjects for this clinical study will be adults who participated in the prior nemolizumab PN 
LTE study (RD.06.SPR.202699) with uninterrupted dosing for 3 months before the Week 52 visit 
and achieved a clinical response (i.e., IGA score of 0 or 1 and ≥4-point improvement in weekly 
average of PP NRS score from baseline of the lead-in study) at Week 52. By randomizing subjects 
from the PN LTE study who achieved a current clinical response to nemolizumab to either 
nemolizumab or placebo treatment arms, the durability of the response to nemolizumab following 
discontinuation of active treatment (i.e., in the placebo treatment arm) can be measured. This will be 
done to understand how long the effects of nemolizumab treatment are expected to last in controlling 
signs and symptoms of PN when treatment is removed. Subjects who experienced an AE during their 
participation in the prior lead-in study that in the opinion of the Investigator could indicate that 
continued treatment with nemolizumab might present an unreasonable risk for the subject are 
ineligible. Furthermore, subjects must not use restricted topical and systemic treatments, including 
rescue therapy, within 6 months of the Week 52 visit in the PN LTE study. 
A 24-week treatment period is considered adequate to evaluate the long-term durability of response 
and safety of nemolizumab based on the results of the prior Phase 2a study.
The efficacy endpoints selected for the Phase 3b trial are relevant to the underlying long-term 
manifestations associated with the disease under study (i.e., skin lesions, chronic itch, sleep 
disturbance, and QoL impairment), and are designed to measure the maintenance or loss of clinical 
response. 
The study includes an 8-week follow-up period and/or 12 weeks (±7 days) after the last study drug 
injection for subjects who will not continue in the LTE study. The duration of the follow-up period 
from the final nemolizumab dose (12 weeks [±7 days]) corresponds to approximately 5 half-lives of 
nemolizumab, which is considered adequate to ensure subject safety. 
Blinding subjects and the designated study team to the dosing assignment(s) helps ensure objectivity 
and minimize bias. Randomization through the IRT guards against selection bias. To avoid bias 
further and to ensure the integrity of the blind, personnel directly involved with the ongoing conduct 
of the study from the Sponsor, contract research organization (CRO), or other investigational study 
centers will not have access to any information that may lead to unblinding.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 34 of 100
Differences may be detectable during the study drug reconstitution process between active study drug 
and placebo but they appear similar after reconstitution is complete (approximately 10 minutes). 
Throughout the study, a pharmacist (or other qualified personnel) will prepare study drug for 
injection, including confirmation of complete reconstitution, prior to delivery of study drug for 
injection. The pharmacist (or other qualified personnel) preparing study drug should not be involved 
with any study assessments and should not discuss any aspects of study drug reconstitution with the 
subject or study staff involved in subject interviews or study assessments.
7.3
End of Study 
A subject will have fulfilled the requirements for study completion if/when the subject has completed 
all study periods, including the follow-up visit or the last scheduled visit as indicated in the Schedule 
of Assessments (Table 7).
The end of the study will be the last subject’s last visit as indicated in the Schedule of Assessments 
(Table 7).
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 35 of 100
8
SELECTION OF STUDY POPULATION
Section 7.1 provides information regarding number of subjects planned to be randomized. Refer to 
Section 14.1 for the statistical considerations on which the sample size is based.
8.1
Inclusion Criteria
Individuals must meet all of the following criteria to be included in the study:
1. Subjects who achieved a clinical response at Week 52 of the LTE study RD.06.SPR.202699, 
defined as: 

IGA score of 0 (clear) or 1 (almost clear) 
AND

≥4-point improvement in weekly average of PP NRS score from baseline of the lead-in 
study 
Note: Lead-in study baseline is defined as baseline PP NRS score in the Phase 3 studies 
RD.06.SPR.202685 or RD.06.SPR.203065 for subjects who rolled over into the LTE from 
these studies. For subjects who entered the LTE study from the Phase 2 study 
RD.03.SPR.115828, the baseline PP NRS score at entry into the LTE study 
RD.06.SPR.202699 will be used.
2. Subjects with uninterrupted dosing of nemolizumab in the LTE study RD.06.SPR.202699 for 
3 months before the Week 52 visit
3. Subjects willing and able to transfer into the study at the time of completion of the Week 52 
visit in the LTE study RD.06.SPR.202699
4. Female subjects of childbearing potential (i.e., fertile, following menarche and until becoming 
postmenopausal unless permanently sterile) must agree to use an adequate and approved 
method of contraception throughout the study and for 12 weeks after the last study drug 
injection
Adequate and approved methods of contraception applicable for the subject and/or her partner 
are defined below:

True abstinence, when in line with the preferred and usual lifestyle of the subject. Periodic 
abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and 
withdrawal are not acceptable methods of contraception (see Appendix 2).

Progestogen-only oral hormonal contraception 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 36 of 100

Combination of male condom with cap, diaphragm, or sponge with spermicide (double 
barrier methods) 
Note: “Double barrier methods” refers to simultaneous use of a physical barrier by each 
partner. Use of a single barrier method (e.g., condom) with a spermicide is not acceptable. 

Combined (estrogen- and progestogen-containing) oral, intravaginal, or transdermal 
hormonal contraception

Injectable or implanted hormonal contraception

Intrauterine devices or intrauterine hormone-releasing system

Bilateral tubal ligation or tube insert (such as the Essure system) at least 3 months before 
the study

Bilateral vasectomy of partner at least 3 months before the study
5. Female subjects of non-childbearing potential must meet one of the following criteria:

Absence of menstrual bleeding for 1 year prior to baseline without any other medical 
reason, confirmed with follicle-stimulating hormone (FSH) level in the postmenopausal 
range 

Documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least 3 
months before the study
Note: Bilateral tubal ligation is not accepted as reason for non-childbearing potential
6. Subject willing and able to comply with all of the time commitments and procedural 
requirements of the clinical study protocol, including periodic weekly recordings by the 
subject using an electronic handheld device provided for this study
7. Understand and sign an ICF before any investigational procedure(s) are performed
8.2
Exclusion Criteria
Individuals meeting any of the following criteria at baseline are ineligible to participate in this study:
1. Subjects who, during their participation in a prior nemolizumab study, experienced an AE 
which in the opinion of the Investigator could indicate that continued treatment with 
nemolizumab may present an unreasonable risk for the subject
2. Body weight <30 kg
3. Receipt of prohibited medications, including rescue therapy, in the LTE study 
RD.06.SPR.202699 within 6 months of the Week 52 visit (Section 9.6.3). 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 37 of 100
4. Pregnant women (positive pregnancy test result at baseline visit), breastfeeding women, or 
women planning a pregnancy during the clinical study
5. Any medical or psychological condition that may put the subject at significant risk according 
to the Investigator’s judgment, if he/she participates in the clinical study, or may interfere with 
study assessments (e.g., poor venous access or needle-phobia)
6. Planning or expected to have a major surgical procedure during the clinical study 
7. Subjects unwilling to refrain from using prohibited medications during the clinical study
8. History of alcohol or substance abuse within 6 months of baseline
9. Subjects with confirmed or suspected COVID-19 infection within 2 weeks before baseline
10. Any condition the Investigator deems incompatible with subject participation in the study
8.3
Removal of Subjects from Therapy or Assessments
Although the importance of completing the entire clinical study will be explained to the subjects, any 
subject is free to discontinue his/her participation in the study at any time and for whatever reason, 
specified or unspecified, and without any prejudice. No constraints are to be imposed on the subject, 
and when appropriate, a subject may be treated with other conventional therapy when clinically 
indicated. Investigators or the Sponsor can also withdraw subjects from the clinical study if deemed 
to be necessary.
Reasons for discontinuing study drug include:

Subject request (i.e., consent withdrawal)

Non-compliance with the study drug or study schedule

Lost to follow-up

Occurrence of AEs, including TEAE and laboratory abnormalities, not compatible with the 
continuation of subject participation in the study, in the Investigator's opinion, or unacceptable 
to the subject to continue, including but not limited to the following:
o
Serious immediate-type allergic manifestations including anaphylactic reaction
o
Serious worsening of asthma considered related to study drug administration 
o
Diagnosis of a malignancy (except curatively treated in situ cervical carcinoma, 
squamous cell carcinoma [Bowen's disease], or basal cell carcinoma)
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 38 of 100
o
Opportunistic infections such as but not limited to active tuberculosis (TB) and other 
infections whose nature or course suggest an immune-compromised or immune-
suppressed status 
o
Any serious infection or any severe infection requiring treatment with parenteral 
antibiotics or oral antibiotics/antivirals/antifungals for >2 weeks considered related to 
study drug administration
o
Confirmed or suspected COVID-19 infection (temporary discontinuation may be 
acceptable; for instructions on resuming study drug administration, see Section 8.3.2).

Pregnancy (see Section 8.3.1)

Use of non-permitted concurrent therapy (as specified in Section 9.6.3, unless discussed and 
agreed upon with the Investigator and Medical Monitor)

Use of systemic rescue therapy (as specified in Section 9.6.2)

Treatment failure (subjects who relapse may be eligible to re-enroll in the LTE study)

Investigator request

Sponsor request, including any of the above criteria
The reason(s) for withdrawal will be documented in the electronic case report form (eCRF). Subjects 
who have been enrolled and treated will not be replaced by another subject.
Subjects who prematurely discontinue study drug for reasons other than relapse will be encouraged 
to complete the scheduled study visits. These subjects will only be eligible for continued treatment 
with nemolizumab in the LTE study if they continue with study visits through Week 24.
When a subject is withdrawn from the study, he/she will be fully assessed whenever possible, and 
followed according to guidelines presented in Section 10.3.1 (ET Visit). 
Reasonable efforts will be made to contact subjects who are lost to follow-up. These efforts must be 
documented in the subject's file. 
The Sponsor has the right to terminate the study at any time in case of SAEs or if special 
circumstances concerning the investigational product or the company itself occur, making further 
treatment of subjects impossible. In this event, the Investigator(s) will be informed of the reason for 
study termination.
Pregnancy
Subjects will be instructed that known or suspected pregnancy occurring during the study should be 
confirmed and reported to the Investigator. If a subject becomes pregnant, the Investigator must 
withdraw the subject from the study without delay. The subject must not receive any further 
injection(s) of the study drug.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 39 of 100
The Investigator must:

Follow the procedures for reporting/follow-up of a pregnancy within 24 hours (see Section 
12.7.7) of receipt of the information.

Complete as fully as possible the applicable Pregnancy Surveillance Form(s) (see Section 
12.7.7).

Monitor and record the progress of the pregnancy until its outcome. Contact the subject’s 
regular physician (general practitioner or gynecologist) or hospital staff to obtain further 
details and ask for regular follow-up information.

Provide tri-monthly updates until the final outcome of the pregnancy. If the subject can no 
longer be reached (lost to follow-up), documentation of the nonresponse/contact with 2 phone 
calls and a letter (certified with return receipt) is required.

If the pregnancy leads to an abortion (i.e., voluntary abortion, spontaneous abortion, or 
therapeutic abortion), in utero death, or congenital anomaly, follow the procedure for 
declaration of/reporting an SAE (Section 12.7.4). 
The Investigator should also be notified of pregnancy occurring during the study (and within 12 weeks 
[±7 days] after the last dose of study drug) but confirmed after completion of the study. In the event 
that a subject is subsequently found to be pregnant after inclusion in the study, any pregnancy will be 
followed to term, and the status of mother and child will be reported to the Sponsor after delivery.
Full details will be recorded on the withdrawal page (exit form), or an SAE report will be completed 
if the subject has completed the study. Pregnancy is not to be considered as an AE; however, it must 
be monitored and reported as described in Section 12.7.7.
Coronavirus Disease 2019 (COVID-19) Infection
Study drug administration will be discontinued in a subject in whom a COVID-19 infection is 
confirmed or suspected. COVID-19 must be specified as the reason for study drug discontinuation.
Study drug administration may resume in subjects with confirmed or suspected COVID-19 infection 
based on Investigator judgment after discussion with the Medical Monitor or Sponsor and only if the 
following minimum conditions are met:

For symptomatic subjects: At least 14 days have passed since recovery, defined as resolution 
of fever without the use of fever-reducing medications and improvement in respiratory 
symptoms (e.g., cough, shortness of breath) 

For asymptomatic subjects: At least 21 days have passed since the positive polymerase chain 
reaction test and no symptoms
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 40 of 100
Note: The above conditions should be considered minimum criteria. Where the local guidelines are 
more stringent for infection resolution criteria, those guidelines must be applied.
See Appendix 1 for additional guidance for management of subjects and study conduct during the 
COVID-19 pandemic.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 41 of 100
9
TREATMENTS
9.1
Details of Study Drug
Study Drug Administered
“Study drug” or “study medication” refers to nemolizumab or placebo drug product for purposes of 
this double-blind study. The list of excipients is detailed in the IB.
Study drug will be provided as lyophilized powder for solution for injection for SC use only after 
reconstitution in a pre-filled, single-use, dual-chamber syringe (DCS). 
The DCS is a self-contained system that holds the lyophilized nemolizumab or placebo and solution 
(sterile water) for reconstitution, separately. The concentration of nemolizumab in the DCS will be 
61.5 mg/mL once reconstituted (volume of 0.49 mL per injection). 
Subjects will receive nemolizumab or placebo according to their dosage group (1 or 2 SC injections) 
in the LTE study, as assigned by IRT Q4W.
Subjects will have the option to self-inject study drug while at the study center under staff supervision. 
Subjects will be trained on injecting the study drug and will be allowed to inject study drug following 
appropriate training. If the subject does not wish to perform the injections, study staff can administer 
study drug at each visit.
Identity of the Study Drugs
Table 4 provides a description and overview of study drug usage.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 42 of 100
Table 4.
Description and Usage of Study Drug
Investigational Product
Comparator/Placebo
Name (internal code)
Nemolizumab (CD14152)
CD14152 placebo (N/A)
Pharmaceutical form
Lyophilized powder for solution for 
injection in a DCS 
Lyophilized powder for solution for 
injection in a DCS 
Storage conditions
Stored between 2 to 8°C (36 to 46°F); 
protected from light; protected from 
freezing
Stored between 2 to 8°C (36 to 46°F); 
protected from light; protected from 
freezing
Dosagea
30 mg (1 injection) or 60 mg (2 injections); 
see Table 3
1 injection or 2 injections; see Table 3
Dose regimen
Q4W
Q4W 
Route
SC use by subjects or clinic staff after 
reconstitution
SC use by subjects or clinic staff after 
reconstitution
Duration of treatment 
24 weeks with last injection at Week 20
24 weeks with last injection at Week 20
Abbreviations: DCS = dual-chamber syringe (single use); N/A = not applicable; Q4W = every 4 weeks; SC = 
subcutaneous.
a Subjects will receive blinded study medication as assigned by IRT, based on the assigned dosage in the lead-in study 
RD.06.SPR.202699.
Preparation
A pharmacist (or other qualified personnel) will prepare study drug for injection according to 
instructions provided in the current version of the pharmacy manual and the “Instructions for Use” 
(IFU). Study medication preparation should be conducted in a secured and clean area with limited 
access to only designated personnel at the time of the preparation. Good hygiene practices and clean 
techniques must apply at all times. 
Differences may be detectable during the study drug reconstitution process between active study drug 
and placebo, but active study drug and placebo appear similar after reconstitution is complete 
(approximately 10 minutes). Throughout the study, a pharmacist (or other qualified personnel) will 
prepare study drug for injection, including confirmation of complete reconstitution, prior to delivery 
of study drug for injection. The pharmacist (or other qualified personnel) preparing study drug should 
not be involved with any study assessments and should not discuss any aspects of study drug 
reconstitution with the subject/caregiver or study staff involved in study assessments. 
The study drug does not contain preservatives. From a microbiological point of view, the preparation 
of the study drug has to be done as close to subject administration as possible, and the study drug 
should be used immediately (less than 1 hour) after reconstitution. If not used immediately, the study 
drug has to be used within 4 hours maximum after reconstitution stored at room temperature (below 
30°C) and only if the preparation has taken place applying strictly good hygiene practices and clean 
techniques to ensure controlled aseptic conditions.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 43 of 100
Injection
All study drug injections will occur at the study center, following instructions provided in the current 
versions of the pharmacy manual and IFU. After confirming that the study drug is fully reconstituted, 
the pharmacist (or other qualified personnel) will deliver the DCS to the Investigator or other qualified 
personnel, for SC injection in the subject’s abdomen or alternative injection site. A different injection 
site should be selected for each injection. Refer to the current versions of the pharmacy manual and 
the IFU for further details. The site of injection should be recorded in the subject’s treatment record 
as well as the eCRF at each time point.
Clinic staff will provide injection training (or re-training, as needed) for subjects willing and able to 
self-inject study drug. Subjects will then be allowed to inject study drug. Based on the subject’s 
preference, clinic staff can also perform all injections.
After study drug administration, subjects will be monitored closely for any signs or symptoms of 
hypersensitivity reaction before being discharged.
Packaging and Labeling
All packaging and labeling operations will be performed according to Good Manufacturing Practice 
for Medicinal Products in the local language, national regulations/guidelines, and the relevant 
regulatory requirements, specifying that the drug is for use in a clinical trial. Each DCS will be 
packaged in an individual carton, including a 27G 1/2” needle and a plunger rod (not assembled), and 
will be identified by a unique kit number. Local adaptation of the kit design may be required; specific 
details for each country are provided in the pharmacy manual.
Storage
All DCS units must be stored together in a safe and secure area with restricted access. Upon receipt, 
the DCS must be removed from the shipping cooler, kept in the outer carton until use, and stored 
securely in a refrigerator between 2°C to 8°C (36°F to 46°F), protected from light and protected from 
freezing.
The refrigerator must be monitored daily, and if a temperature excursion occurs, the designated 
personnel should promptly inform the study monitor, as specified in the current version of the 
pharmacy manual.
9.2
Dosage Schedule
Table 5 summarizes study drug dosing for the 24-week treatment period. 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 44 of 100
Table 5.
Dosage Schedule by Treatment Group
Treatment Group
Dose a/route
Week(s)
Schedule
Clinical responders b with 1× 
dosing in lead-in LTE study
Nemolizumab (CD14152) 
30 mg × 1 SC injection
OR
Placebo × 1 SC injection
0, 4, 8, 12, 16, 20
Q4W for 24 weeks
Clinical responders b with 2× 
dosing in lead-in LTE study
Nemolizumab (CD14152) 
30 mg × 2 SC injections
OR
Placebo × 2 SC injections
0, 4, 8, 12, 16, 20
Q4W for 24 weeks
Abbreviation(s): IGA=Investigator Global Assessment; IRT=interactive response technology; LTE = long-term 
extension; PP NRS=Peak Pruritus Numeric Rating Scale; Q4W = every 4 weeks; SC = subcutaneous.
a Subjects will receive blinded study medication as assigned by IRT, based on the assigned dosage in the lead-in study 
RD.06.SPR.202699.
b Clinical responders are defined as subjects with IGA score of 0 or 1 and improvement in PP NRS score of ≥4 from 
baseline of the lead-in study at Week 52 visit of the LTE study. Note: Lead-in study baseline is defined as baseline PP 
NRS score in the Phase 3 studies RD.06.SPR.202685 or RD.06.SPR.203065 for subjects who rolled over into the LTE 
from these studies. For subjects who entered the LTE study from the Phase 2 study RD.03.SPR.115828, the baseline PP 
NRS score at entry into the LTE study RD.06.SPR.202699 will be used.
9.3
Measures to Minimize Bias: Study Treatment Assignment and Blinding
Method of Study Treatment Assignment
At the baseline visit, a unique subject identification number will be assigned to an eligible subject via 
IRT. Subjects will be randomized in a 1:1 ratio to receive either 1 or 2 injections of nemolizumab or 
placebo. The randomization scheme will be stratified by dosing regimen.
Blinding
All attempts will be made to keep the study center staff and subjects blinded throughout the study. 
Members of the study center staff, including those responsible for DCS preparation, will not have 
access to the randomized treatment assignment. 
To ensure double-blind administration of study drug, the study center pharmacist(s) or other qualified 
personnel will prepare all nemolizumab or placebo treatments, according to the current version of the 
pharmacy manual, the IFU, and assigned DCS provided by the IRT system.
As there may be detectable differences between active study drug and placebo during the 
reconstitution process, the DCS is delivered for injection after the reconstitution is complete. The 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 45 of 100
pharmacist (or other qualified personnel) preparing study medication should not be involved with any 
study assessments and should not discuss any aspects of study drug reconstitution with the 
subject/caregiver or study staff involved in subject interviews or study assessments.
Local unblinding will occur for bioanalytical POE and ADA testing. POE and ADA sample assays 
will only be performed on samples from subjects treated with nemolizumab. Prior to sample assays, 
local unblinding at the bioanalytical CRO will be restricted to the bioanalytical manager and his/her 
direct reports only, in order to select the appropriate samples for the assay.
To maintain the integrity of the study blinding, the bioanalytical laboratory staff who process/analyze 
the proof of exposure (POE)/ADA samples will not provide any information to Sponsor, CRO, or 
investigational study center personnel directly involved with the ongoing conduct of the study that 
may lead to unblinding during the ongoing study. The POE and ADA results will be released by the 
bioanalytical laboratory after database lock.
Unblinding of a subject’s individual treatment code should occur only in case of a medical emergency 
or in the event of a serious medical condition that necessitates identification of the study drug for the 
welfare of that subject, as judged by the Investigator. The emergency unblinding process utilizes IRT 
to allow the Investigator to have unrestricted, immediate, and direct access to the subject’s individual 
study treatment. When possible (i.e., when the health of the subject is not immediately at risk), the 
Investigator or Sub-investigator is encouraged to consult with the Medical Monitor and the Sponsor 
before breaking the blind.
If emergency unblinding is required:

Only the Investigator will make the decision to unblind the treatment assignment.

Only the affected subject will be unblinded.

The IRT system will provide the treatment assignment to the Investigator.
Refer to the Randomization and Trial Supply Management (RTSM) User Guide for information on 
the steps for breaking the blind in the IRT system.
When the blinding code is broken, the reason must be fully documented. If the code is broken by the 
Investigator, the subject must be withdrawn from the study and must also be appropriately followed 
for 12 weeks (±7 days) after the last dose of study drug.
The reporting requirements for unblinding are the same as the requirements for reporting an SAE (see 
Section 12.7.4).
The randomization code will remain blinded to all study centers and study team members until 
completion of the study and until the study database has been locked. 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 46 of 100
The IDMC will review data at periodic intervals throughout the study as defined in the IDMC charter. 
The IDMC charter will specify the procedures for unblinding to ensure that treatment assignment 
remains undisclosed to all individuals involved in the direct execution and management of the study 
until the final database is locked. 
9.4
Dosage Modification
Dose modification of the study drug will not be permitted during the clinical study. 
Any inadvertent dose modification(s) should be reported to the Sponsor/CRO. 
In the event of a missed dose (i.e., temporary discontinuation of the study drug), it will be documented 
in the eCRF that the drug has not been administered at the study visit, with the reason (e.g., for safety). 
Subjects will be asked to return to the study centers for all remaining visits and complete all study 
assessments and procedures as described in Section 10.
Dosing frequency of study drug (nemolizumab or placebo) is scheduled for Q4W, based on the 
baseline/Day 1 visit date. If a study visit occurs outside of the visit window, study drug can be 
administered provided there is a minimum of 3 weeks but not more than 5 weeks since the last 
injection. If 5 weeks or more, the next study drug injection should then occur at the next planned visit. 
Future visits should be scheduled as soon as possible and within the required windows based on the 
baseline/Day 1 visit date, while maintaining the minimum 3-week interval between doses. 
See Appendix 1 for additional guidance for management of subjects and study conduct during the 
COVID-19 pandemic.
9.5
Accountability and Compliance
Study drug (nemolizumab and placebo) will be provided to the investigational study center. Study 
center personnel will acknowledge receipt of the study drug using IRT to confirm the shipment 
condition and content. If a damaged shipment is received and/or a temperature excursion has been 
experienced, the site personnel will notify the Sponsor/CRO and follow the guidelines according to 
the current version of the pharmacy manual. 
The designated personnel will maintain accurate records of the study drug throughout the clinical 
study, including the inventory delivered to the study center, the use by each subject, the reconciliation 
of all delivered and received DCS units, and the return/destruction of unused study drug as specified 
in the current version of the pharmacy manual. No unauthorized use is permitted. Used DCS units 
will be properly documented in drug accountability records. Unless a product technical complaint 
(PTC) is detected or an event occurs before, during, or just after the injection, the used DCS units can 
be disposed of in an appropriate sharps container and according to waste regulation(s) in the country. 
A DCS involved in a malfunction or an Investigator or subject complaint must be retained on site and 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 47 of 100
designated personnel must proceed as defined in the current version of the pharmacy manual. Refer 
to Section 9.6.4 for PTCs.
The study monitor may check the study supplies at each study center at any time during the study. It 
is the responsibility of the study monitor to ensure that the Investigator (or designee) has correctly 
documented the amount of the study drug received, dispensed, and returned/destroyed on the 
dispensing log that will be provided. A full drug accountability log will be maintained at the study 
center at all times. The study monitor will arrange collection of any unused study drug to the 
destruction depot. The study monitor will also perform an inventory of study drug at the close-out 
visit to the study center. All discrepancies must be accounted for and documented.
Dispensing and Return of Study Drug
All drug preparation must be appropriately performed and documented by the designated personnel. 
Any error in the preparation of dosing solution must be reported to the study monitor promptly and 
be properly documented. At the end of the study, the reconciliation/return/destruction process for all 
unused study drug will be conducted according to the study centers’ standard operating procedures, 
local regulations, and best practices, as described in the current version of the pharmacy manual. The 
unused study drug will be returned to the drug depot for destruction.
Treatment Compliance
Treatment compliance will be assessed through the treatment records and drug dispensation logs.
As study drug is administered in the clinic, treatment compliance will be overseen and documented 
by the Investigator and study staff (using the treatment records and drug accountability records). At 
a minimum, the date, time, dose, injector (subject or study center staff), and site of injection should 
be accurately recorded to confirm that each dose of study treatment was properly administered.
9.6
Prior and Concomitant Therapies
Prior therapies and medications are defined as therapies/medications that have been stopped within 
the 3 months before the baseline period, unless relevant to the inclusion/exclusion criteria. Whenever 
possible, all prior therapies/medications for PN should be documented. 
Concomitant therapies/medications are defined as follows:

Any existing therapies ongoing at the time of the baseline assessment

Any changes to existing therapies (such as changes in dose, formulation, or application 
frequency) during the course of the study
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 48 of 100

Any new therapies received by the subject since the baseline assessment  
The following 2 categories are to be considered for prior and concomitant therapies: 

Drugs/therapies include but are not limited to prescription, over-the-counter, birth control 
pills/patches/hormonal 
devices, 
vitamins, 
moisturizers, 
sunscreens, 
herbal 
medicines/supplements, homeopathic preparations, and other alternative medications

Medical and surgical procedures (e.g., phototherapy, exodontia). Procedures whose sole 
purpose is diagnosis (non-therapeutic) are not included
Prior and concomitant therapies or medical/surgical procedures are to be recorded in the appropriate 
eCRF. 
Concomitant therapies are to be recorded, reviewed, and updated at each visit. 
At each visit, Investigators should also confirm concomitant therapies for contraception. 
Contraceptive counseling should occur at baseline. 
Any new concomitant therapy or modification of an existing therapy may be linked to an AE. In such 
cases, a corresponding AE form should be completed to account for the new therapy or change in 
therapy.
Prohibited therapies are provided in Section 9.6.3. 
Permitted Concomitant Therapy
Unless specified as prohibited therapies (see Section 9.6.3), all therapies are authorized, including 
basic skin care (cleansing and bathing), moisturizers (without “anti-itch” claim), bleach baths, and 
topical anesthetics.
Use of the following non-live vaccines is permitted in this study:

seasonal vaccinations (e.g., influenza)

emergency vaccinations (e.g., rabies or tetanus) 

COVID-19 vaccinations
Wherever possible, it is recommended to avoid administration of seasonal and COVID- 19 
vaccinations within 1 week before or after study drug dosing, and that a different anatomical location 
should be used for study drug administration and vaccine administration.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 49 of 100
In the event of emergency vaccination during the study, the study drug administration should be 
discontinued until the immune response to vaccination is verified.
The formation of cytochrome P450 (CYP450) metabolic enzymes can be altered by increased levels 
of certain cytokines (e.g., IL-1, IL-6, and IL-10) during chronic inflammation. Although there is no 
known evidence suggesting that IL-31 affects the level or activity of CYP450 enzymes, the impact of 
nemolizumab on such enzymes has not been studied. Therefore, Investigators should be attentive to 
clinical or laboratory signs that might indicate a potential effect of nemolizumab in subjects using 
other therapies that are CYP450 substrates and have a narrow therapeutic index. Typical examples of 
substrates with a narrow therapeutic range include warfarin, drugs that may cause torsades de pointes, 
almost all cytotoxic antineoplastic drugs, and aminoglycoside antibiotics. 
Rescue Therapy
Rescue therapies are not permitted in this study. Subjects enrolled in this study have demonstrated a 
clinical response to nemolizumab; therefore, if a subject experiences relapse, they will be 
discontinued from this study and may be eligible to continue to receive nemolizumab by re-enrolling 
in the LTE study (see Figure 2). 
Prohibited Therapy
Treatment with the following concomitant medications/therapies is prohibited during the study unless 
otherwise specified.
Table 6.
Prohibited Therapy
Treatments
Timeframe
Before Baseline/
Day 1
Day 1 –
Week 32
Topical calcineurin inhibitors (e.g., tacrolimus, pimecrolimus) 
and topical corticosteroids
6 months
Prohibited
Topical vitamin D analogs 
6 months
Prohibited
Topical or systemic PDE-4 inhibitors
6 months
Prohibited
Any other topical treatment other than moisturizer (e.g., 
capsaicin, cryotherapy for treatment of PN)
6 months
Prohibited
Emollients or moisturizers with menthol, capsaicin, 
polidocanol or other having “anti-itch” claim
6 months
Prohibited
Systemic or intralesional corticosteroids (corticosteroid 
inhalers are permitted)
6 months
Prohibited
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 50 of 100
Treatments
Timeframe
Before Baseline/
Day 1
Day 1 –
Week 32
Immunosuppressive or immunomodulatory drugs (e.g., 
cyclosporine A, methotrexate, thalidomide, oral tacrolimus, 
cyclophosphamide, azathioprine, mycophenolate mofetil, JAK 
inhibitors)
6 months
Prohibited
Biologics and their biosimilars (e.g., dupilumab, etanercept, 
adalimumab, infliximab, omalizumab, etc.)
6 months
Prohibited
Systemic retinoids 
6 months
Prohibited
Systemic roxithromycin, erythromycin
6 months
Prohibited
Opioid antagonists (e.g., naltrexone, naloxone), opioid 
partial/mixed agonists (e.g., nalbuphine, butorphanol) or opioid 
agonists (except when used for short term/acute pain); NK1 
receptor antagonists (e.g., aprepitant)
6 months
Prohibited
Anti-epileptics (e.g., gabapentin, pregabalin) unless used at a 
stable dose for 6 months or for a non-pruritic condition
6 months
Prohibited
Alternative and complementary medicine for PN (e.g., 
traditional Chinese medicine)
6 months
Prohibited
Live attenuated vaccines
6 months
Prohibited
Non-live vaccines (excluding seasonal [e.g., influenza], 
emergency [e.g., rabies or tetanus], and COVID-19 
vaccinations)
6 months 
(exceptions apply; 
Section 9.6.1)
Prohibited 
(exceptions apply; 
Section 9.6.1)
Oral antihistamines (unless these treatments were taken at a 
stable dose for 3 months prior to baseline or for a seasonal 
allergy)
6 months
Prohibited
Drugs with sedative effect such as benzodiazepines, 
imidazopyridines, barbiturates, or sedative antidepressants such 
as amitriptyline, paroxetine, except if these treatments were 
taken at a stable dose for at least 3 months before baseline
6 months
Prohibited
UVB Phototherapy or tanning beds, PUVA phototherapy
6 months
Prohibited
Cannabinoids (eg, dronabinol)
6 months
Prohibited
COVID-19=coronavirus disease 2019; JAK=Janus kinase; NK=neurokinin; PDE-4=phosphodiesterase-4; PN=prurigo 
nodularis; PUVA=psoralen+ultraviolet A; UVB=ultraviolet B.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 51 of 100
If a prohibited therapy becomes necessary for the safety of the subject, the Investigator should notify 
the Medical Monitor and discuss possible alternatives. If a subject receives a prohibited therapy 
during the clinical study (e.g., inadvertent short-term use), the Investigator should also notify the 
Medical Monitor and discuss whether or not it is acceptable for the subject to continue receiving the 
study drug. 
It is recommended that all subjects should be up to date with respect to standard of care vaccinations 
as defined by the local guidance. For subjects who have vaccination planned during the study, it will 
be determined after consultation with the treating physician, whether the administration of vaccine 
can be postponed until after the end of study without compromising the health of the subject. See also 
Section 9.6.1.
Vaccinations during the study and follow-up period are not permitted, with the exception of the 
specified non-live vaccines in Section 9.6.1. 
Product Technical Complaints
All DCS units must be inspected prior to preparation/injection by the persons performing the 
preparation/injection to ensure absence of visual defects that could lead to a DCS PTC. This also 
includes the DCS plunger rod. In case of doubt, the DCS should not be used, and the deficiency must 
be reported as defined in the pharmacy manual.
All PTCs should be reported to the Sponsor/designee by filing the relevant forms available in the 
Investigator Site File and the pharmacy manual and as required by local regulations. A PTC is any 
written, electronic, or oral communication that alleges deficiencies related to the identity, quality, 
reliability, safety, durability, effectiveness, or performance of a drug or delivery system. Examples 
may include but are not limited to appearance issues, discoloration, odor, broken/cracked syringe, 
missing parts, damaged stoppers, and foreign matter in lyophilized powder or diluent. These 
complaints may or may not represent a potential risk to the subject. For these types of events, a form 
must be completed as per the specific instruction by the study center personnel, pictures of the 
defective DCS must be attached, and forwarded to the Sponsor/designee at the latest on the next 
working day. Reporting to health authorities will be in accordance with local regulations. The 
defective DCS/items must be kept in case of investigation need as defined in the pharmacy manual 
and may be requested to be sent to the Sponsor/designee in accordance with regulations.
Refer to the current version of the pharmacy manual for further details.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 52 of 100
10 STUDY PROCEDURES
10.1 Informed Consent
Before performing any study-related procedures, the Investigator (or designee) will obtain written 
informed consent from the subject. 
Upon ICF signature, each subject will be assigned, via electronic data capture (EDC), a unique subject 
identification number which will be used for the entire duration of the study. 
10.2 Study Procedures
Assessments and their timing are to be performed as outlined in the Schedule of Assessments 
(Table 7). 
At each visit, assessments/procedures should be performed in the following order: 
1. Patient-reported efficacy and safety measurements
2. Investigator assessments (including efficacy and safety)

Electrocardiogram (ECG) should be done before vital signs measurements and blood draws 
(see Section 12.4).
3. Sample collections for laboratory assessments
4. Sample collections for correlative assessments (POE and ADA)
5. Administration of study drug injections
Assessments and procedures scheduled at a visit where study drug is administered should be 
performed before administration of treatment unless otherwise indicated in the Schedule of 
Assessments (Table 7).
Efficacy assessments are described in Section 11 and include IGA, PP NRS, SD NRS, DLQI. 
Safety assessments are described in Section 12 and include AEs, including TEAEs, AESIs, and SAEs, 
physical examination and vital signs, clinical laboratory tests, ECG, and respiratory assessments. 
Section 12.5 specifies laboratory assessment samples to be obtained. 
The Investigator may, at his/her discretion, arrange for a subject to have an unscheduled assessment, 
especially in the case of AEs that require follow-up or are considered by the Investigator to be possibly 
related to the use of study drug. The unscheduled visit page in the eCRF must be completed. 
Study discontinuation procedures, for various reasons including occurrence of AEs, are described in 
Section 8.3.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 53 of 100
Early termination visit procedures are described in Section 10.3.1 and unscheduled visit procedures 
are described in Section 10.3.2.
Schedule of Assessments 
Table 7 outlines the timing of procedures and assessments to be performed throughout the study.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0






Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 56 of 100
a)
After signing the ICF, all subjects will be evaluated for study participation, based on eligibility criteria. The Week 52 study assessments from the LTE 
lead-in study RD.06.SPR.202699 will be used as baseline assessments for the current study. 
b)
Subjects who relapse or discontinue prematurely (before the Week 24 visit) should complete an ET visit. If the subject discontinues for reasons other than 
relapse before Week 24, or will not continue with nemolizumab treatment in the LTE study, a follow-up visit should also be completed, 12 weeks (±7 
days) after the last study drug injection.
c)
Assessments to be conducted at the unscheduled visit depend on the reason for the visit. POE and ADA analyses should only be performed at unscheduled 
visits that are conducted for safety reasons when safety labs are collected for the management/monitoring of an AE. When a series of unscheduled visits 
is needed for the monitoring of the same AE, the POE and ADA collection is not required if already done at the first unscheduled visit of the series. 
Additional collection of samples for POE and ADA analysis should be performed per Investigator’s judgment. 
d)
PP NRS to be recorded by subjects once daily in the evening. SD NRS to be recorded by subjects once daily in the morning and if possible, within 1 hour 
of getting out of bed. 
e)
Patient-reported outcome assessments and designated safety measurements (including AE and concomitant therapies/procedures assessments) should 
occur before Investigator assessments, laboratory sample collections, and study drug administration.
f)
Subjects with a history of asthma will complete the ACT testing at all visits. Subjects with a new (de novo) diagnosis of asthma will complete the ACT 
testing beginning from de novo diagnosis and at all subsequent scheduled visits. 
g)
Respiratory exams and PEF measurements are required at these visits for subjects with a medical history of asthma or newly-diagnosed (de novo) asthma 
only. Whenever possible, it is preferable that the PEF measurements be performed before noon or at the same time during each study visit. Subjects should 
be asked to withhold asthma medication on study visit days until after PEF testing is complete, to the extent it does not pose an undue risk to the subject. 
h)
Vital signs will include pulse rate, systolic and diastolic blood pressure (after the subject has been sitting for at least 5 minutes), and body temperature.
i)
12-lead ECGs should be performed in the supine position and before any scheduled vital sign measurements and blood draws. 
j)
Subjects should be reminded to be well hydrated and fast for at least 8 hours before the visit(s) when clinical chemistry testing is planned. See Section 12.5
for details.
k)
Only for females of childbearing potential. If UPT is positive, it must be confirmed with a serum pregnancy test. Pregnancy test results must be available 
prior to the administration of the study drug.
l)
For postmenopausal subjects (i.e., no menses for 12 consecutive months), confirm status with a high FSH level in the postmenopausal range unless 
previously confirmed as part of a lead-in study. The blood chemistry sample at the baseline visit (V1) will also be used for an FSH test for the confirmation 
of postmenopausal status, if applicable.
m)
At scheduled visits with laboratory, POE, and/or ADA assessments, the samples are to be collected before study drug injection(s). As a guideline, POE 
and ADA samples should be collected at approximately the same time of day throughout the study, to the extent possible.
n)
Study drug reconstitution will be performed by the pharmacist (or other qualified personnel), and complete reconstitution confirmed, prior to delivery for 
injection. 
 
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V0
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 57 of 100
o)
Clinic staff will provide injection training (or re-training, as needed) for subjects willing and able to self-inject study drug. Subjects will then be allowed 
to inject study drug. Based on the subject’s preference, clinic staff can also perform all injections.
p)
After study drug administration, subjects should be monitored closely for any signs or symptoms of hypersensitivity reaction before being discharged. 
q)
If a study visit occurs outside of the visit window, study drug injection(s) can still be administered provided there is a minimum of 3 weeks but not more 
than 5 weeks since the last injection. If 5 weeks or more, the next study drug injection should then occur at the next planned visit. Future visits should be 
scheduled as soon as possible and within the required windows based on the baseline/Day 1 visit date, while maintaining the minimum 3-week interval 
between doses.
r)
The dose will depend on the dose received in the LTE lead-in study RD.06.SPR.202699; see Table 3 for details.
 
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V0
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 58 of 100
10.3 Duration of Subject Participation
The expected duration for each subject’s participation in the study is up to 32 weeks, including a 
24-week treatment period, and an 8-week follow-up period (12 weeks after the last study drug 
injection at Week 20). 
Early Termination Visit
If a subject meets the criteria for relapse at any point during the treatment period, the subject will 
be eligible to re-enter the LTE study (see Figure 2). Subjects who exit the study before Week 24 
should complete an ET visit. For subjects re-entering the LTE study, a minimum of 3 weeks is 
required between doses of study drug. Subjects who prematurely discontinue study drug for 
reasons other than relapse will be encouraged to complete the scheduled study visits. These 
subjects will only be eligible for re-enrollment in the LTE study if they continue with study visits 
through Week 24.
A follow-up visit will be conducted 8 weeks after completing the treatment period and/or 12 weeks 
(±7 days) after the last study drug injection for all subjects who will not continue nemolizumab 
treatment in the LTE study. Twelve weeks corresponds to approximately 5 half-lives of 
nemolizumab when administered subcutaneously Q4W at the doses used in this study.
Unscheduled Visit
The subject should be reminded to adhere to the study schedule. Unscheduled visits are defined as 
visits to repeat testing for abnormal laboratory results, for follow-up of AEs, or to conduct efficacy 
assessments for subjects requiring rescue medication between regularly scheduled study visits. 
Visits occurring outside of the visit window are not considered unscheduled visits.
Assessments to be conducted at the unscheduled visit will depend on the reason for the visit: any 
of the procedures/assessments listed in Table 7 may be conducted, but not all are required. Blood 
sample collection for POE and ADA analyses are required during unscheduled visits that are 
conducted for safety reasons when safety labs are collected for the management/monitoring of an 
AE. When a series of unscheduled visits is needed for the monitoring of the same AE, the POE 
and ADA collection is not required if already done at the first unscheduled visit of the series. 
Additional collection of samples for POE and ADA analysis should be performed per 
Investigator’s judgment.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 59 of 100
11
EFFICACY ASSESSMENTS
11.1 Investigator Global Assessment
The IGA is a 5-point scale used by the Investigator or trained designee to evaluate the global 
severity of PN. The Investigator will review the subject’s skin and give a score of 0 (clear), 1 
(almost clear), 2 (mild), 3 (moderate), or 4 (severe). Treatment response/success is defined as 0 
(clear) or 1 (almost clear) (see Appendix 3). 
The same evaluator should perform all assessments for the same subject in order to reduce intra-
subject variability. 
11.2 Numeric Rating Scales
Peak Pruritus Numeric Rating Scales
An NRS relating to maximum intensity itch/pruritus (PP NRS) will be completed by the subject 
(see Appendix 4). The NRS will ask for a unit score on an 11-point scale (0 to 10) where 0 is “no 
itch” and 10 is the “worst itch imaginable”. 
 
Sleep Disturbance Numeric Rating Scale
An NRS relating to sleep disturbance (SD NRS) will be completed by the subject to report the 
degree of their sleep loss related to PN (see Appendix 5). The SD NRS will ask for a unit score on 
an 11-point scale (0 to 10). The question asked will be: “On a scale of 0 to 10, with 0 being “no 
sleep loss related to the symptoms of my skin disease (prurigo nodularis)” and 10 being 
 
 
 
11.3 Quality of Life Questionnaires
Dermatology Life Quality Index
The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, 
daily activities, leisure, work/school, personal relationships, and treatment (see Appendix 6). 
The subject will rate each question ranging from 0 (not at all) to 3 (very much). A higher total 
score indicates a poorer QoL. 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0
CCI
CCI


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 60 of 100
12
SAFETY ASSESSMENTS 
Vital signs will be evaluated at all visits as indicated in the Schedule of Assessments (Table 7). 
Vital signs will include pulse rate, systolic and diastolic blood pressure (after the subject has been 
sitting for at least 5 minutes), and body temperature. All abnormal values at the baseline visit 
identified as clinically significant by the Investigator will be recorded in the medical history form. 
Any clinically significant changes from the baseline visit (and onwards) will be recorded as an 
AE.
Height and weight will be measured according to the Schedule of Assessments (Table 7).
A complete physical examination should be performed according to the Schedule of Assessments 
(Table 7) at designated visits. A complete physical examination will include assessments of the 
head, ears, eyes, nose, throat, neck (including thyroid), skin/integumentary system, cardiovascular 
system, respiratory system (for additional respiratory assessments, see Section 12.6), 
gastrointestinal system, musculoskeletal system, lymph nodes, nervous system, and extremities. 
A symptom-directed physical examination should be performed at all other visits according to the 
Schedule of Assessments (Table 7).
The Investigator should assess all abnormal findings for clinical significance. All clinically 
significant abnormal findings at the baseline visit will be recorded in the medical history form. 
Any clinically significant changes from the baseline visit will be recorded as an AE.
A 12-lead, resting ECG will be performed and read centrally according to visits indicated in the 
Schedule of Assessments (Table 7). The 12-lead ECGs for each subject should be obtained using 
the electrocardiograph machine provided for the study. The 12-lead ECGs will be performed in 
the supine position and before any scheduled vital sign measurements and blood draws. Subjects 
should be monitored for potentially clinically significant ECG results (refer to the current version 
of the central laboratory manual). Tests with abnormal results at the baseline visit should be 
recorded in the medical history form. Results that are deemed clinically significant should be 
repeated to ensure reproducibility of the abnormality. Any abnormalities considered by the 
Investigator to be clinically significant after the baseline visit are to be recorded as AEs and 
discussed with the Medical Monitor, as needed.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 61 of 100
Laboratory assessment samples are to be obtained at designated visits as detailed in the Schedule 
of Assessments (Table 7).
The hematology laboratory analyses, clinical chemistry laboratory analyses, and urinalyses will be 
performed at a central laboratory. Reference ranges will be supplied by the central laboratory and 
used by the Investigator to assess the laboratory data for clinical significance and pathological 
changes.
The Investigator or medically qualified Sub-investigator must review and evaluate laboratory 
values for each subject in a timely manner. Study centers should refer to the current version of the 
laboratory manual for laboratory values outside of normal limits.  For each out-of-range laboratory 
result, the Investigator or designee will evaluate whether he/she considers it to be clinically 
significant, defined as meeting at least 1 of the following conditions:

The abnormality suggests a disease and/or organ toxicity, or 

The abnormality is of a degree that requires additional active management, 
e.g., discontinuation of the drug, close observation, more frequent follow-up assessments, 
or further diagnostic investigation.
If the Investigator observes a clinically significant laboratory result, the test will be repeated as 
soon as possible, and the subject will be monitored until the value returns to normal and/or an 
adequate explanation for the abnormality is found.
Investigators will also be allowed to repeat specific laboratory test(s) or procedure(s) where the 
Investigator suspects an inaccuracy or false result and that which may impact the safety of the 
subject or the interpretation of the trial results. This should occur only after discussion with 
Medical Monitor.
All clinically significant out-of-range laboratory values at the baseline visit will be recorded (report 
a diagnosis rather than the laboratory value whenever possible) in the medical history form. All 
clinically significant out-of-range laboratory values after the baseline visit are to be reported as an 
AE if this abnormality was not present at the baseline visit, or is assessed as having worsened since 
the baseline visit (i.e., changed significantly from the baseline visit). Whenever possible, the 
Investigator should provide a diagnosis of an AE when reporting the abnormal laboratory value. 
See Section 12.7 for details. 
Subjects should be reminded to be well hydrated before all visits for phlebotomy purposes. 
Subjects should fast for at least 8 hours before the visits when blood chemistry testing is planned. 
Laboratory testing conducted in a non-fasting state will not be a protocol deviation.
Total blood volumes to be drawn at each visit are provided in the clinical laboratory manual and 
in  Appendix 8. Additional samples may be required if medically indicated (e.g., at unscheduled 
visits for safety reasons, when an abnormal laboratory value is observed and requires a re-test). 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 62 of 100
Hematology
The hematology tests include: hemoglobin, hematocrit, white blood cell count (with differential 
including eosinophils), red blood cell count, platelet count, and mean cell volume.
Clinical Chemistry
The clinical chemistry tests include: creatinine, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), gamma 
glutamyl 
transferase, alkaline 
phosphatase, lactate 
dehydrogenase, total bilirubin, direct bilirubin, albumin, total protein, uric acid, sodium, 
potassium, calcium, chloride, glucose, urea, total cholesterol, triglycerides, low-density 
lipoprotein, high-density lipoprotein, creatine phosphokinase (CPK). CPK isoenzyme test will be 
performed only if CPK is elevated to >2.5 × upper limit of normal (ULN). The Investigator should 
also contact the Medical Monitor in such situations.
For postmenopausal subjects (i.e., no menses for 1 year), the blood chemistry sample at the 
baseline visit will also be used to confirm postmenopausal status by a high FSH level in the 
postmenopausal range, unless previously confirmed as part of the lead-in study.
Urinalysis
The urinalysis tests include: pH, glucose, ketones, blood, protein, leukocytes, nitrites, bilirubin, 
urobilinogen, and specific gravity.
Pregnancy Testing
Urine pregnancy tests (UPTs) will be conducted for all women of childbearing potential beginning 
at baseline and continuing at subsequent visits according to the Schedule of Assessments (Table 7). 
Pregnancy test results must be available prior to the administration of the study drug.
UPTs with a sensitivity <25 IU/L will be provided to the study centers for use in the trial.
UPTs will be performed at the study centers, and all other samples will be sent to central laboratory 
for analysis.
If the result of a UPT is positive, it must be confirmed with a serum pregnancy test, and no study 
drug should be administered pending the serum pregnancy test result. Subjects with a positive 
serum pregnancy test result during the trial must discontinue treatment and be withdrawn from the 
trial.
Follicle-stimulating Hormone
The postmenopausal status (defined as no menses for 1 year) of a subject will be confirmed at the 
baseline visit, unless previously confirmed as part of the lead-in study. For these subjects, 
postmenopausal status will be confirmed with a FSH level in the postmenopausal range.
Blood chemistry sample at the baseline visit will also be used for an FSH test for the confirmation 
of postmenopausal status, if applicable.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 63 of 100
Virology
Virology including hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), 
hepatitis C virus (HCV), human immunodeficiency virus 1, and human immunodeficiency virus 2 
antibodies may be assessed at unscheduled visits for safety purposes based on Investigator 
judgment. Subjects with a positive HBcAb and a negative HBsAg will also be assessed for hepatitis 
B surface antibody. Subjects with positive HCV antibodies will have a confirmatory test for HCV 
(e.g., polymerase chain reaction).
Tuberculosis Testing
Subjects may be assessed for active or latent tuberculosis (TB) at unscheduled visits for safety 
purposes based on Investigator judgment. A subject who tests positive for latent TB (with a 
positive QuantiFERON-TB Gold test) should be referred to the subject’s treating physician for 
appropriate follow-up.
At baseline, the Investigator should specifically question all subjects about any medical history or 
changes in their asthma and respiratory health (e.g., wheezing, coughing, allergies, and infections). 
Subjects with a history of asthma will be questioned about the seasonality of their asthma and 
known triggers, such as allergens. Newly-diagnosed asthma or worsening of asthma during the 
study will be reported as an AESI.
Asthma Control Test
Subjects with a medical history of asthma will take the ACT at all visits according to the Schedule 
of Assessments (Table 7) before questioning and physical examination by the Investigator. 
Subjects with a new (de novo) diagnosis of asthma will take the ACT at the visit the diagnosis was 
first confirmed and thereafter, at all subsequent study visits. Subjects with an ACT score ≤19 will 
be referred to the physician managing their asthma.
The ACT is an assessment to determine if a subject’s asthma symptoms are well controlled. The 
ACT is designed for adults and adolescents 12 years or older, and is composed of 5 questions. For 
each question, the subject will choose the best answer out of 5 possible answers. The test provides 
a numerical score ranging from 5 to 25 to assess asthma control; a higher score indicates better 
asthma control while a score of 19 or less indicates the subject’s asthma may not be under control. 
A copy of the ACT can be found in Appendix 7. 
Respiratory Examination
A respiratory examination will be required to be performed for all subjects at specified visits 
according to the Schedule of Assessments (Table 7). Only subjects reporting a medical history of 
asthma will require a respiratory examination at all visits. Subjects with a new (de novo) diagnosis 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 64 of 100
of asthma will require a respiratory examination at all scheduled visits after the diagnosis is first 
made according to the Schedule of Assessments (Table 7).
The ACT will also aid the Investigator’s questioning of subjects with a medical history of asthma 
and should be completed before the clinical questioning. All subjects will be asked non-leading 
questions about any respiratory changes. The Investigator or designee will then perform a 
respiratory examination of all subjects at all visits. 
Subjects with a medical history of asthma will be referred to the physician managing their asthma 
if unexpected worsening of asthma is observed or reported. Subjects without a medical history of 
asthma who experience respiratory changes (examination findings or newly-reported signs and/or 
symptoms suggestive of asthma) will be referred to a respiratory specialist.
Peak Expiratory Flow
All subjects will undergo PEF testing at specified visits according to the Schedule of Assessments 
(Table 7). Only subjects reporting a medical history of asthma will undergo PEF testing at all 
visits. 
Subjects with a new (de novo) diagnosis of asthma will undergo PEF testing at all scheduled visits 
after the diagnosis is first made according to the Schedule of Assessments (Table 7).
Peak expiratory flow testing during the clinical study will be performed under the supervision of 
qualified study personnel. Peak expiratory flow measurements should consist of 3 good efforts, 
with the best result documented. It is preferable that the PEF measurement be performed before 
noon or at the same time during each study visit whenever possible. Obtained PEF values will be 
compared to predicted values based on the subject’s age, sex and height. 18, 19
To avoid interference with PEF measurements, attempts should be made to withhold asthma 
medication on study visit days until after PEF testing is complete; to the extent it does not pose an 
undue risk to the subject. 
Subjects with a medical history of asthma with a PEF <80% of the predicted value will be referred 
to the physician managing their asthma.
Respiratory Referrals
Subjects with a medical history of asthma will be referred to the physician who manages their 
asthma when:

PEF <80% of the predicted value

ACT score ≤19 because an ACT score ≤19 conveys asthma that may not be adequately 
controlled

Unexpected worsening of asthma is observed or reported at any time during the study
At any study visit, subjects without a medical history of asthma will be referred to an appropriate 
respiratory/asthma specialist physician whenever:
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 65 of 100

Signs and/or symptoms suggestive of asthma are newly observed or reported

Respiratory assessments (i.e., examination, PEF) suggest a decline in the subject’s 
respiratory health
Adverse Events
An AE is defined as any untoward medical occurrence in a clinical study subject administered a 
medicinal product which does not necessarily have a causal relationship with this treatment. An 
AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of a medicinal (investigational) 
product, whether or not it is related to the medicinal (investigational) product. This includes an 
exacerbation of pre-existing conditions or events, intercurrent illnesses, drug interaction, or the 
significant worsening of the indication under investigation that is not recorded elsewhere in the 
eCRF under specific efficacy assessments. 
Note(s): 

Any new sign or symptom reported by the subject that appears after accidental or 
intentional overdose or misuse should be reported as an AE.

Whenever possible, a diagnosis should be reported on the AE form, instead of signs, 
symptoms, or abnormal laboratory values. 

Pregnancy is not to be considered an AE; however, it must be monitored and reported as 
described in Section 12.7.7.

Each worsening of a chronic disease from the baseline visit should be reported as a new 
AE.
The Investigator or designee will report all AEs that occur from the time the ICF is signed until 
the end of the study. The Sponsor/CRO should be informed if the Investigator becomes aware of 
any safety information that appears to be drug related, even after the subject has completed the 
clinical study.
At each post enrollment visit, the Investigator (or Sub-investigator) will question the subject about 
AEs using an open non-persuasive question to elicit reporting of AEs (for example, “Have you 
noticed any change in your health since the last visit?”). Directed questioning and examination 
will then be performed as appropriate. 
Any AE occurring during the AE reporting period, whether it is related to the study drug or not, 
will be recorded immediately in the source document and described on the Adverse Event Form 
(“AE Form”) along with the date of onset, severity, relationship to the study drug(s), and outcome, 
without omitting any requested and known information. Additional information will be requested 
under certain circumstances.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 66 of 100
Adverse events assessed as related to the treatment or study procedure will be monitored until they 
have resolved or reached a stable condition. Other AEs will be monitored until the last visit if they 
have not resolved or reached a stable condition. 
The Investigator will obtain and maintain in the subject’s files all pertinent medical records, 
information and medical judgment from colleagues who assisted in the treatment and follow-up of 
the subject. If necessary, the Investigator will contact the subject’s personal physician or hospital 
staff to obtain further details.
Assessment of Severity
Each AE will be assigned a category by the Investigator as follows:
Mild:
An AE that is easily tolerated by the subject, causes minimal discomfort, and does 
not interfere with everyday activities.
Moderate:
An AE that is sufficiently discomforting to interfere with normal everyday 
activities; intervention may be needed.
Severe:
An AE that prevents normal everyday activities; treatment or other intervention 
usually needed.
If there is a change in severity of an AE, it must be recorded as a separate event.
Assessment of Causality
The Investigator is to determine whether there is a reasonable causal relationship between the 
occurrence of the AE, and exposure to the study drug (i.e., nemolizumab or placebo) and/or study 
procedure (e.g., injection, blood sample collection). Medical judgment should be used to determine 
the relationship, considering all relevant factors including the pattern of the reaction, temporal 
relationships, relevant medical history, and confounding factors such as co-medication or 
concurrent diseases.
The expression “reasonable causal relationship” is meant to convey in general that there are facts 
or arguments to suggest a causal relationship (International Council for Harmonisation [ICH] E2A, 
Section IIIA 1).
The relationship assessment for an AE is to be completed using the following definitions as a 
guideline for all AEs occurring during this clinical study:
Reasonable Possibility:
According to the reporting Investigator, there is a reasonable possibility (i.e., suggestive evidence 
or arguments) that there is a causal relationship irrespective of the dose administered:

Between the study drug (nemolizumab) and the AE, and/or

Between the clinical study protocol procedure (e.g., injection, blood sample collection) and 
the AE
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 67 of 100
No Reasonable Possibility:
No suggestive evidence or arguments can be identified regarding a causal relationship between the 
study drug or the clinical study protocol procedure and the AE.
Action Taken
The Investigator will describe the action taken in the appropriate section of the eCRF, as follows:

None

Study drug stopped

Study drug temporarily interrupted

Concomitant medication (any additions or discontinuations)

Other, specify
Follow-up of Adverse Events
All Investigators should follow-up with subjects with AEs until the event is resolved or until, in 
the opinion of the Investigator, the event is stabilized or determined to be chronic. Details of AE 
resolution must be documented in the eCRF.
Subjects should be followed up for 12 weeks (±7 days) after receiving the last dose of study drug, 
and any AEs that occur during this time should be reported according to the procedures outlined 
above.
Documentation and Reporting of Adverse Events
Adverse events should be reported and documented in accordance with the procedures outlined 
below. All AEs occurring during the study must be documented on the relevant eCRF pages. The 
following data should be documented for each AE:

Description of the symptom event

Classification of “serious” or “not serious”

Severity

Date of first occurrence and date of resolution (if applicable)

Action taken

Causal relationship

Outcome of event (unknown, recovered, not yet recovered, recovered with sequelae, and 
death [with date and cause reported])
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 68 of 100
Adverse Events of Special Interest
An AESI is a noteworthy treatment-emergent event for the study drug that should be monitored 
closely and reported promptly. See Section 12.7.5 for reporting procedure(s). An AESI can be 
either serious or nonserious.
Based on the potential risks of nemolizumab and the risks associated with biologics (and their 
biosimilar equivalents) in general (i.e., class effects), the following AEs will be considered AESIs:

Injection-related reactions 
o
Anaphylactic reactions
o
Acute allergic reactions requiring treatment
o
Severe injection site reaction (i.e., lasting >24 hours)

Newly-diagnosed asthma or worsening of asthma
o
More specifically, subjects with a medical history of asthma will be referred to the 
physician who manages their asthma when:

ACT score ≤19: An ACT score ≤19 conveys asthma that may not be 
adequately controlled. An AESI is reported based on the Investigator’s 
clinical judgment, including consideration of the managing physician’s 
report.

PEF <80% of the predicted value: An AESI is to be reported based on the 
investigator’s clinical judgment, including consideration of the managing 
physician’s report.

Unexpected worsening of asthma is observed or reported. An AESI is 
reported based on the Investigator’s clinical judgment.
o
Subjects without a medical history of asthma will be referred to an appropriate 
respiratory physician/specialist when:

Signs and/or symptoms suggestive of asthma have been observed or 
reported. An AESI is reported based on the Investigator’s clinical judgment 
of the specialist’s report.

Respiratory assessments (i.e., examination, PEF) suggest a decline in the 
subject’s respiratory health. An AESI is reported based on the Investigator’s 
clinical judgment of the specialist’s report.

Infections
o
Any severe infection or any infection requiring treatment with parenteral antibiotics 
or oral antibiotics/antivirals/antifungals for >2 weeks
o
Any confirmed or suspected COVID-19 infection (Section 8.3.2)

Peripheral edema: limbs, bilateral

Facial edema

Elevated ALT or AST (>3 × ULN) in combination with elevated bilirubin (>2 × ULN)
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0




Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 70 of 100
Note: Immediate SAE reporting is required by the Investigator if it occurs during the clinical 
study or within 12 weeks (±7 days) of receiving the last dose of study drug, whether or not the 
event is considered to be related to the investigational product.
The demographics, medical history, drugs/therapies, and medical and surgical procedures 
forms must also be available for review in the eCRF, at that time.
3. Send any relevant information or anonymized medical records (e.g., laboratory test results) to 
the 
see contact details above), within 
24 hours of receipt of this relevant information.
4. Monitor and record the progress of the event until it resolves or reaches a stable condition, with 
or without sequelae. For all additional follow-up evaluations, complete an updated SAE report 
within 24 hours of receipt of the updated information.
5. Obtain and maintain in the subject files all pertinent medical records, information, and medical 
judgments from colleagues who participate in the treatment and follow-up of the subject. If 
necessary, contact the subject’s personal physician or hospital staff to obtain further details.
6. When the outcome of the event is known, complete an updated SAE report, if appropriate.
7. Prompt notification of SAEs by the Investigator is essential so that legal obligations and ethical 
responsibilities toward the safety of subjects are met. The Sponsor has a legal responsibility to 
notify both the local regulatory authority and other regulatory agencies about the safety of a 
product under clinical investigation. The Sponsor or its delegate (i.e., the CRO) will comply 
with country-specific regulatory requirements relating to safety reporting to regulatory 
authorities, institutional review board (IRB)/independent ethics committee (IEC) and 
Investigators. Investigator safety reports are prepared for suspected unexpected serious adverse 
reactions (SUSARs) according to local regulatory requirements and are forwarded to 
Investigators as necessary.
An Investigator who receives an Investigator safety report describing a SAE(s) or other specific 
safety information (e.g., summary or listing of SAEs) from the Sponsor or its delegate (i.e., the 
CRO) will file it accordingly (i.e., within the Trial Master File), and will notify the IRB/IEC, 
if appropriate according to local requirements.
8. Comply with the applicable regulatory requirement(s) related to the reporting of SAEs to the 
IRB/IEC.
Procedure for Reporting Adverse Events of Special Interest
For any AESI occurring during the clinical study, regardless of whether or not related to the 
treatment, the Investigator must:
1. Take prompt and appropriate medical action, if necessary. The safety of subjects is the first 
priority.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0
CCI


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 71 of 100
2. Ensure that the event is evaluated as an AESI. Notify (within 3 days of receipt of the event) 
the 
 of an AESI report, by email or fax. 
Refer to Section 12.7.4.
Note: AESI reporting is required by the Investigator if it occurs during the clinical study 
following the first dose of study drug or within 12 weeks (±7 days) of receiving the last dose 
of study drug, whether or not the event is considered to be related to the investigational product.
The demographics, medical history, drugs/therapies, and medical and surgical procedures 
forms must also be available for review in the eCRF, at that time.
3. Send any relevant information or medical records (e.g., laboratory test results) to the 
 within 3 days of receipt of this relevant 
information.
4. Monitor and record the progress of the event until it resolves or reaches a stable condition, 
with or without sequelae. For all additional follow-up evaluations, update the AESI report 
within 3 days of receipt of the updated information.
5. Obtain and maintain in the files all pertinent medical records, information, and medical 
judgments from colleagues who participate in the treatment and follow-up of the subject. If 
necessary, contact the subject’s personal physician or hospital staff to obtain further details.
6. When the outcome of the event is known, update the AESI report, if appropriate.
Suspected Unexpected Serious Adverse Reactions
AEs that meet all of the following criteria will be classified as SUSARs and reported to the 
appropriate regulatory authorities in accordance with applicable regulatory requirements for 
expedited reporting:

serious

unexpected (i.e., the event is not consistent with the Reference safety information in the 
IB)

there is at least a reasonable possibility for a causal relationship between the event and the 
study treatment
The Investigator will assess whether an event is causally related to study treatment. The Sponsor 
will consider the Investigator’s assessment and determine whether the event meets the criteria for 
being reportable as a 7-day or 15-day safety report. SUSARs that are fatal or life-threatening must 
be reported to the regulatory authorities and the IEC/IRBs (where required) within 7 days after the 
Sponsor (or 
) has first knowledge of them, with a follow-up report submitted within 
a further 8 calendar days. Other SUSARs must be reported to the relevant regulatory authorities 
and the IEC/IRBs within 15 calendar days after the Sponsor (or 
 first has knowledge 
of them.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0
CCI
CCI
CCI
CCI


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 72 of 100
The Sponsor (or 
 is responsible for reporting SUSARs and any other events 
required to be reported in an expedited manner to the regulatory authorities and for informing 
Investigators of reportable events, in compliance with applicable regulatory requirements within 
specific timeframes. Investigators will notify the relevant IEC/IRBs of reportable events within 
the applicable timeframes, according to local requirements.
Procedures for Reporting Pregnancy
Women of childbearing potential must have a negative pregnancy test result at baseline. Following 
administration of study drug, any known cases of pregnancy in female subjects will be reported 
until the subject completes or withdraws from the study. 
Any pregnancy occurring during clinical studies where the fetus could have been exposed to the 
study drug must be monitored until its outcome in order to ensure the complete collection of safety 
data. If a subject becomes pregnant, the Investigator must:
1. Withdraw the subject from the clinical study. The subject must not receive any more injections 
of the study drug.
2. Complete as fully as possible the Pregnancy Surveillance Form – Part I: History and Start of 
Pregnancy. Send by email or fax along with the exit form within 24 hours of receipt of the 
information, to the 
. Refer to 
Section 12.7.4.
Note: Immediate pregnancy reporting is required by the Investigator if it occurs during the 
clinical study or within 12 weeks (±7 days) of receiving the last dose of study drug, whether 
or not the event is considered to be related to the investigational product.
3. Monitor and record the progress of the pregnancy until its outcome. Contact the subject’s 
regular physician (general practitioner or gynecologist) or hospital staff to obtain further details 
and ask for regular follow-up information.
4. Provide tri-monthly updates until the final outcome of the pregnancy, by completing the 
Pregnancy Surveillance Form – Part II: Course and Outcome of Pregnancy. For all additional 
follow-up evaluations, send the form by email or fax to the 
 
 within 24 hours of receipt of the information. If the subject can no 
longer be reached (i.e., lost to follow-up), documentation of the non-response/contact with 
2 phone calls and a letter (certified with return receipt) is required.
5. At the outcome of the pregnancy, complete as fully as possible the Pregnancy Surveillance 
Form – Part II: Course and Outcome of Pregnancy. Print and send the form by email or fax to 
the 
 within 24 hours of receipt of the 
information.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0
CCI
CCI
CCI
CCI


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 73 of 100
6. If the pregnancy leads to an abortion (i.e., voluntary abortion, spontaneous abortion, or 
therapeutic abortion), in utero death or congenital anomaly, follow the procedure for 
declaration of/reporting an SAE (see Section 12.7.4).
Overdose
Study drug overdose is the accidental or intentional use of the drug in an amount higher than the 
dose being studied. The Investigator must immediately notify the Medical Monitor of any 
occurrence of overdose with study drug.
An IDMC will review and monitor subject safety throughout the study. The IDMC will provide 
recommendations on the safety of subjects. The IDMC charter will provide details on the IDMC, 
including the plan of analysis for IDMC outputs; the composition of the IDMC; and the procedures, 
roles, responsibilities, and communications.
An IAC will review all asthma-related AEs throughout the study. The IAC charter will provide 
details on the IAC, including the plan of analysis for IAC outputs; the composition of the IAC; 
and its procedures, roles, responsibilities, and communications.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 74 of 100
13
OTHER ASSESSMENTS
13.1 Proof of Exposure
Blood Samples
Blood samples for proof of nemolizumab systemic exposure (POE) will be collected at the time 
points indicated in the Schedule of Assessments (Table 7) and the clinical laboratory manual. At 
each sampling time point for POE assessments, the collected blood will be placed to clot at room 
temperature (no more than 60 minutes after collection) and then centrifuged. The serum will be 
collected into storage tubes. 
As a guideline, POE samples should be collected at approximately the same time of day throughout 
the study, to the extent possible, before study drug injection (pre-dose samples). The date and the 
time of each sample collection will be recorded in the eCRF, with the time of study drug injection 
at the same visit (or missed injection if applicable).
CD14152 Quantification in Biological Sampling
Concentration of nemolizumab (CD14152) in the serum will be determined by the designated CRO 
using a validated enzyme-linked immunosorbent assay method (lower limit of quantification 
[LLOQ]: 100ng/mL). Details related to the processing of serum samples and the assessments of 
nemolizumab will be described in the bioanalytical plan, which will be finalized before the 
beginning of sample analysis. Results will be described in the bioanalytical report, which will be 
included as an appendix in the final clinical study report.
13.2 Immunogenicity Analysis
Blood samples will be collected at the time points indicated in the Schedule of Assessments 
(Table 7) and the clinical laboratory manual to assess anti-nemolizumab ADA.
The ADA will be determined by the designated CRO using a multi-tiered testing approach. A 
sensitive screening assay will first be used to assess clinical samples. Positive samples in the initial 
screening assay will be subjected to a confirmatory assay to demonstrate that ADA are specific for 
nemolizumab and not a result of non-specific interactions. Samples identified as positive in the 
confirmatory assay will be further characterized in 2 other assays, titering and neutralization 
antibody (Nab) assays. 
Details related to the processing of serum samples and the assessments of ADA will be described 
in the bioanalytical plan, which will be finalized before the beginning of sample analysis. Results 
will be described in the bioanalytical report, which will be included as an appendix in the final 
clinical study report.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 75 of 100
14 STATISTICAL ANALYSIS
A statistical analysis plan (SAP) will be prepared after the protocol is approved. This document 
will provide further details regarding the definition of analysis variables and analysis methodology 
to address all study objectives. The SAP will serve as a compliment to the protocol and supersedes 
it in case of differences.
The statistical evaluation will be performed using SAS® software version 9.4 or higher 
(SAS Institute, Cary, NC). All data will be listed. All primary and secondary efficacy endpoints, 
and safety endpoints will be summarized.  Summary statistics will be presented by treatment group 
and dose regimen. For continuous variables, data will be summarized with the number of subjects
(N), mean, standard deviation, median, minimum, and maximum by treatment group and dosing 
regimen. For categorical variables, data will be tabulated with the number and proportion of 
subjects for each category by treatment group and dosing regimen. For time-to-event, data will be 
summarized using Kaplan-Meier method. 
14.1 Determination of Sample Size
No formal sample size calculations were performed for this study. The sample size will be based 
on the sample size and the actual response rate of the LTE study. Based on the current assumption, 
it is expected that approximately 40 subjects will be randomized.
14.2 Analysis Populations
Intent-to-Treat Population
The intent-to-treat (ITT) population will consist of all randomized subjects. All primary and 
secondary efficacy endpoints will be analyzed based on the ITT population. All analyses on the 
ITT population will be analyzed under the treatment group “as randomized”. 
Safety Population
The safety population will comprise all randomized subjects who receive at least 1 dose of study 
drug. All safety data will be summarized based on the safety population under the treatment group 
“as treated”.
Proof of Exposure Analysis Population
The POE analysis population will include all subjects in the safety population who provide at least 
1 measurable post-baseline evaluable drug concentration value. 
Per-Protocol Population
The per-protocol population will comprise all subjects in the ITT population who have no major 
protocol deviations that would have a significant effect on the efficacy of the study treatment. Only 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 76 of 100
primary and selected secondary efficacy endpoints will be analyzed using the per-protocol 
population, as defined in the SAP.
14.3 Efficacy Analysis
A summary based on observed case (OC) will be provided for all primary and secondary efficacy 
endpoints. For OC, no data will be imputed. 
Analysis of Primary Efficacy Endpoint
The primary endpoint is the time to relapse which is defined as meeting at least 1 of the following 
criteria:

Increase in (weekly average of the) PP NRS score ≥4 points from baseline

Increase in IGA score ≥2 points from baseline
The estimand of primary endpoint is shown in Table 8. Treatment interruption and use of 
prohibited medication are considered as intercurrent events.
Table 8.
Estimand of Primary Endpoint
Treatment
Population
Endpoint
Intercurrent 
events
Summary 
measure
Randomized 
treatment with 
subcutaneous 
injections of 
nemolizumab or 
placebo at Week 
0, 4, 8, 12, 16 and 
20
All randomized 
subjects (intent-
to-treat 
population)
Time to relapse 
meeting at least 1 
of the defined 
criteria
Time to relapse 
will be censored 
at the last 
observation prior 
to treatment 
discontinuation or 
use of prohibited 
medication
Hazard ratio of 
nemolizumab and 
placebo
As the primary analysis, the time to relapse will be analyzed using Cox proportional hazard model 
with treatment group, dosing regimen as a factor, and baseline PP NRS score and IGA score as 
covariates. The estimated hazard ratio and the corresponding 95% CI will be presented. If the 
assumption of proportionality is not met, other appropriate methods will be used and documented 
in the SAP.
In addition, Kaplan-Meier survival plots will be presented for time to relapse. The median time, 
25th and 75th percentiles, and the corresponding CI will be reported.
If a subject withdraws from the study, takes prohibited medication, or completes the study without 
any relapse, time to relapse response will be censored respectively at the time of the last efficacy 
assessment (PP NRS and IGA) prior to study withdrawal, use of prohibited medication, or the 
completion of the study. If a subject has no efficacy assessment after randomization, then time to 
relapse will be censored at Day 1.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 77 of 100
For the purpose of efficacy analysis, subjects receiving any prohibited therapies will be censored 
from the primary analysis. 
As a supporting analysis, the time to relapse will also be analyzed using the same methods in the 
per-protocol population. 
Analysis of Secondary Efficacy Endpoints
The following binary efficacy endpoints will be analyzed using a Cochran-Mantel-Haenszel test 
adjusted for dosing regimen based on OC and imputation with missing efficacy response 
considered as the non-responder (i.e., IGA success) and missing relapse response considered as a 
relapse (i.e., increase in PP NRS or IGA): 

Proportion of subjects with increase in PP NRS score ≥2 points from baseline at each 
scheduled visit

Proportion of subjects maintaining IGA success, defined as IGA score of 0 (clear) or 
1 (almost clear) at each scheduled visit

Proportion of subjects with increase in IGA ≥2 points from baseline at each scheduled visit
The estimate of treatment difference (nemolizumab minus placebo), the corresponding 2-sided 
95% CI, and p-values will be presented.
The following continuous efficacy endpoints will be analyzed using analysis of covariance 
(ANCOVA) based on OC with treatment group and dose regimen as factors, and baseline value as 
the covariate. They will also be analyzed using the mixed effect model for repeated measure 
(MMRM) approach, including treatment group and dose regimen as factors, visit, interaction term 
between treatment and visit, and the corresponding baseline value as independent covariate.

Absolute and percent change from baseline in PP NRS at each scheduled visit

Absolute and percent change from baseline in SD NRS at each scheduled visit

Change from baseline in DLQI at Week 16 and Week 24
The multiple imputation methods may be used as sensitivity analysis for some selected secondary 
efficacy endpoints.
14.4 Safety Analysis
Extent of Exposure
The duration of exposure will be summarized by treatment and dosing regimen. The number of 
subjects exposed to study medication will be summarized by visit, treatment group, and dosing 
regimen. 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 78 of 100
Adverse Events
All reported AEs will be coded using the most recent version of Medical Dictionary for Regulatory 
Activities (MedDRA). Treatment-emergent AEs, defined as those AEs occurring after the first 
administration of study treatment until the end of the follow-up period, will be tabulated in 
frequency tables by system organ class and preferred term. These TEAEs may also be reported 
separately for treatment period and follow-up period. Additional summary tables will be provided 
for SAEs, treatment-related AEs (reasonable possibility, no reasonable possibility), AESIs, and 
AEs leading to treatment discontinuation. For a given AE, a subject will be counted once even if 
he/she has experienced multiple episodes of that particular AE. 
Clinical Laboratory
Laboratory data (absolute values and change from baseline) will be summarized by visit, treatment 
group and dosing regimen. In addition, the number and percentage of subjects below, within, and 
above the laboratory reference ranges, and the number and percentage of subjects who met criteria 
of potential clinically significant value will be summarized by visit, treatment group, and dosing 
regimen. Shift tables will be generated using the reference ranges. Reference ranges will be 
provided in the laboratory manual.
Vital Signs 
All vital signs (absolute values and change from baseline) will be summarized by visit, treatment 
group, and dose regimen. In addition, the number and percent of subjects with clinically significant 
abnormal values (of clinical concern as identified by the Investigator) will be summarized by visit, 
treatment group, and dosing regimen.
12-Lead ECG
The number and percentage of subjects who have ECGs that are abnormal/clinically significant 
and abnormal/not clinically significant will be displayed by visit, treatment, and dosing regimen.
Respiratory Assessments
The results (absolute values and change from baseline) of PEF testing and respiratory examination 
will be summarized by visit, treatment group, and dose regimen. ACT for subjects with a medical 
history of asthma or newly-diagnosed asthma will be listed.
Concomitant Therapies and Procedures 
Concomitant therapies will be coded according to the most recent version of the World Health 
Organization (WHO) Drug Dictionary Enhanced for Concomitant Medication.  Concomitant 
therapies and procedures will be summarized.
Summary tables will be provided for concomitant medications initiated during the study period.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 79 of 100
14.5 Proof of Exposure and Anti-Drug Antibody Analysis
The nemolizumab serum concentration and ADA will be summarized by visit in the POE analysis 
population. 
For serum concentrations (POE), descriptive statistics will include arithmetic and geometric mean, 
standard deviation, coefficient of variation [%CV], median, minimum, maximum. A 95% 
confidence interval [CI] of mean and number of Below Limit of Quantifications will be presented. 
Any potential exposure-safety relationship will also be explored. Below Limit of Quantifications 
will be considered as missing and excluded from the descriptive summary.
For ADA analyses, the incidence of positive ADA results will be summarized (absolute 
occurrence, percent of subjects, and treatment-related ADA). A presentation of ADA results will 
be detailed in the SAP.
14.6 Interim Analysis 
An interim analysis may be conducted for the submission of the regulatory registration of 
nemolizumab. To maintain blinding, the interim analysis would be carried out by an independent 
group who are not directly involved in the conduct of the trial.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 80 of 100
15
STUDY MANAGEMENT
15.1 Approval and Consent
Regulatory Guidelines
This study will be conducted in accordance with the accepted version of the Declaration of 
Helsinki and/or all relevant regulations, as set forth in Parts 50, 56, 312, Subpart D, of Title 21 of 
the US Code of Federal Regulations (CFR), in compliance with ICH and Good Clinical Practice 
(GCP) guidelines, and according to the appropriate regulatory requirements in the countries where 
the study is conducted.
Institutional Review Board/Independent Ethics Committee
Conduct of the study must be approved by an appropriately constituted IEC/IRB. Approval is 
required for the study protocol, protocol amendments (if applicable), IB, ICFs, recruitment 
material, and subject information sheets and other subject-facing material.
Informed Consent
For each study subject, written informed consent will be obtained before any protocol-related 
activities. As part of this procedure, the Principal Investigator (PI) or designee must explain orally 
and in writing the nature of the study, its purpose, procedures, expected duration, alternative 
therapy available, and the benefits and risks involved in study participation. The subject should be 
informed that he/she may withdraw from the study at any time, and the subject will receive all 
information that is required by local regulations and guidelines for ICH. The PI will provide the 
Sponsor or its representative with a copy of the IEC-/IRB-approved ICF before the start of the 
study.
15.2 Data Management
The designated CRO will be responsible for activities associated with the data management of this 
study. This will include, but is not limited to, setting up a relevant database and data transfer 
mechanisms, along with appropriate validation of data and resolution of queries. All data 
management activities will be detailed in the data management plan.
Study centers will enter data directly into an EDC system by completing the eCRF via a secure 
internet connection. Data entered into the eCRF must be verifiable against source documents at 
the study center. Data to be recorded directly on the eCRF will be identified and the eCRF will be 
considered the source document. Any changes to the data entered into the EDC system will be 
recorded in the audit trail.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 81 of 100
15.3 Source Documents
Source documents are considered to be all information in original records and certified copies of 
original records of clinical findings, observations, data, or other activities in a clinical study 
necessary for the reconstruction and evaluation of the study. The Investigator will provide direct 
access to source documents and/or source data in the facilitation of trial-related monitoring, audits, 
review by IECs/IRBs, and regulatory inspections.
The Investigator/institution should maintain adequate and accurate source documents and trial 
records that include all pertinent observations on each of the study center’s trial subjects. Source 
data should be attributable, legible, contemporaneous, original, accurate, and complete. Changes 
to source data should be traceable, not obscure the original entry, and be explained if necessary.
Sponsor monitors, auditors, and regulatory inspectors should have direct access to source data.
15.4 Record Retention
Study records and source documents must be preserved for at least 15 years after the completion 
or discontinuation of/withdrawal from the study, at least 2 years after the drug being studied has 
received its last approval for sale, or at least 2 years after the drug development has stopped, and 
in accordance with the applicable local privacy laws, whichever is the longer period.
The Investigator agrees to comply with all applicable federal, state, and local laws and regulations 
relating to the privacy of subject health information, including, but not limited to, the Standards 
for Individually Identifiable Health Information, 45 CFR, Parts 160 and 164 (Health Insurance 
Portability and Accountability Act [HIPAA] Privacy Regulation). The Investigator shall ensure 
that study subjects authorize the use and disclosure of protected health information in accordance 
with HIPAA Privacy Regulation and in a form satisfactory to the Sponsor.
15.5 Monitoring
The study will be monitored according to the monitoring plan to ensure that it is conducted and 
documented properly according to the protocol, GCP, and all applicable regulatory requirements.
Monitoring visits and contacts will be made at appropriate times during the study. The PI will 
assure he/she and adequate study center personnel are available throughout the study to collaborate 
with clinical monitors. Clinical monitors must have direct access to source documentation in order 
to check the completeness, clarity, and consistency of the data recorded in the eCRFs for each 
subject.
The Investigator will make available to the clinical monitor all source documents and medical 
records necessary to review protocol adherence and eCRFs. In addition, the Investigator will work 
closely with the clinical monitor and, as needed, provide them appropriate evidence that the study 
is being conducted in accordance with the protocol, applicable regulations, and GCP guidelines.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 82 of 100
See Appendix 1 for additional guidance for management of subjects and study conduct during the 
COVID-19 pandemic.
15.6 Quality Control and Quality Assurance
The Sponsor or its designee will perform the quality assurance and quality control activities of this 
study; however, responsibility for the accuracy, completeness, security, and reliability of the study 
data presented to the Sponsor lies with the Investigator generating the data.
The Sponsor will arrange audits as part of the implementation of quality assurance to ensure that 
the study is being conducted in compliance with the protocol, standard operating procedures, GCP, 
and all applicable regulatory requirements. Audits will be independent of and separate from the 
routine monitoring and quality control functions. Quality assurance procedures will be performed 
at study centers and during data management to assure that safety and efficacy data are adequate 
and well documented.
15.7 Protocol Amendment and Protocol Deviation
Protocol Amendment
Amendments to the protocol that entail corrections of typographical errors, clarifications of 
confusing wording, changes in study personnel, and minor modifications that have no effect on 
the safety of subjects or the conduct of the study will be classed as administrative amendments and 
will be submitted to the IEC/IRB for information only. The Sponsor will ensure that 
acknowledgment is received and filed. Amendments that are classed as substantial amendments 
must be submitted to the appropriate regulatory authorities and the IECs/IRBs for approval and 
will not be implemented at study centers until such approvals are received other than in the case 
of an urgent safety measure.
Protocol Deviations
Should a protocol deviation occur, the Sponsor must be informed as soon as possible. Protocol 
deviations and/or violations and the reasons they occurred will be included in the clinical study 
report. Protocol deviations will be reported to the IRB/IEC and in accordance with applicable 
regulatory authority mandates. 
Changes that involve only logistical or administrative changes to the clinical study protocol are 
authorized. The Investigator should document and explain any deviation from the clinical study 
protocol. Major deviations are categorized into the following categories:

Eligibility deviations (inclusion/exclusion criteria)

Improper reconstitution and administration of study medication

Non-compliance with study medication per the Investigator’s discretion
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 83 of 100

Non-compliance with study procedures if the consequence of non-compliance would 
compromise either the subject’s safety and/or the study integrity, primary endpoint, and/or 
is not in line with GCP/ICH guidelines

Use of prohibited concomitant therapies

Visit/treatment windows (i.e., if a study visit occurs outside the visit window defined in 
the Schedule of Assessments)
All protocol deviations will be identified, evaluated, and closed before the respective database lock 
(final analysis) and will be described in the clinical study report. Protocol deviations incurred as a 
direct result of the COVID-19 pandemic should be specifically recorded as a COVID-19 deviation. 
Further details of protocol deviations will be provided in the Protocol Deviation and 
Non-Compliance Management Plan.
15.8 Ethical Considerations
This study will be conducted in accordance with this protocol, the accepted version of the 
Declaration of Helsinki and/or all relevant federal regulations, as set forth in Parts 50, 56, 312, 
Subpart D, of Title 21 of the CFR; EU 536/2014, Annex 1, D, 17 (a); and in compliance with GCP 
guidelines.
IECs/IRBs will review and approve this protocol and the ICF. All subjects are required to give 
written informed consent before participation in the study.
15.9 Financing and Insurance
Before the study commences, the Sponsor (or its designee) and the Investigator (or the institution, 
as applicable) will agree on costs necessary to perform the study. This agreement will be 
documented in a financial agreement that will be signed by the Investigator (or the institution 
signatory) and the Sponsor (or its designee).
The Investigator is required to have adequate current insurance to cover claims for negligence 
and/or malpractice. The Sponsor will provide no-exclusion insurance coverage for the clinical 
study as required by national regulations.
15.10 Publication Policy/Disclosure of Data
Both the use of data and the publication policy are detailed within the clinical study agreement. 
Intellectual property rights (and related matters) generated by the Investigator and others 
performing the clinical study will be subject to the terms of a clinical study agreement that will be 
agreed between the institution and the Sponsor or their designee. With respect to such rights, the 
Sponsor or its designee will solely own all rights and interests in any materials, data, and 
intellectual property rights developed by Investigators and others performing the clinical study 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 84 of 100
described in this protocol, subject to the terms of any such agreement. In order to facilitate such 
ownership, Investigators will be required to assign all such inventions either to their institution or 
directly to the Sponsor or its designee, as will be set forth in the clinical study agreement.
15.11 Subject Confidentiality
Monitors, auditors, and other authorized agents of the Sponsor and/or its designee, the IEC(s) 
approving this research, as well as that of any other applicable agency(ies), will be granted direct 
access to the study subjects’ original medical records for verification of clinical study procedures 
and/or data, without violating the confidentiality of the subjects to the extent permitted by the law 
and regulations. In any presentations of the results of this study or in publications, the subjects’ 
identities will remain confidential.
All personal data collected and processed for the purposes of this study should be managed by the 
Investigator and his/her staff with adequate precautions to ensure confidentiality of those data, and 
in accordance with the applicable national and/or local laws and regulations on personal data 
protection.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 85 of 100
16 REFERENCES
1. Hyde JN. Prurigo nodularis. In: Hyde JN, Montgomery FH, eds. A Practical Treatise on 
Diseases of the Skin for the Use of Students and Practitioners. 8th ed. Lea & Febiger, 
1909;174-175.
2. Bobko S, Zeidler C, Osada N, et al. Intraepidermal nerve fibre density is decreased in 
lesional and inter-lesional prurigo nodularis and reconstitutes on healing of lesions. Acta 
Derm Venereol. 2016;96(3):404-406. doi:10.2340/00015555-2232
3. Warlich B, Fritz F, Osada N, et al. Health-related quality of life in chronic pruritus: An 
analysis related to disease etiology, clinical skin conditions and itch intensity. Dermatology. 
2015;231(3):253-259. doi:10.1159/000437206
4. Iking A, Grundmann S, Chatzigeorgakidis E, Phan NQ, Klein D, Ständer S. Prurigo as a 
symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 
108 patients. J Eur Acad Dermatol Venereol. 2013;27(5):550-557. doi:10.1111/j.1468-
3083.2012.04481.x
5. Huang AH, Canner JK, Khanna R, et al. Real-world prevalence of prurigo nodularis and 
burden of associated diseases. J Invest Dermatol. 2020;140(2):480-483.
6. Zeidler C, Ständer S. The pathogenesis of prurigo nodularis–‘super-itch’ in exploration. Eur 
J Pain. 2016;20(1):37-40. doi:10.1002/ejp.767
7. Ständer S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of 
the International Forum for the Study of Itch. Acta Derm Venereol. 2007;87(4):291-294. 
doi:10.2340/00015555-0305
8. Fostini AC, Girolomoni G, Tessari G. Prurigo nodularis: an update on etiopathogenesis and 
therapy. J Dermatol Treat. 2013;24(6):458-462. doi:10.3109/09546634.2013.814759
9. Weisshaar E, Szepietowski JC, Darsow U, et al. European guideline on chronic pruritus. Acta 
Derm Venereol. 2012;92(5):563-581. doi:10.2340/00015555-1400
10. Berth-Jones J, Smith SG, Graham-Brown RA. Nodular prurigo responds to cyclosporine. Br 
J Dermatol. 1995;132(5):795-799. doi:10.1111/j.1365-2133.1995.tb00729.x
11. Mazza M, Guerriero G, Marano G, Janiri L, Bria P, Mazza S. Treatment of prurigo nodularis 
with pregabalin. J Clin Pharm Ther. 2013;38(1):16-18. doi:10.1111/jcpt.12005
12. Andersen TP, Fogh K. Thalidomide in 42 patients with prurigo nodularis Hyde. 
Dermatology. 2011;223(2):107-112. doi:10.1159/000331577
13. Brune A, Metze D, Luger TA, Ständer S. Antipruritic therapy with the oral opioid receptor 
antagonist naltrexone. Open, non-placebo controlled administration in 133 patients. Article in 
German. Hautarzt. 2004;55(12):1130-1136. doi:10.1007/s00105-004-0802-8
14. Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin 
receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5(6):e10968. 
doi:10.1371/journal.pone.0010968
15. Horiuchi Y, Bae S, Katayama I. Uncontrollable prurigo nodularis effectively treated by 
roxithromycin and tranilast. J Drugs Dermatol. 2006;5(4):363-365.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 86 of 100
16. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T-cells and pruritus in 
atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411-417. 
doi:10.1016/j.jaci.2005.10.033
17. Nemolizumab (CD14152/CIM331) Investigator’s brochure. Version R14. Galderma S.A.; 
2022.
18. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes 
and forced ventilatory flows. Eur Respir J. 1993;6 Suppl 16:5-40. 
doi:10.1183/09041950.005s1693
19. Polgar G, Weng TR. The functional development of the respiratory system from the period of 
gestation to adulthood. Am Rev Respir Dis. 1979;120(3):625-695. 
doi:10.1164/arrd.1979.120.3.625
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 87 of 100
17 APPENDICES
Appendix 1
Specific Guidance for Study Conduct and Subject Safety during the 
Coronavirus Disease 2019 (COVID 19) Pandemic
This guidance applies during the COVID-19 pandemic, as defined by regional and/or local 
authorities. The updates summarized below are relevant to the referenced sections of the protocol.
Section 5.3 Risk/Benefit Assessment
During the COVID-19 pandemic, additional risks to participants may exist, including general 
environmental risks (e.g., being outside of the home, possible contact with unsanitized surfaces) 
and study-related activities (e.g., interaction with study staff). Potential new subjects with known 
or suspected COVID-19 infection are ineligible for study enrollment until the infection has 
resolved. Furthermore, potential new subjects in a high-risk population for COVID-19 (e.g., 
60 years and older or with comorbidities), should be temporarily deferred until the COVID-19 risk 
has subsided at the location of the enrolling site, according to Investigator judgment. Risk 
mitigation measures to be implemented for enrolled subjects and for new subjects during the 
COVID-19 pandemic are detailed in Additional Measures for Subjects Amidst COVID-19 
Pandemic below. Subjects with a known or suspected COVID-19 infection will immediately 
discontinue study drug; instructions for resuming treatment are described in Section 8.3.2. Known 
or suspected COVID-19 infection will also be followed as an AESI.
New Subsection to Section 7.1, Description of Overall Study Design and Plan:
Additional Measures for Subjects Amidst COVID-19 Pandemic
All investigational sites should act according to applicable site regulations, to guidelines and 
restrictions implemented by local authorities, and to best practices for conducting clinical research 
during the COVID-19 pandemic. 
Guidance for New Subjects:
Best practices currently in place must be followed when evaluating eligibility of subjects to 
participate in the study during the COVID-19 pandemic.
For potential subjects in a high-risk population for COVID-19 as defined by the American 
Academy of Dermatology (AAD)1 (e.g., 60 years and older or with comorbidities) or local 
guidelines, deferring participation in the study should be considered. Deferment of enrollment is 
based on the potential risk posed by generic environmental risks (e.g., being outside of the home, 
possible contact with unsanitized surfaces) and study-related activities (e.g., interaction with study 
staff).
For potential subjects in the low-risk population for COVID-19 (e.g., less than 60 years of age and 
without comorbidities), the risks and benefits of participation in the study should be assessed on a 
case-by-case basis. 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 88 of 100
If at baseline, in the opinion of the Investigator, the subject will not be willing and able to reach 
the investigational site and comply with all of the time commitments and requirements of the 
clinical study protocol, the subject should not be considered for enrollment. 
Pre-baseline phone calls should be conducted to exclude potential candidates/subjects who display
possible symptoms of COVID-19 or are at high risk of having been exposed to COVID-19.
Guidance for Enrolled Subjects:
If the local situation allows for subjects to reach the clinical investigational site and complete all
study procedures, the following measures should be taken:
-
Implement and document in the subject records regular communication with 
the subject between visits to attempt to ensure early detection of potential 
signs/symptoms of COVID-19 infection, and provide adequate advice, as per 
local medical practice and public health guidelines for suspected COVID-19 
infection. Please refer to the 
•
Centers for Disease Control and Prevention (CDC) 
https://www.cdc.gov/coronavirus/2019-ncov/symptoms-
testing/symptoms.html
•
European CDC
https://www.ecdc.europa.eu/en/covid-19/questions-answers
•
Local disease prevention agency and applicable local guidelines for 
assessment of subjects’ COVID-19 status
-
Following the same guidelines, implement and document in the subject records 
an additional communication to the subject just before the scheduled visit. 
-
Discontinue study drug administration in case of confirmed or suspected 
COVID-19 infection until the infection is resolved. See Section 8.3.2.
-
Report any COVID-19 infection (confirmed or suspected) as an AE: 
•
if any seriousness criterion is met, also report as an SAE (see 
Section 12.7.4). 
•
if it occurs during the clinical study following the first dose of study drug 
administration, also report as an AESI (see Section 12.7.5).
-
Implement preventive infection control measures against COVID-19 infection 
following local guidelines (e.g., good hygiene practice, clean techniques, and 
use of personal protective equipment such as gloves, goggles, and masks). 
-
Implement preventive measures in handling all subject-facing study-mandated 
assessment devices and parts: 
•
PEF meter device body is to be cleaned after each use, with recommended 
wipes, as per user manual 
•
PEF meter flow sensor is to be disposed of after each set of measurements 
is taken
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 89 of 100
•
Approved bacterial/virus filters may be used; if used, they must be 
disposed of after each set of measurements is taken
•
Offer protective gloves to subjects for use while filling out assessments on 
a tablet and provide training on hygienic removal and disposal of gloves
If the local situation allows for subjects to reach the investigational site and complete only some
study procedures where visit duration needs to be limited, the above measures also apply. All 
assessments should be conducted if possible. Subject-reported assessments that would usually be 
collected on the site tablet (e.g., ACT) may be collected remotely (e.g., completed over the phone), 
as available.
Subjects can be dosed only if, taking into account the local situation and risk of exposure to 
COVID-19, the site considers that:
-
The study drug subcutaneous injection can be performed at the investigational 
site according to the instructions in the protocol, pharmacy manual and IFU, 
including preparation of study drug by an independent pharmacist or other 
qualified personnel.
-
ACT (for subjects with a medical history of asthma or newly-diagnosed 
asthma) and PEF (for all subjects at specified visits and more frequently for 
subjects with a history of asthma or newly-diagnosed asthma) should be 
performed according to the protocol. 

Exceptionally, if sites cannot perform PEF safely on site, the subjects 
should perform it at home prior to the on-site visit, on the same day. 
See section below for remote PEF testing instructions.
-
All other safety assessments are to be performed as per-protocol: physical 
examination, vital signs, ECG, laboratory assessments, pregnancy test, 
monitoring of AEs and concomitant medications. 
-
All missing assessments should be appropriately documented with COVID-19 
recorded as the reason, where applicable.
If the local situation does not allow for subjects to reach the investigational site:
-
See New Subsection to Section 9.4, Dosage Modification: Management of 
Subjects with Missed Doses of Study Drug due to COVID-19 Pandemic
(below) for guidance on further dosing of subjects.
-
Remote collection of data by Investigator or delegate is still to be done for the 
following assessments at the regularly scheduled visit time, by phone or video 
call:

AE collection 

ACT (for subjects with history of asthma or newly-diagnosed asthma) 

Concomitant therapies used

Urine pregnancy test results (for women of childbearing potential)

PEF results
Note: For remote PEF measurements the following should be done:
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 90 of 100

To prepare subjects to do remote PEF measurement at home in case 
it is needed during the course of the study, all subjects should be 
trained on site at baseline visits. 

During the remote visits, subjects can receive additional support (if 
needed) over the phone or video call by site staff when performing
PEF. 

If a subject has a PEF <80% of the predicted value:

Site staff can try to evaluate whether this is due to poor 
technique and ask the subject to repeat the set of 
measurements
-
If the subject’s best PEF measurement is still <80% of the 
predicted value or if there are other concerns regarding the 
subject’s respiratory health, refer to appropriate physician 
and report an AESI depending on the judgment of the 
investigator (see Section 12.7.5)
-
All laboratory samples should be collected at the site and analyzed at the 
central lab. Only in exceptional situations when subject safety cannot be 
assured otherwise and subject cannot reach the site, a local laboratory test (i.e., 
hematology, blood chemistry, urinalysis) can be performed and reported, based 
on Investigator judgment. 

Subject-reported assessments that would usually be collected on 
the site tablet (e.g., ACT) may be completed over the phone, as 
available.
All missing assessments should be appropriately documented with COVID-19 recorded as the 
reason, where applicable.
New Subsection to Section 9.4, Dosage Modification:
Management of Subjects with Missed Doses of Study Drug due to COVID-19 Pandemic
If a subject misses a dose of study drug due to the COVID-19 pandemic, study drug administration 
may be continued. Study drug can be administered provided that there is a minimum 3-week 
interval between injections. If a subject cannot come to a planned visit due to COVID-19, the visit 
should be conducted remotely according to Additional Measures for Subjects Amidst COVID-
19 Pandemic. If a subject misses 3 doses, the Investigator must contact the Sponsor for further 
guidance. Subjects will complete a follow-up visit 12 weeks after the last study drug injection.
15.5 Monitoring
On-site interim monitoring visits may not be feasible during COVID-19 restrictions; therefore, 
remote monitoring will be completed until on-site monitoring can be conducted again. Site 
monitoring activity will comply with the processes documented within the COVID-19 Site 
Management Risk Assessment Form.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 91 of 100
1. https://assets.ctfassets.net/1ny4yoiyrqia/PicgNuD0IpYd9MSOwab47/2461e6c12cd88953632
a13cd68952b71/Guidance_on_medications__10-12-20.pdf
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 92 of 100
Appendix 2
Contraception Guidelines
Women of childbearing potential (WOCBP) must use at least 1 adequate method of contraception 
during the study and for 12 weeks after the last dose of study treatment. 
A woman is considered to be a WOCBP (fertile) following menarche and until becoming 
postmenopausal, unless she is permanently sterile. Permanent sterilization methods include 
hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is 
defined as no menses for 12 months without an alternative medical cause. A high 
follicle-stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or hormonal replacement 
therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is 
insufficient. 
A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy.
Adequate methods of contraception include:

combined (containing estrogen and progestogen) hormonal contraception associated 
with inhibition of ovulation (administration may be oral, intravaginal, or transdermal)

progestogen-only hormonal contraception associated with inhibition of ovulation 
(administration may be oral, injectable, or implantable)

intrauterine device

intrauterine hormone-releasing system

combination of male condom with cap, diaphragm, or sponge with spermicide (double 
barrier methods) 

bilateral tubal ligation or occlusion

bilateral vasectomy (provided that the male partner has a medical assessment of 
surgical success) at least 12 weeks (3 months) before the study

sexual abstinence (defined as refraining from heterosexual intercourse during the entire 
period of risk in relation to the duration of the clinical trial, in line with the preferred 
and usual lifestyle of the subject)
All subjects will be strongly advised that they should not become pregnant while on study 
treatment or for 12 weeks (3 months) after the last dose. A female subject will be advised that she 
must report immediately to the study site for pregnancy testing and appropriate management in the 
event that she may be pregnant.
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 93 of 100
Reference:
1. Heads of Medicines Agencies. Clinical Trial Facilitation Group page. Recommendations 
related 
to 
contraception 
and 
pregnancy 
testing 
in 
clinical 
trials. 
http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf. Published 
September 15, 2014. 
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 94 of 100
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0
CCI


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 95 of 100
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0
CCI


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 96 of 100
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0
CCI


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 97 of 100
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0
CCI


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 98 of 100
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0
CCI


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 99 of 100
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0
CCI


Galderma S.A./Galderma R&D, LLC 
RD.06.SPR.203890
NemolizumabVersion 2.0
This document is confidential.
Page 100 of 100
              
31-Jan-2023 00:00:00
CD14152.RD.06.SPR.203890 Protocol V02 - 12Dec
Approved
3.0
CCI

SAP_001.pdf: 
 
 
This document is confidential. 
SAP Version: 2.0 19-Jan-2024 
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020 
Filing requirements: TMF 
Page 1 of 94 
Statistical Analysis Plan 
 
SAP Text Version Number: Final Version 
SAP Text Date: 19-Jan-2024 
 
Sponsor Name: Galderma S.A./Galderma R&D, LLC 
 
Protocol Number: RD.06.SPR.203890 
Protocol Title: A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect 
and Safety of Nemolizumab for 24 Weeks in Subjects with Prurigo Nodularis  
 
Protocol Version and Date: 
V1.0, 20-Jul-2021 
V2.0, 12-Dec-2022 
V2.0, 22-Mar-2022  For Germany 
V3.0, 12-Dec-2022  For Germany 
 
 
 
Authors: 
 
 
 
 
 
 
 
Notice of Confidential and Proprietary Information: 
The information contained in this document is confidential belonging to Galderma S.A./Galderma R&D, 
LLC. Acceptance of this document constitutes agreement by the recipient that no information contained 
herein will be published or disclosed without prior written authorization from an official of Galderma 
S.A./Galderma R&D, LLC. However, this document may be disclosed to appropriate Institutional Review 
Board and Ethics Committees or duly authorized representatives of a national regulatory authority under 
the condition that they are requested to keep it confidential. In the event of an actual or suspected breach 
of this obligation, 
 should be notified promptly. 
PPD
CCI
CCI
CCI






Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 4 of 94
Table of Contents
Revision History..........................................................................................................................2
Approvals ..................................................................................................................................3
Glossary of Abbreviations...................................................................................................7
Purpose............................................................................................................................12
Study Objectives ..............................................................................................................13
Study Details/Design........................................................................................................14
Endpoints .........................................................................................................................25
Analysis Sets....................................................................................................................27
Estimands ........................................................................................................................29
General Aspects for Statistical Analysis ...........................................................................31


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 5 of 94
Demographic, Other Baseline Characteristics and Medication .........................................36
Efficacy ............................................................................................................................40
Pharmacokinetics.............................................................................................................47
Immunogenicity................................................................................................................48
Safety...............................................................................................................................49


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 6 of 94
Changes from Analysis Planned in Protocol.....................................................................58
Programming Considerations ...........................................................................................59
Quality Control .................................................................................................................65
Index of Tables.................................................................................................................66
Index of Figures................................................................................................................81
Index of Listings ...............................................................................................................82
Appendices ......................................................................................................................85












Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 12 of 94
Purpose
The purpose of this statistical analysis plan (SAP) is to ensure that the data listings, summary tables and 
figures which will be produced, and the statistical methodologies that will be used, are complete and 
appropriate to allow valid conclusions regarding the study objectives. The planned analyses identified in 
this SAP will be included in regulatory submissions and/or future manuscripts. Exploratory analyses not 
identified or defined in this SAP may be performed to support the clinical development program. Any post-
hoc or unplanned analyses performed and not identified in this SAP will be documented in the respective 
clinical study report (CSR).
Responsibilities
 will perform the statistical analyses and is responsible for the production and quality control 
of all tables, figures and listings.
Timings of Analyses
The final analysis may be carried out once all subjects have completed the final study visit or terminate 
early from the study. No personnel directly involved with the conduct of the study shall have access to the 
unblinded data before the completion of the trial in order to avoid introducing bias to the remaining study 
data.
An interim analysis may be conducted for the submission of the regulatory registration of nemolizumab.
An independent data monitoring committee (IDMC) will review and monitor subject safety throughout the 
study, and an independent adjudication committee (IAC) will review all asthma-related adverse events 
throughout the study. Details on the IDMC and IAC, including the plan of analysis for outputs; the 
composition of the committees; and the procedures, roles, responsibilities, and communications are 
provided in the respective IDMC (v1.0, dated 24-Aug-2020) and Appendix 2 of IAC charters (v1.0, dated 
27-Aug-2020).
CCI


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 13 of 94
Study Objectives
Primary Objective
To assess the long-term durability of response over a 24-week period following withdrawal of nemolizumab 
in subjects with Pruigo Nodularis(PN) who previously responded to treatment in the Long-Term Extension 
(LTE) study RD.06.SPR.202699.
Secondary Objectives
To assess the safety of nemolizumab compared to placebo over a 24-week period in subjects with PN who 
previously responded to treatment in the LTE study.


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 14 of 94
Study Details/Design
Brief Description
This is a Phase 3b multicenter, randomized, double-blind, placebo-controlled, parallel-group study to 
evaluate the durability of response and safety of nemolizumab in adult subjects who participated in the 
nemolizumab PN LTE study (RD.06.SPR.202699) and achieved a clinical response (i.e., IGA score of 0 or 
1 and 
-point improvement in weekly average of PP NRS score from baseline of the lead-in study) at 
Week 52 of the LTE study.
Subjects who agree to enroll in this study must do so at the time of completion of the Week 52 visit in the 
LTE study (RD.06.SPR.202699) to prevent any lapse in study treatment. After the Week 52 visit of the LTE 
study is complete, approximately 100 subjects who choose to enter this study will be randomized 1:1 to 
receive either 1 or 2 injections of nemolizumab or placebo, stratified by dosing regimen. Subjects will 
continue to receive the same dosing regimen received in the LTE study (i.e., 1 or 2 SC injections of study 
drug administered every 4 weeks [Q4W]). Subjects with a body weight <90 kg in LTE study will receive a 
30-mg dose. 
-mg dose.
consists of a 24-week 
treatment period and an 8-week follow-up period (12 weeks after their last study drug injection at Week 20).
baseline or an 
subject meets the criteria for 
relapse, then the subject may be considered for re-entry into the LTE study (RD.06.SPR.202699). Refer to 
Figure 4-1 for subject transition between studies 202699 and 203890.


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 15 of 94
Figure 4-1: Subject Transition between Studies 202699 and 203890
*Clinical responder is defined as a subject with an Investigator Global Assessment (IGA) score= 0 or 1 and
improvement in Peak 
lead-
in study at Week 52 visit of the LTE study. Note: Lead-in study baseline is defined as baseline PP NRS 
score in the Phase 3 studies RD.06.SPR.202685 or RD.06.SPR.203065 for subjects who rolled over into 
the LTE from these studies. For subjects who entered the LTE study from the Phase 2 study
RD.03.SPR.115828, the baseline PP NRS score at entry into the LTE study RD.06.SPR.202699 will be
used.
** Relapse is defined as an 
during the treatment period or who complete through Week 24 are eligible for LTE re-entry.
Baseline Assessment
After signing the informed consent form (ICF), all subjects will be evaluated for study participation, based 
on eligibility criteria. The study assessments at the time of completion of the Week 52 visit from the PN LTE 
lead-in study RD.06.SPR.202699 will be used as baseline assessments for the current study.
Treatment Period
Eligible subjects will be randomized to receive either 1 or 2 injections of nemolizumab or placebo according 
to their dosage group in the LTE study, as assigned by interactive response technology (IRT). Study drug 


Statistical Analysis Plan for Interventional Studies 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890 
This document is confidential. 
SAP Version: 2.0 19-Jan-2024 
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020 
Filing requirements: TMF 
Page 16 of 94 
will then be administered Q4W for 24 weeks with final dose administered at Week 20. 
Refer to the below table for summary of the study treatment. 
LTE Lead-in Study 
Lead-in 
Study 
Assigned 
Treatment 
Dose Q4W for 24 weeksa 
RD.06.SPR.202699 
Nemolizumab  
30 mg 
(1 injection) 
Blinded 
Nemolizumab 30 mg 
(1 injection) 
Blinded Placebo 
(1 injection) 
Nemolizumab  
2 x 30 mg 
(2 injections) 
Blinded 
Nemolizumab 2 x 30 mg 
(2 injections) 
Blinded 2 x Placebo 
(2 injections) 
Abbreviation: LTE = long-term extension; Q4W = every 4 weeks. 
a Dose will be assigned based on dose received in LTE lead-in study 
 
Clinical assessments will occur according to the Schedule of Assessments in the protocol through the Week 
24 visit. 
 
If a subject meets the criteria for relapse at any point, the subject will exit the study and re-enter the LTE 
study (see Figure 4-1). Subjects who exit the study before Week 24 should complete an early termination 
(ET) visit. Subjects who complete the study through Week 24 are eligible to re-enroll in the LTE study. 
 
Subjects who prematurely discontinue study drug for reasons other than relapse will be encouraged to 
complete the scheduled study visits. These subjects will only be eligible for re-enrollment in the LTE study 
if they continue with study visits through Week 24. 
 
Subjects who discontinue the study for reasons other than relapse before Week 24 or who will not continue 
nemolizumab treatment in the LTE study should complete a follow-up visit, 12 weeks (±7 days) after the 
last study drug injection. 
 
Follow-up Period 


Statistical Analysis Plan for Interventional Studies 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890 
This document is confidential. 
SAP Version: 2.0 19-Jan-2024 
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020 
Filing requirements: TMF 
Page 17 of 94 
 
A follow-up visit will be conducted 8 weeks (±7 days) after completing the treatment period and/or 12 weeks 
(±7 days) after the last study drug injection for all subjects who will not continue nemolizumab treatment in 
the LTE study. Twelve weeks corresponds to approximately 5 half-lives of nemolizumab when administered 
subcutaneously Q4W at the doses used in this study.  
 
An overview of the study is presented in Figure 4-2. 
 
Figure 4-2: Study Design 
 
 
*Clinical responder is defined as a subject with an Investigator Global Assessment (IGA) score= 0 or 1 and 
 lead-
in study at Week 52 visit of the LTE study. Note: Lead-in study baseline is defined as baseline PP NRS 
score in the Phase 3 studies RD.06.SPR.202685 or RD.06.SPR.203065 for subjects who rolled over into 
the LTE from these studies. For subjects who entered the LTE study from the Phase 2 study 
RD.03.SPR.115828, the baseline PP NRS score at entry into the LTE study RD.06.SPR.202699 will be 
used. 
 


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 18 of 94
y point
during the treatment period or who complete through Week 24 are eligible for LTE re-entry.
Abbreviations: BL = baseline; LTE = long-term extension; R = randomization; W = week.
indicated in the Schedule of Assessments (Table 
4-1).
Subject Selection
Eligible subjects for this clinical study will be adults who participated in the prior nemolizumab PN LTE study 
(RD.06.SPR.202699) with uninterrupted dosing for 3 months before the Week 52 visit and achieved a 
-point improvement in weekly average of PP NRS score 
from baseline of the lead-in study) at Week 52. By randomizing subjects from the PN LTE study who 
achieved a current clinical response to nemolizumab to either nemolizumab or placebo treatment arms, the 
durability of the response to nemolizumab following discontinuation of active treatment (i.e., in the placebo 
treatment arm) can be measured. This will be done to understand how long the effects of nemolizumab 
treatment are expected to last in controlling signs and symptoms of PN when treatment is removed. 
Subjects who experienced an AE during their participation in the prior lead-in study that in the opinion of 
the Investigator could indicate that continued treatment with nemolizumab might present an unreasonable 
risk for the subject are ineligible. Furthermore, subjects must not use restricted topical and systemic 
treatments, including rescue therapy, within 6 months of the Week 52 visit in the PN LTE study.
Inclusion Criteria
Section 8.1.
Exclusion Criteria
Section 8.2.
Determination of Sample Size
No formal sample size calculations were performed for this study. The sample size will be based on the 
sample size and the actual response rate of the LTE study. Based on the current assumption, it is expected 
that approximately 40 subjects will be randomized.
Treatment Assignment and Blinding
Upon confirmation of eligibility for a given subject to participate in the study, a unique randomization number 
will be assigned to that subject via Interactive Response Technology (IRT). 


Statistical Analysis Plan for Interventional Studies 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890 
This document is confidential. 
SAP Version: 2.0 19-Jan-2024 
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020 
Filing requirements: TMF 
Page 19 of 94 
The randomization number for a given subject will be used to identify the treatment arm the subject will be 
assigned to.  
Subjects will be randomized in a 1:1 ratio to receive treatment of either Nemolizumab (CD14152) or 
placebo. The randomization scheme will be stratified by dosing regimen (1 or 2 injections) using the IRT 
system.   
All attempts will be made to keep the study center staff and subjects blinded throughout the study. Members 
of the study center staff, including those responsible for dual-chamber syringe (DCS) preparation, will not 
have access to the randomized treatment assignment. 
To ensure double-blind administration of study drug, the study center pharmacist(s) or other qualified 
personnel will prepare all Nemolizumab (CD14152) or placebo treatments, according to the current version 
of the pharmacy manual and assigned DCS provided by the IRT system. 
As there may be detectable differences between active and placebo during the reconstitution process, the 
DCS is delivered for injection after the reconstitution is complete. The pharmacist (or other qualified 
personnel) preparing study drug should not be involved with any study assessments and should not discuss 
any aspects of study drug reconstitution with the subject or study staff involved in subject interviews or 
study assessments. 
To maintain the integrity of the study blinding, the bioanalytical laboratory staff who process/analyze the 
anti-drug antibody (ADA) samples will not provide any information to the Sponsor, CRO, or investigational 
study center personnel directly involved with the ongoing conduct of the study that may lead to unblinding 
during the ongoing study. ADA results will be released by the bioanalytical laboratory after data base lock 
(DBL).  
the event of a serious medical condition that necessitates identification of the study drug for the welfare of 
that subject, as judged by the investigator. The emergency unblinding process utilizes IRT to allow the 
When possible (i.e., when the health of the subject is not immediately at risk), the investigator or sub-
investigator is encouraged to consult with the medical monitor and the Sponsor before breaking the blind. 
If emergency unblinding is required: 
 
Only the investigator will make the decision to unblind the treatment assignment. 
 
Only the affected subject will be unblinded. 


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 20 of 94
The IRT system will provide the treatment assignment to the investigator.
Refer to the Randomization and Trial Supply Management (RTSM) User Guide for information on the steps 
for breaking the blind in the IRT system.
When the blinding code is broken, the reason must be fully documented. If the code is broken by the 
investigator, the subject must be withdrawn from the study and must also be appropriately followed for a 
minimum of 12 weeks after the last dose of study drug.
The reporting requirements for unblinding are the same for reporting an SAE. See also Section 12.7.4 of 
protocol.
The randomization code will remain blinded to all study sites and study team members until completion of 
the study and after the study database has been locked.
An independent unblinded team will perform unblinded analysis at the time of interim analysis. Further 
details are provided in unblinding plan. 
The IDMC will review data at periodic intervals throughout the study as defined in the IDMC charter. The 
IDMC charter will specify the procedures for unblinding to ensure treatment assignment remains 
undisclosed to all individuals involved in the direct execution and management of the study until the final 
database is locked.
Administration of Study Medication
double-blind study. The list of excipients is detailed in the 
chure(IB).
Study drug will be provided as lyophilized powder for solution for injection for SC use only after 
reconstitution in a pre-filled, single-use, dual-chamber syringe (DCS). 
The DCS is a self-contained system that holds the lyophilized nemolizumab or placebo and solution (sterile 
water) for reconstitution, separately. The concentration of nemolizumab in the DCS will be 61.5 mg/mL 
once reconstituted (volume of 0.49 mL per injection). 
Subjects will receive nemolizumab or placebo according to their dosage group (1 or 2 SC injections) in the 
LTE study, as assigned by IRT Q4W. 
Subjects will have the option to self-inject study drug while at the study center under staff supervision. 
Subjects will be trained on injecting the study drug and will be allowed to inject study drug following 


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 21 of 94
appropriate training. If the subject does not wish to perform the injections, study staff can administer study 
drug at each visit.
Study Procedures and Flowchart
See Table 4-1  for study procedures. 






Statistical Analysis Plan for Interventional Studies 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890 
This document is confidential. 
SAP Version: 2.0 19-Jan-2024 
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020 
Filing requirements: TMF 
Page 24 of 94 
g) 
Respiratory exams and PEF measurements are required at these visits for subjects with a medical history of asthma or 
newly-diagnosed (de novo) asthma only. Whenever possible, it is preferable that the PEF measurements be performed 
before noon or at the same time during each study visit. Subjects should be asked to withhold asthma medication on study 
visit days until after PEF testing is complete, to the extent it does not pose an undue risk to the subject.  
h) 
Vital signs will include pulse rate, systolic and diastolic blood pressure (after the subject has been sitting for at least 5 
minutes), and body temperature. 
i) 
12-lead ECGs should be performed in the supine position and before any scheduled vital sign measurements and blood 
draws.  
j) 
Subjects should be reminded to be well hydrated and fast for at least 8 hours before the visit(s) when clinical chemistry 
testing is planned. See Section 12.5 of the protocol for details. 
k) 
Only for females of childbearing potential. If UPT is positive, it must be confirmed with a serum pregnancy test. Pregnancy 
test results must be available prior to the administration of the study drug. 
l) 
For postmenopausal subjects (i.e., no menses for 12 consecutive months), confirm status with a high FSH level in the 
postmenopausal range unless previously confirmed as part of a lead-in study. The blood chemistry sample at the baseline 
visit (V1) will also be used for an FSH test for the confirmation of postmenopausal status, if applicable. 
m) 
At scheduled visits with laboratory, POE, and/or ADA assessments, the samples are to be collected before study drug 
injection(s). As a guideline, POE and ADA samples should be collected at approximately the same time of day throughout 
the study, to the extent possible. 
n) 
Study drug reconstitution will be performed by the pharmacist (or other qualified personnel), and complete reconstitution 
confirmed, prior to delivery for injection.  
o) 
Clinic staff will provide injection training (or re-training, as needed) for subjects willing and able to self-inject study drug. 
injections. 
p) 
After study drug administration, subjects should be monitored closely for any signs or symptoms of hypersensitivity reaction 
before being discharged.  
q) 
If a study visit occurs outside of the visit window, study drug injection(s) can still be administered provided there is a minimum 
of 3 weeks but not more than 5 weeks since the last injection. If 5 weeks or more, the next study drug injection should then 
occur at the next planned visit. Future visits should be scheduled as soon as possible and within the required windows 
based on the baseline/Day 1 visit date, while maintaining the minimum 3-week interval between doses. 
The dose will depend on the dose received in the LTE lead-in study RD.06.SPR.202699. 


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 25 of 94
Endpoints  
Primary Efficacy Endpoints
Time from baseline to relapse, defined as meeting at least 1 of the following criteria: 
Increase in (weekly average of the) PP 
Secondary Efficacy Endpoints
The secondary efficacy endpoints are as follows:
visit 
Proportion of subjects maintaining IGA success, defined as IGA score of 0 (clear) or 1 (almost 
clear) at each scheduled visit
Proportion of subjects with
Absolute and percent change from baseline in PP NRS at each scheduled visit
Absolute and percent change from baseline in Sleep Disturbance Numeric Rating Scale (SD NRS) 
at each scheduled visit
Change from baseline in DLQI at Week 16 and Week 24
Safety Endpoints
The safety endpoints of this study are as follows:
Incidence and severity of AEs, including treatment-emergent AEs (TEAEs), AESIs, serious AEs 
(SAEs), treatment-related AEs, and AEs that lead to discontinuation.
Physical examination and Vital signs
Clinical laboratory tests
Electrocardiogram
Peak expiratory flow
Asthma Control Test (ACT)


Statistical Analysis Plan for Interventional Studies 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890 
This document is confidential. 
SAP Version: 2.0 19-Jan-2024 
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020 
Filing requirements: TMF 
Page 26 of 94 
 
Anti-drug antibody (ADA) concentrations 
 
Incidence of positive ADA assays 
 
Nemolizumab (CD14152) serum concentrations 


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 27 of 94
Analysis Sets
Intent-to-Treat Population
The intent-to-treat (ITT) population will consist of all randomized subjects. All primary and secondary 
efficacy endpoints will be analyzed based on the ITT population. All analyses on the ITT population will be 
.
Safety Population
The safety population will comprise all randomized subjects who receive at least 1 dose of study drug. All 
safety data will be summarized based on the safety 
.
Proof of Exposure Analysis Population
The proof of exposure (POE) analysis population will include all subjects in the safety population who 
provide at least 1 measurable post-baseline evaluable drug concentration value.
Per-Protocol Population
The Per-Protocol (PP) population will consist of all subjects in the ITT population who have no major 
protocol deviations that would have a significant effect on the efficacy of the study treatment (see Section
6.5). Only primary and selected secondary endpoints will be analyzed using the Per-Protocol Population, 
under the treatment group as randomized.
Protocol Deviations
Protocol deviations will be recorded by the Clinical Research Associate (CRA) in the Clinical Trial 
Management System (CTMS). All protocol deviations will be categorized by the associated deviation type 
and will be assessed individually on a regular basis on whether they are major or minor. Details can be 
found in the Protocol Deviation and Non-compliance Management Plan.
Major protocol deviations that are analysis relevant lead to an exclusion of the subject from the per-protocol 
population. A case by case decision regarding exclusions of subjects from the per-protocol analysis will be 
made in a blind data review meeting (BDRM) which will take place prior to unblinding the study. The criteria 
for exclusion from the Per-Protocol Population will be specified in the BDRM Preparation Plan. Only major 
protocol deviation which have a significant effect on the efficacy will result in exclusion from the Per-Protocol 
Population. 
Individual deviations (major and minor) will be presented in a data listing on the ITT population. A 
summary table for number and percentage of subjects with major protocol deviation will be generated by 
type of deviation and treatment group for the ITT population.


Statistical Analysis Plan for Interventional Studies 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890 
This document is confidential. 
SAP Version: 2.0 19-Jan-2024 
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020 
Filing requirements: TMF 
Page 28 of 94 
Protocol deviations incurred as a direct result of the COVID-19 pandemic should be specifically recorded 
and presented as a COVID-19 deviation. The number and percentage of subjects with major (including 
COVID-19) deviation will be provided by type of deviation and treatment group for the ITT population. 
All protocol deviations will be listed. 






Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 31 of 94
General Aspects for Statistical Analysis
General Methods
All data will be listed, and summary tables will be provided. 
Unless otherwise specified, summaries will be presented for each treatment , if indicated, by visit. 
Continuous variables will be summarized using the number of observations (n), mean, standard 
deviation (SD), median, minimum and maximum. Categorical variables will be summarized using 
number of observations (n), frequency and percentages of subjects
Unless otherwise stated, all statistical tests will be two-sided and conducted at the 5% level; all 
presented confidence intervals (CIs) will be two-sided 95% CIs.
Key Definitions
The 24-week treatment period is defined as Day 1/Baseline to Week 24. If early discontinued during 
treatment period, it is defined as the period until 4 weeks (<=28 days) after last dosing date or early 
termination date whichever is earlier.
The Baseline value is defined as the last non-missing value before the first dose of study drug. In case 
that the date of first injection is not available, the date of randomization is considered. 
For diary data (PP NRS, SD NRS), the Baseline values will be week 52 value from LTE trial.
The date of first treatment is defined as the date of first injection of study drug.
The date of last treatment is defined as the date of last injection of study drug.
Study day is defined as the number of days from the date of first treatment (randomization date if not 
treated) and will be calculated as follows:
If the event date
date of first treatment, then study day = event date
date of first treatment + 1. 
Treatment Day 1 is therefore defined as the day of first treatment.
If the event date < date of first treatment, then study day = event date - date of first treatment.
If subject is randomized, but not treated, then study day = event date - date of randomization.
date of last participation in the trial is the last date of contact.
Only the subjects infected by COVID-19 during study participation will be considered subjects with 
COVID-19 infection. 


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 32 of 94
Missing Data
When analyses are not based on OC, the primary method to impute the missing values will be as follows:
Continuous Endpoints: For continuous secondary endpoints during treatment period,  the MMRM 
approach will be used to handle the missing data.
Binary Endpoints: For binary secondary endpoints during treatment period, missing data will be imputed 
to failure.
Adverse events and concomitant medications/procedures: Missing assessment times will have 
imputed times for
the purposes of assessing treatment emergence for AEs or classifying 
medications/procedures into prior/concomitant. However, the assessment date and time (start date, stop 
date, and time if collected from CRF) without imputation will be presented in the listings.
For the start of a concomitant medication/procedure or AE:
Only the year is reported: If the subject received the first study drug dose in the year reported, then 
the date of the first dose of study drug will be used as the start date; otherwise, January 1 of the 
year reported will be used as the start date.
The month and year are reported: If the subject received the first study drug in the month and year 
reported, then the date of the first dose of study drug will be used as the start date; otherwise, the 
first day of the month and year will be used as the start date.
The time is collected but missing: If the start date is the same as the date the subject started 
receiving study drug, then the time of the first dose of study drug will be used as the start time; 
otherwise, 00:00 will be used as the start time.
For the end of a concomitant medication/procedure or AE:
Only the year is reported: The earlier between December 31 of the year reported and the date of 
the last study contact with the subject will be used as the stop date.
The month and year are reported: The earlier between the last date of the month and year reported 
and the date of the final contact with the subject will be used as the stop date.
The time is collected but missing: 23:59 (or 23:59:59 if collected up to seconds) will be used as the 
stop time.




Statistical Analysis Plan for Interventional Studies 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890 
This document is confidential. 
SAP Version: 2.0 19-Jan-2024 
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020 
Filing requirements: TMF 
Page 34 of 94 
Table 8-2: Analysis Visit Window for Evening and Morning Assessments 
Analysis Visit 
Target Study Day 
of Analysis Visit 
Visit 
Window 
for 
evening 
assessment (PP NRS, AP 
NRS) 
Visit Window for morning 
assessment 
(SD 
NRS, 
morning sleep diary) 
Baseline 
1 
 -7 to -1  
 -6 to 1  
Week 1 
8 
1 to 7 
2 to 8 
Week 2 
15 
8 to 14 
9 to 15 
Week 3 
22 
15 to 21 
16 to 22 
Week 4 
29 
22 to 28 
23 to 29 
Week 5 
36 
29 to 35 
30 to 36 
Week 6 
43 
36 to 42 
37 to 43 
Week 7 
50 
43 to 49 
44 to 50 
Week 8 
57 
50 to 56 
51 to 57 
Week 9 
64 
57 to 63 
58 to 64 
Week 10 
71 
64 to 70 
65 to 71 
Week 11 
78 
71 to 77 
72 to 78 
Week 12 
85 
78 to 84 
79 to 85 
Week 13 
92 
85 to 91 
86 to 92 
Week 14 
99 
92 to 98 
93 to 99 
Week 15 
106 
99 to 105 
100 to 106 
Week 16 
113 
106 to 112 
107 to 113 
Week 17 
120 
113 to 119 
114 to 120 
Week 18 
127 
120 to 126 
121 to 127 
Week 19 
134 
127 to 133 
128 to 134 
Week 20 
141 
134 to 140 
135 to 141 
Week 21 
148 
141 to 147 
142 to 148 
Week 22 
155 
148 to 154 
149 to 155 
Week 23 
162 
155 to 161 
156 to 162 
Week 24a 
169 
162 to 175 
163 to 176 
Early 
Termination* 
UN 
7 
days 
prior 
until 
Early 
termination visit (excluding 
early termination visit date) 
6 
days 
prior 
until 
early 
termination 
visit 
(including 
early termination visit date) 
a First 7 days data available will be used for weekly average calculation. 
*For subjects with early termination, if weekly average is not available based on the slotting, additional 
analysis window was added and will be assigned to the week based on the slotting above. i.e., if subject 


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 35 of 94
early terminated day 142, and week 21 is not available, the new window defined will be used to determine 
the weekly average at that week.
Safety and pharmacokinetics data will not be windowed for by-visit summary. i.e., scheduled visit data will 
be used for analysis.
Subgroups
Subgroup analysis will not be conducted in this study, regarding the small sample size.


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 36 of 94
Demographic, Other Baseline Characteristics and Medication
Subject Disposition and Withdrawals
All subjects of the ITT population will be accounted for in this study.
Subject accounting will summarize subjects randomized and randomized but not treated for all subjects by 
overall and site.
Subject accounting by visit will be summarized by treatment group and overall at each visit (scheduled visits 
only).
Subject disposition will be summarized based on the ITT population by treatment and overall. Summaries 
will include subjects randomized, subjects randomized but not treated, subjects treated, subjects completed 
treatment, subjects discontinued treatment, primary reason for discontinuation of treatment (including 
summary of subjects who stopped treatment due to COVID-19), subjects completed the study, subjects 
discontinued from the study, primary reason for discontinuation from the study (including summary of 
subjects who discontinued due to COVID-19) and subjects completed Follow-up. Subjects who stopped 
treatment or discontinued study due to COVID-19 will be identified using other specify field in CRF.
Subject disposition will also be summarized by site on the ITT population.
Subjects in each analysis population (ITT, SAF, PP, POE analysis population) will be summarized by 
treatment group on the ITT population.
In addition, time (days since the first dose of study drug) to permanent discontinuation of study drug by 
reason for discontinuation will be displayed graphically in subjects having permanently discontinued from 
the study drug.
Randomization, study completion, drug completion, visit dates will be listed for the ITT population.
Additional listings of discontinuation reason, missed visit and missed assessment for subjects who 
discontinued due to COVID-19 will be presented for the ITT population.
Analysis populations will be summarized and listed on the ITT population.
Demographic and Baseline Disease Characteristics
Summary statistics for demographic and other Baseline disease characteristics will be presented for the
ITT, SAF, PP and POE analysis population.
Age (years), height (cm), weight (kg), and BMI (kg/m2) will be summarized using summary statistics for 
continuous variables. Age groups (18-65, and > 65), sex, region (Europe, North America, and Asia Pacific),


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 37 of 94
race, ethnicity, and smoking history will be summarized using the summary statistics for categorical 
variables. Weight will additionally be presented for each subgroup < 90 kg and 
90 kg as well as dosing 
regimen (1 or 2 injections).
The Baseline disease characteristics IGA, weekly average PP NRS, weekly SD NRS and baseline DLQI
will be summarized. IGA, will be summarized as a categorical variable.
A summary table for the stratification factor dosing regimen will be provided to show any discrepancies 
between what was reported through Interactive Voice Response System (IVRS)/Interactive Web Response 
System (IWRS) versus eCRF data (at baseline visit).
All demographic and baseline disease characteristics data will be listed on the ITT population.
Medical History 
Medical history will be collected only at baseline and will be coded using Medical Dictionary for Regulatory 
Activities (MedDRA, Version 25.0).
Medical history will be summarized by treatment group. The summary will include number and percentage 
of subjects reporting each system organ class (SOC) and preferred term (PT) and will be sorted 
alphabetically by SOC and descending frequency of PT within SOC in the Nemolizumab treatment group. 
Summary tables will be presented for the ITT population.
Medical history data listings will be presented by subject number, start date, stop date, SOC, and PT for
the ITT population.
Medical and Surgical Procedure
Medical and surgical procedures will be coded using the latest version of Medical Dictionary of Regulatory 
Activities (MedDRA).
Prior medical and surgical procedures are defined as those which have been stopped before first treatment.
Concomitant medical and surgical procedures will be defined as those started or stopped on or after the 
first treatment, or were ongoing during the study. If a procedure is started before the first treatment but is 
ongoing or stopped on or after the first treatment, it will be considered concomitant.
Procedures during treatment period will be defined from start of treatment till 4 weeks (<= 28 
days) after the last treatment or early discontinuation date whichever is earlier.
Procedures during follow-up period is defined from post treatment period (4 weeks (> 28 days) 
after the last treatment or early discontinuation date, whichever is earlier) to follow-up visit date.


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 38 of 94
procedure will be considered concomitant. If stop date 
is partially missing, the procedure will be considered concomitant unless the non-missing part of date 
proves it ended prior to the first treatment date.
The following medical and surgical procedures (prior and concomitant) will be summarized by treatment 
group using the number and percent of subjects reporting each SOC and PT and sorted alphabetically by 
SOC and descending frequency of PT within SOC in the Nemolizumab treatment group. Summary tables 
will be presented for the ITT population.
Prior procedure 
Concomitant procedure during treatment period
Concomitant procedure during follow-up period
Medical and surgical procedures listings will be presented by treatment group on the ITT population and 
sorted by subject number, start date, stop date, SOC, and PT.
Medication
Medications will be classified and summarized on the ITT population as follows:
Prior medications are defined as those which stop before the first injection of study drug during the study.
Concomitant medications are defined as those started, stopped or ongoing on or after the first injection of 
study drug.
Medication during treatment period is defined from start of treatment till 4 weeks (<= 28 days) after 
the last treatment or early discontinuation date whichever is earlier.
Medication during follow-up period is defined from post treatment period (4 weeks (> 28 days) after 
the last treatment or early discontinuation date, whichever is earlier) to follow-up visit date. 
ant medication. 
If stop date is partially missing, the medication will be considered as concomitant unless the non-missing 
part of date proves it ended prior to the first treatment date.
Medications (prior, concomitant and prohibited medications) will be coded using Version B3 Sep2021 of 
(ATC) coding will be performed. 
The following summaries by ATC level 2, ATC level 4 and preferred term (PT) will be produced on the ITT 
population. Subjects with more than one medication in a given ATC level and preferred name will be 
counted only once in that category. It will be sorted ATC level alphabetically and descending frequency in 
PT within ATC level term.


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 39 of 94
Prior medication 
Concomitant medication during treatment period 
Concomitant medication during follow-up period
Prohibited medication during treatment period
Prohibited medication during follow-up period
All medications (prior and concomitant medications, prohibited medications) will be listed for the ITT 
population.
Extent of Exposure
Following parameters will be summarized: 
Treatment duration (in days) is calculated as follows, where date of first treatment is defined as the 
first day: [(date of last treatment 
date of first treatment) + 1].
Total dose administered (mg) will be calculated as the sum of all doses of study drug administered.
Total dose planned (mg) will be calculated as the sum of all doses of study drug planned 
(dispensed) according to the treatment schedule of the treatment group.
The number of subjects who missed at least one dose
The number of subjects who missed at least one dose due to COVID-19
The number of doses missed
The number of doses missed due to COVID-19
Note: The missed dose due to COVID-19 are captured as other-reason reported in CRF. 
Treatment Compliance 
Treatment compliance will be assessed through the treatment records and drug dispensation logs. As study 
drug is administered in the clinic, treatment compliance will be overseen and documented by the 
investigator and study staff (using the treatment records and drug accountability records).
Treatment compliance (%) is calculated as the total number of actual injections / the total number of 
expected injections * 100. The total number of actual injections is counted based on collected study drug 
administration data. The total number of expected injections is counted based on the dosage schedule and 
dispensed as per protocol.


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 40 of 94
Efficacy
Unless otherwise stated, all efficacy analyses will be performed on the ITT population.
All efficacy variables will be summarized by treatment group at each analysis visit. The primary comparison 
of interest is Nemolizumab compared to placebo.
Primary Efficacy Endpoints
Primary Analysis of Primary Efficacy Endpoint
The primary endpoint is the time to relapse which is defined as meeting at least 1 of the following criteria:
;
For primary endpoint, any subjects with missing data for PP NRS and IGA Score both at visit will be 
censored at the respective timepoint. If any one of PP NRS or IGA Score data is available for the visit, 
calculation for primary endpoint will be made using available results. If a subject has taken prohibited 
medication at any point of time during treatment period, then subject will be censored at the respective visit.
The primary endpoint will be analyzed using Cox proportional hazard model with treatment group, dosing 
regimen as a factor, and baseline PP NRS score and IGA score as covariates on ITT population. The 
estimated hazard ratio and the corresponding 95% CI will be presented. A supportive analysis also will be 
performed using Per-Protocol Population. 
Kaplan-Meier survival plots will also be presented for time to relapse. The median time, 25th and 75th
quantiles along with corresponding CI will be presented using ITT/PP.
Censoring rule for primary endpoint variable is as follows:
Situation 
Date of Progression or Censoring
Outcome 
Relapse as described
Date of Relapse
Event
Subject withdrawn without relapse
Date of last efficacy assessment (PP NRS and 
IGA) prior to withdrawal
Censored
Treatment Discontinuation
Date of last efficacy assessment (PP NRS and 
IGA) prior to Treatment Discontinuation
Censored
Prohibited medication without relapse
Date of last efficacy assessment (PP NRS and 
IGA) prior to prohibited medication
Censored
Completes the study without relapse
Date of Week 24 completion
Censored 
No Efficacy assessment
Date of study Day 1
Censored
  






Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 43 of 94
The IGA is a 5-point scale used by the Investigator or trained designee to evaluate the global severity of 
PN and the clinical response to a treatment (see Table 10-1).
Table 10-1: Investigator Global Assessment Scale
0
Clear
No nodules
1
Almost Clear
Rare palpable pruriginous nodules
2
Mild
Few palpable pruriginous nodules
3
Moderate
Many palpable pruriginous nodules
4
Severe
Abundant palpable pruriginous nodules
IGA treatment success is defined as 0 (clear) or 1 (almost clear) on the IGA scale.
IGA will be collected at Baseline/Day 1, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Early 
Termination or any unscheduled visit. In case of missing assessment at Baseline, the last available 
assessment prior study drug administration will be considered as Baseline. 
IGA will be summarized as a categorical and continuous variable at each analysis visit. Absolute change 
from Baseline for the IGA score will also be presented in the summary on the ITT and Per-Protocol 
Population.
The proportion of subjects maintaining IGA success and subjects
baseline will be summarized on the ITT based on OC. The estimate of treatment unadjusted and strata-
adjusted differences with the corresponding two-sided 95% confidence intervals, and p-values from the 
CMH test will be presented.
The analysis will be repeated:
-
on Per-Protocol Population, based on OC
-
on ITT population, imputing missing values with non-responder imputation
Line plot for proportion of subjects maintaining IGA success and proportion of subjects with increase in IGA 
using non-responder imputation, will be for the ITT Population.
Pruritus Numeric Rating Scale (NRS)
The Pruritus NRS is a scale to be used by the subjects to report the intensity of their pruritus (itch) during 
the last 24 hours. Peak pruritus (PP NRS) is an assessment of the maximum itch intensity in that period.


Statistical Analysis Plan for Interventional Studies 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890 
This document is confidential. 
SAP Version: 2.0 19-Jan-2024 
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020 
Filing requirements: TMF 
Page 44 of 94 
Subjects will be asked the following question: 
 
The Baseline PP NRS will be the score of Week 52 visit from LTE trial.  
PP NRS at all follow-up visits will be determined as an average of 7 consecutive days data up to the target 
study day and will be set to missing if less than 4 days data are available. Subjects will receive instructions 
on how to record their PP NRS scores and will complete the assessment once daily in the evening 
throughout the clinical study (including the run-in and the follow-up period).  
PP NRS will be determined by an average as described above at every week from Baseline to Week 24 as 
a continuous variable.  
Descriptive summary of PP NRS (OC) will be provided on the ITT and Per-Protocol Populations. Absolute 
change and percent change from Baseline for the PP NRS will also be included in the summary on the ITT 
and Per-Protocol Populations. 
Absolute change from Baseline in PP NRS will be analyzed using ANCOVA based on OC, including 
treatment group dose regimen as factors with baseline value as covariate. The least squares means 
(LSMeans), standard error of LSMeans, and 95% CI for change from baseline, as well as the difference in 
LSMeans between the treatment groups, the two-sided 95% CI, and associated p-value will be presented. 
Percentage change from Baseline in PP NRS will not be analyzed because of the small sample size and 
potential high skewness of the data.  
The analysis will be repeated: 
- 
on Per-Protocol Population, based on OC 
on ITT population, based on OC and using MMRM approach, including treatment group and dose 
regimen as factor, visit, interaction term between treatment and visit, and baseline value as covariate. 
Kenward-Roger approximation is used to estimate denominator degrees of freedom. An unstructured 
covariance is used to model the within-patient errors in the analysis. While applying the model, if 
convergence criteria not met with unstructured covariance matrix, then below mentioned covariance 
matrix will be applied to achieve convergence of the model. The matrix with the minimum AIC criteria will 
be selected for the further analysis.  
 
Compound Symmetry (CS) 
 
Ar(1)  Autoregressive (1) 
The proportion of subjects with PP NRS with 
4 in increase from baseline will be summarized on the ITT 
based on OC. The estimate of treatment unadjusted and strata-adjusted proportion differences with the 
corresponding two-sided, 95% CI, and p-values from the CMH test will be presented.  
The analysis will be repeated: 
CCI


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 45 of 94
-
on Per-Protocol Population, based on OC
-
on ITT population, imputing missing values with non-responder imputation
4 increase will be presented on the ITT Population using 
non-responder imputation.
Sleep Disturbance Numeric Rating Scale (SD NRS)
The SD NRS is a scale to be used by the subjects to report the degree of their sleep loss related to PN.
The baseline SD NRS will be the score of Week 52 visit from LTE trial.
Subjects will be asked the following question:
Descriptive summary of SD NRS (OC) will be provided on the ITT and Per-Protocol Population. Absolute 
change and percent change from Baseline will also be included in the summary.
Absolute change from Baseline in SD NRS will be analyzed using ANCOVA based on OC, including
treatment group dose regimen as factors with baseline value as covariate. The least squares means 
(LSMeans), standard error of LSMeans, and 95% CI for change from baseline, as well as the difference in 
LSMeans between the treatment groups, the two-sided 95% CI, and associated p-value will be presented. 
Percentage change from Baseline in SD NRS will not be analyzed because of the small sample size and 
potential high skewness of the data.
The analysis will be repeated:
-
on Per-Protocol Population, based on OC
on ITT population, based on OC and using MMRM approach, including treatment group and dose regimen 
as factor, visit, interaction term between treatment and visit, and baseline value as covariate. Kenward-
Roger approximation is used to estimate denominator degrees of freedom. An unstructured covariance is 
used to model the within-patient errors in the analysis. While applying the model, if convergence criteria not 
met with unstructured covariance matrix, then below mentioned covariance matrix will be applied to achieve 
convergence of the model. The matrix with the minimum AIC criteria will be selected for the further analysis. 
Compound Symmetry (CS)
Ar(1) 
Autoregressive (1)
-
CCI


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 46 of 94
Dermatology Life Quality Index
The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, daily 
activities, leisure, work/school, personal relationships, and treatment.
The subject will rate each question ranging from 0 (not at all) to 3 (very much). The DLQI total score is 
calculated by summing each questionnaire. Total score will have a maximum score of 30 and a minimum 
of 0. The higher score indicated a poorer quality of life.
DLQI will be collected at Baseline, Week 16, Week 24 and Early Termination. DLQI total score will be 
summarized as a continuous variable using OC on the ITT Population. Absolute change and percentage 
change from Baseline in DLQI total score will also be summarized.
Absolute change from Baseline in DLQI will be analyzed using ANCOVA based on OC, including treatment 
group dose regimen as factors with baseline value as covariate. The least squares means (LSMeans), 
standard error of LSMeans, and 95% CI for change from baseline, as well as the difference in LSMeans 
between the treatment groups, the two-sided 95% CI, and associated p-value will be presented. Percentage 
change from Baseline in DLQI will not be analyzed because of the small sample size and potential high 
skewness of the data.


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 47 of 94
Pharmacokinetics
The serum concentration of Nemolizumab will be assessed at Baseline, Week 24 and Early Termination 
visit. PK analyses are required during any unscheduled visit conducted for safety reasons. As a guideline, 
PK samples should be collected at approximately the same time of day throughout the study, to the extent 
possible, before study drug injection (pre-dose samples).
Pharmacokinetic Concentration Presentation
Serum concentration data (unit: ng/mL) will be summarized on the POE analysis population by visit and by 
dosing regimen from Baseline and Week 24, using the following statistics: arithmetic mean, SD, coefficient 
of variation (CV), geometric mean, geometric CV, median, minimum, maximum, 95% CI of the arithmetic 
mean, and number below the limit of quantification (BLQ).
Mean and individual (spaghetti plot) serum concentration(s) will be plotted by visit and by dosing regimen 
on both a linear and semi-logarithmic scale on the POE analysis population (2 plots).
Individual serum concentrations will be listed on the POE analysis population.


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 48 of 94
Immunogenicity
Blood samples to assess anti-Nemolizumab ADA will be collected at Baseline, Week 24 and Early 
Termination. Immunogenicity analyses will be summarized on the POE analysis population.
Details related to the processing of serum samples and the assessments of ADA will be described in the 
bioanalytical plan, which will be finalized before the beginning of sample analysis. Results will be described 
in the bioanalytical report, which will be included as an appendix in the final clinical study report.
Incidence of positive ADA results will be summarized (absolute occurrence and percent of subjects) and
plotted by dosing regimen at each visit. The concentration of ADA titer (ng/mL) and neutralizing antibodies 
(ng/mL) will be summarized as continuous variables.
The number and percentage of subjects with treatment related ADA will be summarized by visit and dosing 
regimen. A treatment-related ADA is defined when the Baseline or confirmatory ADA result is negative and 
the post-baseline confirmatory ADA result is positive in the Nemolizumab treated group only. 
Individual trough serum drug concentrations will be plotted over time in ADA-positive versus ADA-negative 
subjects. 


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 49 of 94
Safety
All safety data will be summarized and listed on the SAF population.
Safety assessments will be conducted for all subjects at the baseline visit and at every subsequent visit. 
Safety will be assessed on the basis of AEs (including TEAEs, AESIs, and SAEs), physical examination 
and vital signs, clinical laboratory tests, electrocardiogram (ECG) and respiratory assessments. Summary 
of all safety endpoints will be presented for each treatment group.
Adverse Events
AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 24.1.
Treatment-emergent AEs (TEAEs), defined as those AEs occurring after the first administration of study 
treatment until the end of the follow-up period, will be tabulated in frequency tables by System Organ Class 
(SOC) and Preferred Term (PT) based on the MedDRA for treatment and follow-up periods. Missing date 
information will be handled using the algorithm described in Section 8.3.
TEAEs during treatment period are defined as AEs with onset date on or after the first dose date till 4 weeks 
after the last treatment or early discontinuation date whichever is earlier. TEAEs during follow-up period 
are defined as AEs with onset date post treatment period (4 weeks after the last treatment or early 
discontinuation date, whichever is earlier) to follow-up visit date.
AEs will be summarized using the number and percent of subjects reporting each SOC and PT and sorted 
alphabetically by SOC and by descending frequency of PT within SOC.
Subjects who experienced multiple events within the same SOC will be counted once in the SOC summary. 
Subjects who experienced multiple occurrences of events with the same PT will be counted once in the PT 
summary.
When summarizing by causality or maximum severity, if a subject experiences more than 1 occurrence of 
the same AE, the occurrence with the greatest severity and the closest association with the study drug will 
be used in summary tables. TEAEs related to study drug/study procedure are those that are identified as 
reasonable possibility. If relationship or severity are missing, the event will be considered as AE related to 
study drug/study procedure or severe AE.
An AESI is a noteworthy treatment-emergent event for the study drug that should be monitored closely and 
reported promptly. An AESI can be either serious or non-serious. Based on the potential risks of 
Nemolizumab and the risks associated with biologics in general (i.e., class effects), the following AEs will 
be considered as AESIs: 
Injection-related reactions, 
Newly diagnosed asthma or worsening of asthma, 


Statistical Analysis Plan for Interventional Studies 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890 
This document is confidential. 
SAP Version: 2.0 19-Jan-2024 
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020 
Filing requirements: TMF 
Page 50 of 94 
 
Infections  
 
COVID-19 infections 
 
Peripheral edema: limbs, bilateral,  
 
Facial edema 
 
Elevated ALT or AST (> 3 x ULN) in combination with elevated bilirubin (> 2 x ULN). 
The following summary tables for TEAEs will be presented for all TEAEs (i.e., TEAE all causalities) and 
study drug related TEAEs separately by treatment period and follow-up period.  
 
Overall Summary of TEAEs :  
o 
Overall summary table includes summary of subjects reporting TEAEs,  
o 
TEAE by maximum severity [Mild, Moderate, Severe] 
o 
TEAE related to study drug,  
o 
TEAE related to study drug by maximum severity [Mild, Moderate, Severe] 
o 
TEAE related to protocol procedure,  
o 
Serious TEAE,  
o 
Serious TEAE related to study drug,  
o 
TEAE of special interest,  
o 
TEAE leading to study drug interruption,  
o 
TEAE leading to study drug withdrawal,  
o 
TEAE leading to study discontinuation,  
o 
TEAE leading to death,  
o 
TEAE related to study drug leading to death 
 
TEAEs by SOC and PT 
 
Serious TEAEs by SOC and PT 
 
TEAEs by SOC, PT and Maximum Severity 
 
Severe TEAEs by SOC and PT 
 
TEAEs leading to study drug withdrawal by SOC and PT 
 
TEAEs leading to study discontinuation by SOC and PT 


Statistical Analysis Plan for Interventional Studies 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890 
This document is confidential. 
SAP Version: 2.0 19-Jan-2024 
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020 
Filing requirements: TMF 
Page 51 of 94 
 
TEAEs of special interest by category by SOC and PT 
 
TEAEs occurred in >= 5% of subjects by SOC and PT 
 
 
 
Adjudicated TEAEs by SOC and PT 
 
TEAEs of Asthma and AESI reported by investigator with adjudication outcome by IAC 
 
Confirmed adjudicated TEAEs by SOC, PT and maximum severity 
 
TEAEs of special interest by category, SOC, PT and maximum severity  
For overall study period which includes all periods (treatment and follow-up), the following summary tables 
will also be presented and repeated for all TEAEs (all causalities) and study drug related TEAEs. 
 
Overall Summary of TEAEs 
 
TEAEs by SOC and PT 
For the subset of subjects with COVID-19 infection, the following summary tables will be provided 
additionally for all TEAEs and study drug related TEAEs, separately. 
 
Overall summary of TEAEs 
 
TEAEs by SOC and PT 
 
Serious TEAEs by SOC and PT 
 
TEAEs of Special Interest by category by SOC and PT 
In addition, the exposure-adjusted incidence rate (i.e., number of subjects per 100 patient-years) will be 
summarized for all TEAEs (all causalities) and study drug related TEAEs during treatment period.   
Exposure-adjusted incidence rates of TEAEs is defined as the number of subjects exposed to treatment 
and experiencing a certain event divided by the total time of all subjects who are at risk for the event. 
Specially, for subjects with no event the exposure time is the time from the first drug intake to the end of 
treatment period. Exposure years is calculated as last study drug exposure date minus first study drug 
exposure date plus one, divided by 365.25 which is the number of days count in a year. This exposure year 
calculated for each subject is then added cumulatively and is derived for each treatment arm. So each 
treatment arm will have one value for exposure years (
patient years ). The exposure year 
calculation is different in case of subjects who have completed the study or discontinued from the study or 
having withdrawn from the study due to any reason. Only the event occurred during the treatment period 
will account for calculation. 
Subject listings will be presented for all  


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 52 of 94
TEAEs, 
TEAEs of special interest, 
Serious TEAEs, 
Severe TEAEs, 
TEAE leading to permanent discontinuation of study drug, 
TEAEs leading to deaths. 
Pre-treatment AE
Laboratory Evaluations
Clinical Laboratory Evaluations
The hematology laboratory analyses, clinical chemistry laboratory analyses, and urinalyses will be 
performed at a central laboratory. Reference ranges will be supplied by the central laboratory and used by 
the investigator to assess the laboratory data for clinical significance and pathological changes. Reference 
ranges will be provided in the laboratory manual.
The following parameters will be reported for laboratory data.
Hematology: Hemoglobin, hematocrit, white blood cell (WBC) count (with differential including 
eosinophils), red blood cell (RBC) count, platelet count, and mean cell volume (MCV).
Chemistry: Creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma 
glutamyl transferase, alkaline phosphatase, lactate dehydrogenase, total bilirubin, direct bilirubin, 
albumin, total protein, uric acid, sodium, potassium, calcium, chloride, glucose, urea, total cholesterol, 
triglycerides, low-density lipoprotein, high-density lipoprotein, creatine phosphokinase (CPK). CPK 
isoenzyme test will be performed only if CPK is elevated to >2.5 × upper limit of normal (ULN).
Urinalysis: pH, glucose, ketones, blood, protein, leukocytes, nitrites, bilirubin, urobilinogen, and 
specific gravity.
Laboratory assessments are performed at Baseline/Day 1, Week 12, Week 24, Early Termination and Week 
32/Follow-up.
Hematology and chemistry laboratory data (absolute values and change from Baseline) will be summarized 
as continuous variables by visit (Baseline and scheduled visits only). Urinalysis laboratory data will be 
summarized by visit (Baseline and scheduled visits only). Last post-baseline, worst post-baseline and 
maximum post-baseline results will also be included in the summaries and will include unscheduled visits 


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 53 of 94
in the derivation. Worst post-baseline value will be defined as the highest or lowest value relative to the 
reference range. Parameters will be presented in alphabetically order. 
Shift tables will be generated using the reference ranges (Low, Normal, High and Missing) for hematology 
and chemistry laboratory data. The number and percentage of subjects shifting from reference ranges 
between Baseline and each visit (scheduled visits only) will be summarized. Last, worst and maximum post 
baseline values will also be included in the shift tables and will include unscheduled visits in the derivation.
Summary of the number and percentage of subjects who met criteria of potential clinically significant (CS) 
value will be summarized (scheduled visits only) for hematology, chemistry. Last, worst and maximum post-
baseline results will also be included in the summaries. Potentially CS ranges are listed in Section 20.2.
For statistical and graphical summaries of the laboratory tests, values below or above the limit of detection 
detection minus 1% for values below the lower 
limit and are substituted with the upper
is substituted by
the 
< or > sign.
Distribution of continuous hematology and chemistry laboratory data (in particular, Aspartate 
Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Total Bilirubin
(BILI), Creatinine Kinase (CK) and Leukocytes (WBC)) will be displayed graphically as boxplot by treatment 
group for baseline and for each scheduled visits and the maximum post-Baseline (including unscheduled 
visits in the derivation) values.
By-subject listing will be presented for all laboratory data. By-subject listing for subjects with at least one 
abnormal result (out of reference range) will be provided for hematology and clinical chemistry. By-subject 
listing for subjects with at least one potentially CS result will be provided for hematology, clinical chemistry.
All laboratory data will be listed for the Safety population.
Pregnancy Testing
All women of childbearing potential will have a serum pregnancy test at the baseline visit and urine 
pregnancy tests (UPTs) at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24, Early 
Termination visit, and Week 32/Follow-up. Pregnancy test results must be available prior to the 
administration of the study drug.
All confirmed pregnancy test results, premenses status and childbearing potential assessment results will 
be listed on the Safety population.


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 54 of 94
Virology and TB Testing
Virology including hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus 
(HCV), human immunodeficiency virus 1, and human immunodeficiency virus 2 antibodies may be 
assessed at unscheduled visits for safety purposes based on Investigator judgment. Subjects with a positive 
HBcAb and a negative HBsAg will also be assessed for hepatitis B surface antibody. Subjects with positive 
HCV antibodies will have a confirmatory test for HCV (e.g., PCR). All virology results will be listed on the 
Safety population.
Subjects may be assessed for active or latent tuberculosis (TB) at unscheduled visits for safety purposes 
based on Investigator judgment. A subject who tests positive for latent TB (with a positive QuantiFERON-
-up. All TB test 
results will be listed on the Safety population.
Vital Signs 
Vital signs will include pulse rate, systolic and diastolic blood pressure (after the subject has been sitting 
for at least 5 minutes) and body temperature.
Vital signs will be collected at the at Baseline/Day 1, Week 4, Week 8, Week 12, Week 16, Week 20, and 
Week 24, Early Termination visit, and at Week 32/Follow-up.
Height and weight will be measured at Baseline for all subjects. Weight assessments will be conducted at 
Baseline/Day 1, and Week 24 and Early Termination.
All vital signs including height and weight (absolute values and change from Baseline) will be summarized 
as continuous (Baseline and scheduled visits only). Last post-Baseline results (including unscheduled visits 
in the derivation) will also be included.
The number and percentage of subjects who met criteria of potential CS value (Section 20.2) for vital signs 
and weight will be summarized (Baseline and scheduled visits only). Last post-Baseline results (including 
unscheduled visits in the derivation) will also be included.
Distribution of pulse rate, systolic and diastolic blood pressure will be displayed graphically as boxplot by 
treatment group for Baseline and each scheduled visit and maximum post-Baseline (including unscheduled 
visits in the derivation) values.
By-subject listing of subjects with potentially CS vital signs and weight will be provided.
All vital signs results will be listed on the Safety population.


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 55 of 94
ECG
A 12-lead electrocardiogram (ECG) will be performed and read centrally at Baseline/Day 1, Week 24 and 
Early Termination visit.
All ECG data (absolute values and change from Baseline) will be summarized as continuous variables by 
visit (Baseline and scheduled visits only). All parameters will be presented in alphabetically order.
summarized by treatment group and visit (scheduled visit only). Clinical significance will be determined by 
the investigator. 
Additionally, all ECG findings will be summarized with numbers and percentages by visit (Baseline and 
scheduled visits only.
All ECG results will be listed on the Safety population.
Physical Examination
Following body system assessments will be performed at Baseline/Day 1, Week 12, Week 24, Early 
Termination, and Week 32/Follow-up: 
Head, ears, eyes, nose, throat, neck (including thyroid), 
Skin/integumentary system (excluding PN), 
Cardiovascular system, 
Respiratory system, 
Gastrointestinal system, 
Musculoskeletal system, 
Lymph nodes, 
Nervous system, and 
Extremities.
The number and percentage of subjects with physical examination results by body system classified as 
Baseline and scheduled visits only).
Shift from Baseline of the physical examination category will also be summarized by body system.


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 56 of 94
By-subject listing will be provided for subjects who have at least one abnormal result from any body system 
or who missed the assessment due to any reason.
All physical examination results will be listed on the Safety population.
Respiratory Assessments
Asthma Control Test
Subjects with a medical history of asthma will take an Asthma Control Test (ACT) at Baseline/Day 1, Week 
4, Week 8, Week 12, Week 16, Week 20 and Week 24, Early Termination visit, and Week 32/Follow-up.
Subjects with new (de novo) diagnosis of asthma will complete the ACT testing beginning from new (de 
novo) diagnosis and at all subsequent scheduled visits.
The ACT is composed of 5 questions. For each question, the subject will choose the best answer out of 5 
possible answers. The test provides a numerical score ranging from 5 to 25 to assess asthma control; a 
higher score indicates better asthma control while a score of 19 or less
not be under control.
ACT total score (absolute values and change from Baseline) will be summarized as a continuous variable 
(Baseline and scheduled visits only).
The number and percentage of subjects with an
The ACT results and the ACT score will be listed on the Safety population.
Respiratory Examination 
A respiratory examination consists of medical interview. Questions regarding medical history of asthma,
wheeze, dyspnea, and cough, will be performed for all subjects at Baseline/Day 1, Week 12, Week 24, 
Early Termination and Week 32/Follow-up questions are asked regarding: 
newly diagnosed (de novo) with Asthma / experience a worsening of Asthma since last visit
newly diagnosed with Wheeze since last visit / experience a worsening of Wheeze since last visit
newly diagnosed with Dyspnea since last visit / experience a worsening of Dyspnea since last visit
newly diagnosed with Cough since last visit / experience a worsening of Cough since last visit
Only subjects reporting a medical history of asthma will require a respiratory examination at all visits. 
Subjects with a new (de novo) diagnosis of asthma will require a respiratory examination at all scheduled 
visits after the diagnosis is first made.


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 57 of 94
Newly diagnosed asthma or unexpected worsening of asthma are also reported as AESI. Respiratory 
examination questionnaire results will be listed on the Safety population.
Peak Expiratory Flow
Peak expiratory flow (PEF) testing during the clinical study will be performed under the supervision of 
qualified study personnel. Peak expiratory flow measurements should consist of 3 good efforts, with the 
best result documented. Obtained PEF values will be compa
age, sex and height.
PEF testing will be performed for all subjects at Baseline/Day 1, Week 12, Week 24, Early Termination, and 
Week32/Follow-up visits. For subjects reporting a medical history of asthma, PEF testing will be performed 
at all visits during the clinical study. For subjects diagnosed with new (de novo) asthma, PEF testing will be 
performed at all visits, starting with the visit in which the diagnosis was confirmed.
Following PEF parameters will be summarized as a continuous variable (Baseline and scheduled visits 
only): 
Actual peak expiratory flow rate
Predicted peak expiratory flow rate 
Actual PEF of predicted value (%).
These PEF parameters will be summarized separately for the subset of subjects with and without history 
of asthma.
The number and percentage of subjects with PEF < 80% will be summarized by treatment group, visit 
(baseline and scheduled visits only), and medical history of asthma (with and without history of asthma).
All PEF results will be listed on the Safety population.


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 58 of 94
Changes from Analysis Planned in Protocol
by Treatment Group and 


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 59 of 94
Programming Considerations
All TFLs and statistical analyses will be generated using SAS® 9.4 or higher (SAS® Institute Inc., Cary, NC, 
USA) on a SAS Server. Changes to the software version (e.g. upgrades), or use of additional software 
consistent with the SAP will not be considered a violation of the SAP. 
General Considerations
All TFLs will be produced in accordance to 
 (see Section 16). 
A separate SAS program will be created for each output.
Each output will be stored in a separate file.
Output files will be provided in separate Word rtf and as combined PDF format including all outputs 
in one PDF file.
Numbering of TFLs will follow International Conference on Harmonization (ICH) E3 Guidance.
Table, Figure, and Listing Format
General
All TFLs will be produced in landscape format, unless otherwise specified.
All TFLs will be produced on paper size A4 using the Courier New font, size 8.
The data displays for all TFLs will have a 1 inch binding margin on top and bottom of a landscape 
oriented page and a minimum 1.25 inch margin on the left side and a minimum of 0.75 inch right 
side.
Headers and footers for figures will be in Courier New font, size 8.
Legends will be used for all figures with more than 1 variable, group, or item displayed.
TFLs will be in black and white (no colour), unless otherwise specified.
Specialized text styles, such as bolding, italics, borders, shading, and superscripted and 
subscripted text, will not be used in the TFLs, unless otherwise specified. On some occasions, 
superscripts 1, 2, or 3 may be used (see below).
Only standard keyboard characters will be used in the TFLs. Special characters, such as non-
printable control characters, printer-specific, or font-specific characters, will not be used. 
CCI


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 60 of 94
Hexadecimal-derived characters will be used, where possible, if they are appropriate to help display 
rtain subscripts and superscripts (e.g., cm2, Cmax) will be employed on 
a case-by-case basis.
Mixed case will be used for all titles, footnotes, column headers, and programmer-supplied formats, 
as appropriate.
Headers
All output should have the following header at the top left of each page:
Galderma 
Protocol 
RD.06.SPR.203890
Dry-run/Draft/Final
All output should have Page n of N at the top corner of each page. TFLs are internally paginated in 
relation to the total length (i.e., the page number should appear sequentially as page n of N, where 
N is the total number of pages in the table).
The date output was generated should appear along with the program name as a footer on each 
page. 
Display Titles
Each TFL are identified by the designation and a numeral. (i.e., Table 14.1.1.1). ICH E3 numbering 
is used. A decimal system (x.y and x.y.z) are used to identify TFLs with related contents. The title 
is centered. The analysis population are identified on the line immediately following the title. The 
title and table designation are single spaced. A solid line spanning the margins will separate the 
display titles from the table.
Column headers. There will be 1 blank line between the last title and the solid line.
Table 
14.1.1.1
Subject 
Disposition
Screened Population
Column Headers
Column headings are displayed immediately below the solid line described above in Initial upper-
case characters.
In the case of efficacy tables, the variable (or characteristic) column will be on the far left followed 
by the treatment group column.


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 61 of 94
Analysis population sizes will be presented for dose group in the column heading as 
(or in 
the row headings, if applicable). Thi
representing the number of subjects in the analysis population.
Body of the Data Display
15.2.5.1.
General Conventions
Data in columns of a table or listing are formatted as follows:
Alphanumeric values will be left-justified;
Whole numbers (e.g., counts) will be right-justified; and
Numbers containing fractional portions will be decimal aligned
5 (0.6)
15.2.5.2.
Table Conventions
Units will be included where available
If the categories of a parameter are ordered, then all categories between the maximum and minimum 
category are presented in the table, even if n=0 for all treatment groups in a given category that is 
between the minimum and maximum level for that parameter. For example, the frequency distribution 
for symptom severity would appear as:
Severity 
Rating
N
severe
0
moderate
8
mild
3
Where percentages are presented in these tables, zero percentages will not be presented and so 
counts of 0 will be presented as 0 and not as 0 (0).
If the categories are not ordered (e.g., Medical History, Reasons for Discontinuation from the Study, 
etc.), then only those categories for which there is at least 1 subject represented are included.
An Unknown or Missing category will be added to each parameter for which information is not 
available for 1 or more subjects
Unless otherwise specified, the estimated mean, median, Q1 and Q3 for a set of values are printed 
out to 1 more significant digit than the original values, and standard deviations are printed out to 2 
more significant digits than the original values. The minimum and maximum should report the same 


Statistical Analysis Plan for Interventional Studies 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890 
This document is confidential. 
SAP Version: 2.0 19-Jan-2024 
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020 
Filing requirements: TMF 
Page 62 of 94 
significant digits as the original values. Missing descriptive statistics or p-values which cannot be 
-  
 Percentage values will be printed to one decimal 
, with the 
alignment, one 
space after the count (e.g., 7 (12.8), 13 (5.4)). Unless otherwise noted, for all percentages, the 
number of subjects in the analysis set for the treatment group who have an observation will be the 
denominator. Percentages after zero counts will not be displayed and percentages equating to 100% 
will be presented as 100, without decimal places. 
 Tabular display of data for medical history, prior/concomitant medications, and all tabular displays of 
adverse event data are presented by the body system, treatment class, or SOC. The body system, 
drug class and SOC are displayed in alphabetically order. Within body system, drug class and SOC, 
preferred term will be display in descending frequency. If incidence for more than 1 preferred term is 
identical, they should then be sorted alphabetically. 
 P-values will be output in the format: 0.xxxx , where xxx is the value rounded to 4 decimal places. 
Every p-value less than 0.0001 will be presented as <0.0001  If the p-value is returned as >0.9999, 
then present as >0.9999  
 The percentage of subjects is normally calculated as a proportion of the number of subjects assessed 
in the relevant treatment group (or overall) for the analysis population presented. However, careful 
consideration is required in many instances due to the complicated nature of selecting the 
denominator, usually the appropriate number of subjects exposed. These details are described in 
footnotes or programming notes. 
 For categorical summaries (number and percentage of subjects) where a subject can be included in 
more than one category, it is described in a footnote or programming note as needed if the subject 
are included in the summary statistics for all relevant categories or just 1 category and the criteria for 
selecting the criteria. 
 Where a category with a subheading (such as system organ class) has to be split over more than 
cont.
overall summary statistics for the subheading should only be output on the first relevant page. 
15.2.5.3. 
Listing Conventions 
 Listings will be sorted for presentation in order of subject number, visit/collection day, and 
visit/collection time. 


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 63 of 94
Missing data will be represented on subject listings as either a hyphen ( - ) with a corresponding 
footnote ( - = unknown or not evaluated ), or as N/A , with the footnote N/A = not applicable , 
whichever is appropriate.
Dates will be printed in SAS DATE9.format ( DD_MMM_YYYY : 01JUL2000). Missing portions of 
dates will be represented on subject listings as dashes (--JUL2000). Dates that are missing because 
they are not applicable for the subject will be output as N/A , unless otherwise specified.
All observed time values will be presented using a 24-hour clock HH:MM or HH:MM:SS format (e.g., 
11:26:45, or 11:26). Time will only be reported if it was measured as part of the study.
Units will be included where available.
15.2.5.4.
Figure Conventions
Unless otherwise specified, for all figures, study visits will be displayed on the X-axis and endpoint 
(e.g., treatment mean change from Baseline) values will be displayed on the Y-axis.
Footnotes
A solid line spanning the margins will separate the body of the data display from the footnotes. 
All footnotes will be left justified with single-line spacing immediately below the solid line underneath 
the data display.
Footnotes will always begin with Notes: if an informational footnote, or 1, 2, 3, etc. if a reference 
footnote. Each new footnote will start on a new line, where possible.
Subject specific footnotes are avoided, where possible.
Footnotes will be used sparingly and add value to the TFL. If more than 10 lines of footnotes are 
planned, then a cover page is strongly recommended to be used to display footnotes, and only those 
essential to comprehension of the data will be repeated on each page.
The last line of the footnote section will be a standard source line that indicates the name of the 
program used to produce the data display, date the program was run, the date of extraction indicated 
-
and the listing source (i.e
Program: t-14-01-03-02-01.sas, 
Run date: 16MAR2021 12:57 , date cut-off: DDMMMYYYY, Listing Source(s): 16.x.y.z ).
Sources and/or cross-references in footnotes will use the keyword prefix (in singular form) for each 
reference and will be separated by a comma when multiple cross-references are displayed.


Statistical Analysis Plan for Interventional Studies 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890 
This document is confidential. 
SAP Version: 2.0 19-Jan-2024 
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020 
Filing requirements: TMF 
Page 64 of 94 
Example 
Listing source: 16.2.1.1 


Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 65 of 94
Quality Control
SAS programs are developed to produce output such as analysis data sets, summary tables, data listings, 
figures or statistical analyses. An overview of the development of programs is detailed in 
 
Developing Statistical Programs Standard Operation Procedure (SOP) (3907).
 SOPs Developing Statistical Programs (3907) and Conducting the Transfer of Biostatistical 
Deliverables (SDTM, ADaM, TFL) (3908) describes the quality control procedures that are performed for 
all SAS programs and output. Quality control is defined here as the operational techniques and activities 
undertaken to verify that the SAS programs produce the output by checking for their logic, efficiency and 
commenting and by review of the produced output. A detailed description of project specific QC procedure 
CCI
CCI








































Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential.
SAP Version: 2.0 19-Jan-2024
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020
Filing requirements: TMF
Page 85 of 94
Appendices
Example SAS Code
1.
The Example SAS code for Time to Event and Hazard Ratio
proc lifetest data=analysis_data;
time aval*cnsr(1);
strata trtp;
run;
proc phreg data=analysis_data;
class trtp stratum;
model aval*cnsr(1)=trtp stratum;
run;
2.
The example SAS code for CMH model is listed as below:
proc freq data=analysis_data;
tables stratum*trt*resp/ cmh alpha=0.1;
run;
3.
The example SAS code for MMRM model is listed as below:
proc mixed data = analysis_data;
class stratum trtp avisit subjid;
model chg = base stratum trtp avisit trtp*avisit/ ddfm=kr;
repeated avisit / subject=subjid(trtp) type=un;
lsmeans trtp/ cl diff;
lsmeans trtp*avisit/ slice=avisit cl diff;
run;
4.
The example SAS code for ANCOVA model is listed as below:
proc mixed data = analysis_data;
class stratum trtp;
model chg = base stratum trtp;


Statistical Analysis Plan for Interventional Studies 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890 
This document is confidential. 
SAP Version: 2.0 19-Jan-2024 
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020 
Filing requirements: TMF 
Page 86 of 94 
lsmeans trtp/ cl diff;  
run; 














Statistical Analysis Plan for Interventional Studies
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.203890
This document is confidential. 
SAP Version: 2.0 19-Jan-2024 
Controlled Document ID: 3903A.02, Effective Date 31-Aug-2020 
Filing requirements: TMF 
Page 93 of 94 
Test Parameter 
Test 
Parameter 
Code 
Normal Range Lower 
Limit (LLN) 
Normal Range Upper 
Limit (ULN) 
Potentially Clinically Significant Ranges 
 
 
1.40 (70 - < 80 years 
old) 
10.40 (70 - < 80 years 
old) 
 
 
 
1.40 (  80 years old) 
12.10 (  80 years old)